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ABSTRACT 
Beta thalassaemia is caused by mutations in the adult haemoglobin gene (HBB) and is one of the 
most prevalent monogenic blood disorders worldwide. The transplantation of haematopoietic stem 
cells derived from gene-corrected patient induced pluripotent stem cells (iPSCs) could provide a 
promising therapeutic strategy. Here, the generation and characterisation of footprint-free iPSCs 
from dermal fibroblasts of an individual with a homozygous beta thalassaemia-causing mutation 
affecting splicing is described (Chapter III). Successful gene correction of the disease-causing 
mutation was achieved by employing a CRISPR/Cas9 dual nickase approach and two donor design 
strategies aimed at reducing undesired on-target mutagenesis (Chapter IV), followed by the 
seamless piggyBac transposase-aided removal of extraneous sequences. The first strategy involved 
the introduction of a SNP in the protospacer adjacent motif (PAM) sequence in one guide of the 
first gRNA pair, and the second utilised insertion of a large piggyBac transposase-exciseable 
selection cassette (>3 kb) to spatially separate the other gRNA pair. The combined targeting 
efficiency was ≈68.7 per cent (52 per cent heterozygous and 16.6 per cent homozygous) after 
excluding clones with random integration. Surprisingly, indels were observed in the untargeted 
allele in all of the heterozygote clones (25/25), indicating a high rate of on-target non-homologous 
end joining (NHEJ) driven mutagenesis. Significantly, the data also showed that the nickase variant 
of Cas9 elicited unexpected on-target mutagenesis also affecting the targeted allele, as insertions or 
deletions were observed at the binding site of one of the guides in five of the 26 targeted clones (19 
monoallelic and seven biallelic targeted clones with sgRNAs 4/5). No off-target mutagenesis was 
detected upon screening of the five top-scored homologous genomic sites for each of the individual 
gRNAs (10 sites per pair). PiggyBac transposase-mediated excision of the selection cassette(s) 
demonstrated that seamless correction of homozygous clones correctly targeted at both alleles is 
feasible. In order to assess the restoration of normal transcription from the corrected allele, a 
CRISPRa-based approach to activate the HBB proximal promoter region was optimised and 
achieved a significant mRNA expression level from the corrected allele after cassette removal 
(Chapter V). This demonstrated that such an approach can be used to model defective splicing of 
the HBB gene in iPSCs with beta thalassaemia mutations and corroborates restoration of normal 
HBB splicing in gene-corrected cells.  
This study combined cutting-edge cellular reprogramming methods to generate beta thalassaemia 
iPSCs, a double nickase-mediated gene editing approach and piggyBac transposase-aided excision 
to achieve seamless gene repair, and a CRISPRa approach to model the impact of the disease-
causing mutation and demonstrate restoration of normal transcription following genetic repair. 
Having established a platform for precise gene correction and for validation of the restoration of the 
functional allele in this monogenic disease, this strategy may provide a viable avenue for iPSC-
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based cell therapy of beta thalassaemic patients provided mature engraftable blood cells can be 
generated from hiPSCs in the future. 
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1  LITERATURE REVIEW 
 Introduction 
Inherited haemoglobinopathies are considered to be among the most common monogenic human 
disorders. Nearly 5 per cent of the world’s population has been estimated to carry an allele for a 
‘severe’ haemoglobin protein variant that can cause a disease in the homozygous state [1]. To date, 
allogenic haematopoietic stem cell (HSC) transplantation is the only available therapeutic approach 
that restores long-term haematopoietic reconstitution for some severe haemoglobinopathies, such as 
beta thalassaemia. This approach is hindered by the lack of availability of an immunologically 
closely matched donor and the possible serious complications associated with this type of therapy 
[2]. An alternative approach is to use autologous somatic HSCs after ex vivo genetic manipulation 
to insert a functional copy of the gene (gene addition). Although significant advances have been 
reported for gene addition that include the use of a safer viral vector design for inserting the 
therapeutic gene [3, 4], targeted repair-based approaches (non-viral) avoid the adverse effects 
associated with viral vectors while offering the advantage of retaining the natural context of 
endogenous regulatory elements for the corrected gene [5]. The targeted correction of the sickle cell 
disease (beta haemoglobinopathies) mutation in HSCs was recently reported [6]. Because primitive 
HSCs are slow-cycling (quiescent) cells and active cell division is essential for effective gene 
targeting [7] the approach was inefficient in primitive HSCs [5]. While this low efficiency of 
targeting in HSCs can in some cases be counterbalanced by the increased fitness of edited cells, as 
is the case with the IL-2RG gene [5], gene correction of beta haemoglobinopathies does not confer 
any survival advantage to the corrected cells. Recent advances in nuclear reprogramming and gene 
editing technology may be able to circumvent some of these hurdles and offer the potential for 
alternative therapeutic strategies [8]. However, the fidelity of genome modification remains a major 
concern, and limited data is available on its use in induced pluripotent stem cells (iPSCs) in the 
context of gene correction. 
This chapter is divided into four parts. A brief overview of beta thalassaemia and methods for the 
derivation of iPS cell lines with beta thalassaemia mutations will be provided in the first part. This 
will be followed by an outline of the recent nuclease platforms used to stimulate the DNA repair 
mechanism, and their role in site-specific gene correction, with a focus on strategies that enhance 
the specificity of the Cas9 systems. The third part includes an overview of the most relevant aspects 
of DNA break repair mechanisms (single-strand break/double-strand break; SSB/DSB) and their 
role(s) in iPSCs. Lastly, the applicability of CRISPR-Cas9-mediated gene activation for the 
restoration of functionality of the defective -globin gene will be discussed. 
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 Beta thalassaemia 
Haemoglobin is a tetrameric metalloprotein composed of a two alpha-like and two beta-like globin 
chains. The alpha globin cluster is located on the short arm of chromosome 16 (16p13.3), while the 
-globin cluster is located on the short arm of chromosome 11 (11p15.5). The -globin cluster 
contains five genes that are sequentially arranged in order of their temporal expression during 
ontogeny. Class switching refers to the change of globin pattern forming the tetrameric 
haemoglobin during development. Specifically, in the early embryonic stage, haemoglobins 
Grower-1(ζ2ε2), Grower-2 (α2ε2) and Portland (ζ2γ2) are expressed in the yolk sac (Figure 1-1.A). 
The globin pattern then changes to HbF (α2γ2) as haematopoiesis shifts to the liver and bone 
marrow during the foetal stage. The expression of the adult phenotype (HbA: α2β2), is delayed until 
postnatal development, becoming the predominant form of haemoglobin shortly after birth. 
Consequently, as the globin switches to the adult phenotype, the phenotype of the beta 
haemoglobinopathies becomes evident within the first two years in affected infants, as is the case 
with patients with beta thalassaemia major [9]. Reactivation of gamma globin expression has the 
potential to alleviate the severity of the beta haemoglobinopathy phenotype by attenuating the 
globin chain imbalance. Various approaches have been employed to identify modulators of HbF 
reactivation (class switching) [10-12], including gene editing-based studies that have potential to 
advance the management of severe thalassaemia [12]. 
Beta thalassaemia is considered one of the most common inherited disorders affecting -globin 
chain synthesis in red cells[13]. It is a heterogeneous group of genetic blood disorders caused by 
more than 300 different mutations [14]. They are mostly inherited as an autosomal recessive trait. 
The most severe form of the disease is frequently associated with the homozygous or compound 
heterozygote state. The major determinant of the severity of the disease is the type of mutation. The 
-globin gene spans 1.6 kb and encompasses three exons and two introns, in addition to the 5′ and 
3′ UTRs (Figure 1-1.B). The majority of beta haemoglobinopathies are caused by point mutations, 
small deletions or insertions that all affect -globin synthesis but through different molecular 
mechanisms: (1) RNA processing, e.g., mutations of the splice junction (IVSII-1 G>A) or in the 
consensus sequence flanking it (IVSI-6 T>C) that abolish or reduce the formation of the transcribed 
RNA product; (2) RNA translation, e.g., nonsense (CD 39 C>T) or frameshift (Fr 8/9 +G) 
mutations that lead to premature chain termination; (3) RNA post-transcriptional modification, e.g., 
changes in the polyadenylation signal (AATAAA-AACAAA); and (4) Transcriptional, e.g., 
mutations in the promoter element (-31 A>G) or the 5′ UTR region (+10 –T) that can also result in a 
decrease in -globin chain production [14]. HBB gene expression is regulated by elements present 
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upstream of the HBB gene; i.e., TATA, CAAT, CACCC and by the distal long-range enhancers, 
known as the locus control region (LCR). The latter is defined by DNase I hypersensitive sites 
located 6–18 kb upstream of the -globin gene (Figure 1-1). Mutations in both the proximal and 
distal genomic regions involved in the regulation of gene expression have also been reported to 
affect gene expression [9]. Collectively, any of these mutations can result in either a reduction (+) 
or complete elimination (0) of -globin chain synthesis. Consequently, there is an excess of 
unbound alpha chains that aggregate in erythroid progenitors cells, leading to ineffective 
erythropoiesis and causing chronic haemolytic anaemia [9]. Decreasing alpha globin chain 
production has been suggested as an alternative approach to improve the imbalance between alpha 
and beta chains in beta thalassaemia [15]. 
 
Figure 1-1: Schematic of the sequential expression of the different goblins that form the 
tetrameric haemoglobin during ontogeny and the structure of the -globin gene. (A) 
Haemoglobins Grower-1 (ζ2ε2), Grower-2 (α2ε2) and Portland (ζ2γ2) are expressed in the yolk 
sac, while HbF (α2γ2) expression begins during the foetal stage and declines after birth to be 
replaced by the expression of the adult phenotype (HbA: α2β2). HbD (α22) and HbF form a 
minor component of the total haemoglobin in adult erythrocytes. Grey boxes with a number 
indicate distal regulatory regions. (B) Structure of the-globin gene. The red rectangle indicates 
the position of the splice junction mutation IVSII-1 G>A; dark green boxes indicate the UTRs, 
light green boxes the exons and dashed lines the introns. 
In severe forms of the disease, such as beta thalassaemia major, patients require treatment with 
monthly blood transfusions and iron chelation therapy. It has been estimated that approximately 
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40,000 infants are born with beta thalassaemia each year [1], of whom more than half will be 
transfusion dependent. Allogenic bone marrow (HSC) transplantation is the only therapeutic 
approach currently available for these patients. However, a major limitation for the majority of 
affected patients is finding an immune compatible donor and the serious long-term complications 
associated with this type of treatment [2]. 
 iPSCs and beta haemoglobinopathies 
In 2007, Takahashi and colleagues demonstrated that human somatic cells can be reprogrammed to 
produce iPSCs [16]. Nuclear reprogramming introduced the possibility of engineering cell identity 
and reverting terminally differentiated cells into a state, termed iPSCs, that are functionally 
equivalent to embryonic stem cells [16]. This was achieved through the ectopic expression of a 
handful of transcription factors that enabled the manipulation of cell identity. Two different 
combinations of the reprogramming factors OSNL (OCT4, SOX2, NANOG, and LIN28), or OSKM 
(OCT3/4, SOX2, KLF4, and c-Myc) were initially used to facilitate the conversion of human adult 
somatic cells into iPSCs using retroviral vectors [16, 17]. The approach was further optimised to 
generate cells with minimal impact on their genomic integrity [18]. 
iPSCs provide a powerful tool that can be used to generate cell models that facilitate the exploration 
of disease mechanisms and the study of the functional relationships between genotype and 
phenotypic outcomes in haematological disease [19]. They can also be differentiated into various 
types of patient-specific cells, including HSCs [20, 21]. iPSCs thus hold great promise for isogenic 
cell-based therapy, where a patient’s specific somatic cells can be reprogrammed to the pluripotent 
state, genetically corrected, differentiated into haematopoietic progenitors with subsequent potential 
to be useful as a patient-specific cellular therapy [22]. Proof of concept has been realised in a mouse 
model with sickle cell anaemia, where the genetic defect was corrected in iPSCs and used to derive 
autologous HSCs. Transplantation of the corrected HSCs resulted in an improvement in the 
pathological phenotype [23]. Combining iPSC generation and genetic engineering technologies 
provides a platform for the testing of novel therapeutic drug strategies, disease modelling of genetic 
variants, and offers great potential for generating autologous, gene-corrected HSCs that may be 
suitable for possible future clinical application [24, 25]. 
Nonetheless, important aspects of both iPSCs and gene editing technologies remain to be addressed. 
Maintaining the genomic integrity of cells and establishing a balance between efficiency and 
specificity in gene editing are still under evaluation. Optimising technologies that have minimum 
impact on the host genome is therefore an active area of research. 
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1.3.1 Methods for deriving iPSCs with a beta thalassaemia mutation 
The method of iPSC derivation can affect the quality of iPSCs, both in terms of their genome 
integrity, differentiation potential and compatibility with clinical applications. Integrative 
approaches, via lentiviral and retroviral vectors, have been used in several studies to reprogramme 
somatic cells from beta thalassaemia patients into iPSCs [26-28]. The main advantage of viral-based 
reprogramming is the high efficiency of the system compared to most non-integrative approaches 
[18]. However, integration-based strategies are not suitable for the production of high quality 
iPSCs. Indeed, integrative vectors have been shown: 1) to be associated with a high risk of 
tumorigenic insertional mutations that may result in undesired phenotypic alterations [29]; 2) to 
exhibit incomplete silencing of the vector-derived transgenes or inappropriate reactivation of the 
transgenes upon differentiation, thus influencing their differentiation potential [30, 31] and 3) may 
affect the immunogenicity of iPSCs [32, 33]. Integration-free methods can avoid these problems 
and offer a safer alternative for mediated cell reprogramming. To date, various methods for the 
generation of integration-free iPSCs have been reported in the literature [18, 34]. 
The Sendai virus [35] excisable integrating vector (STEMCCA/Cre/loxP) [36] and episomes [37, 
38] were used for the derivation of integration-free iPSCs from patients with inherited 
haemoglobinopathies (Table1-1). Although transgene-free iPSCs can be derived with the 
STEMCCA vector, the excision process leaves a short DNA sequence in the host genome [39] that 
may have consequences for the functionality of the gene [40]. Footprint-free iPSCs can be derived 
using episomal, Sendai virus, mRNA or protein-based approaches. However, protein and mRNA-
based approaches are technically laborious, as these require multiple rounds of transfection [41-43], 
making them less suitable for scale-up in clinical settings. In contrast, Sendai-based reprogramming 
offers the advantage of an efficient process, but is costly and the transgene can persist for up to 20 
passages in iPSCs (unpublished data). Episomal reprogramming, on the other hand, is cheap and 
results in rapid loss of the vector during passive cell division [44]. The EBNA1 (Epstein-Barr 
nuclear antigen-1)/oriP-based episomal vectors have been successfully used for the derivation of 
integration-free human iPSCs from multiple cell types, including human fibroblasts [45, 46], cord 
blood mononuclear cells [47] and peripheral blood mononuclear cells [48]. In comparison to a 
standard plasmid, EBNA1-containing vectors have the advantage of ectopic, autonomous 
replication in synchrony with the host chromosome [49]. In this study, this system was chosen to 
generate footprint-free iPSCs with a beta thalassaemia mutation. Derivation of iPSCs were 
attempted from the fibroblasts of patients homozygous for the frequent Mediterranean splice 
junction mutation IVSII-1(G>A) and the cryptic splice site mutation IVSI-110 (G>A) (Table 1-2). 
Both mutations result in defective RNA processing, and the recovery of the correctly spliced 
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products can be assessed following gene activation using CRISPR/Cas9-mediated protein targeting 
with transcription coactivators (see further discussion in Section 1.5). To date, footprint-free iPSC 
derivation from beta thalassaemia patients with the homozygous mutation IVSII-1(G>A) has not 
been reported (Table 1-1). 
1.3.2 Overview of nuclease-mediated gene targeting in human iPSCs 
Pluripotent stem cells offer an ideal platform as they possess indefinite self-renewal capacity 
coupled with pluripotency, thus enabling the derivation of all cell types through directed 
differentiation. Footprint-free iPSCs may not only be useful in addressing the quantitative obstacle 
of expanding peripheral blood-derived HSCs [50], but may also provide a safer approach (in 
contrast to the viral gene therapy) for correcting the disease-causing mutation. However, gene 
targeting by homologous recombination (HR) in hiPSCs has been reported to be technically 
difficult, with an inherently low efficiency [51]. Recent advances in genetic engineering, namely the 
use of site-specific nucleases that stimulate the endogenous DNA repair mechanisms, can 
significantly improve the efficiency of gene correction, and are thus increasingly used to overcome 
this bottleneck [52, 53]. The efficiency and applicability of the system to a wide range of cell types 
has already facilitated the generation of novel cellular and animal models of disease [8]. However, 
despite the rapid advances in this field, data on the fidelity of targeted modifications (off-target 
assessment) at endogenous genomic loci remain highly variable [54, 55]. This is likely related to the 
fact that the consequences of nuclease activity are modulated by a complex interplay between DNA 
target accessibility, the kinetics and the nature of nuclease target recognition cell-type specific DNA 
repair mechanisms and the cell cycle. 
 Site-specific endonuclease platforms 
Several different classes of endonucleases with programmable specificity have been used for 
genome editing [8, 52, 53]. Generally, they can be grouped into four main classes: meganucleases, 
zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
clustered regularly interspersed short palindromic repeat (CRISPR/Cas9)-based nuclease systems. 
Meganucleases are formed from one protein domain that contains both recognition and cleavage 
functions but possesses limited targeting potential. In contrast, the ZFNs, TALENs, and 
CRISPR/Cas9 systems are composed of two domains; a programmable domain that directs the 
nuclease to bind to the intended DNA locus and a nuclease domain that cleaves chromosomal DNA. 
The programmable domain in the meganucleases, ZFNs and TALENs is a protein, whereas the 
CRISPR/Cas9 systems rely on RNA target specificity, hence the name RNA-guided nuclease 
(RGN) [56, 57]. A comparison between the major characteristics of some commonly used nuclease 
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platforms in pluripotent stem cells is shown in Table1-3. Although both RNA and protein types of 
DNA-recognition domains can be engineered to bind to a specific target sequences, RNA-based 
targeting offers a versatile system, with easier design, is amenable to multiplexing, and in principle 
allows the targeting of any given genomic locus, even if the locus is methylated [58]. 
 
Table 1-1: Method of derivation and source of iPSC lines generated with beta thalassaemia 
mutations 
Cell type Vector Gene 
correction 
strategy 
Allele1 Allele2 Reference 
Fibroblast Retroviral Not done CD 41-42 
(-TCTT) 
CD41-42 
(-TCTT) 
[28] 
Homologous 
recombination 
[26] 
Episome TALEN 
Cas9WT 
[37, 38] 
Fibroblasts Sendai virus Cas9WT CD41-42 (-TCTT) -28 (A/G) [35] 
Fibroblasts Lentivirus 
(STEMCCA), 
excision not 
mentioned 
Cas9WT CD17 (A>T) CD17 (A>T) [36] 
Fibroblasts or 
bone marrow 
MSCs 
Lentivirus Gene addition CD39 (C>T) CD39 (C>T) [27] 
IVSI-110 (G>A) CD39 (C>T) 
IVSI-1 (G>A) CD39 (C>T) 
IVSI-5 (G>C) CD39 (C>T) 
Amniotic fluid 
cells 
Episome TALEN IVSII-654 (C>T) IVSII-654 (C>T) [38] 
 
 
Table 1-2: List of beta thalassaemia mutations (in iPSC lines) and the mechanism by which 
they affect -globin chain synthesis CRISPR/Cas9 platforms 
Mutation Stage of gene expression 
affected 
Mutation category 
-28 (A/G) Transcriptional mutation Promoter element 
IVSI-110 (G>A) RNA processing Cryptic splice site 
IVSI-1 (G>A) RNA processing Splice junction 
IVSII-1(G>A) RNA processing Splice junction 
IVSI-5 (G>C) RNA processing Consensus splice site 
IVSII-654 (C>T) RNA processing Cryptic splice site 
CD 41-42 (-TCTT) RNA translation Frameshift 
CD17 (A>T) RNA translation Nonsense 
CD39 (C>T) RNA translation Nonsense 
 
1.3.2.1.1 Cas9 nuclease structure and mechanism 
The CRISPR/Cas9 nuclease systems are a new class of versatile, programmable nucleases that 
utilise an RNA-mediated editing process to enhance genome engineering [59]. The Streptococcus 
pyogenes (Sp) type II A CRISPR/Cas9 system is one of the most commonly used nucleases in 
genome engineering in mammalian cells. It originally functioned as part of the bacterial adaptive 
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immune system, providing acquired resistance against invading foreign DNA sequences. The 
system was next adapted to recognise and target specific DNA sequences (protospacers) in 
mammalian cells [60]. The recognition process relies on using a complementary sequence (crRNA) 
that requires the presence of a noncoding trans-activating crRNA (tracrRNA) sequence for efficient 
Cas9 nuclease activity [59]. The tracrRNA:crRNA structure can be used in the form of either a dual 
[61] or a chimeric single guide RNA (sgRNA) [58, 62]. The latter can include a 20-nucleotide 
crRNA target sequence within a 100-nucleotide RNA sequence of the fusion transcript where the 
tracrRNA sequence acts as a scaffold. The RNA hybridises to a predetermined complementary 
DNA sequence and directs the Cas9 endonuclease to bind and cleave the matched DNA site 
provided that the sequence is followed by a PAM [60, 62-64]. The PAM motif sequence is 
predominantly composed of NGG (N is a degenerate base), or to a lesser extent NAG, NGA, NCG, 
NGC, NGT, NTG, and NAA. The alternative non-canonical motif sequences have been identified 
using in vitro cleavage assays, a reporter system, or through an unbiased sequencing method that 
captures double-stranded oligodeoxynucleotides into DSBs (GUIDE-Seq) [58, 65, 66]. 
 
 
Figure 1-2: Schematic of Cas9 protein domains. 
The schematic show the bilobe (NUC and REC) and the six domains of Cas9: Rec I, Rec II, 
Bridge helix, RuvC, HNH, and PAM interacting. Numbers indicate amino acid residues. Figure 
adapted from [67]. 
Structural analysis of the Cas9 protein revealed the presence of a cleaving (NUC) and recognition 
(REC) ‘lobe’ (Figure 1-2). The latter interacts with sgRNA and the DNA that resides in a positive 
groove between both lobes in non-specific manner [68]. The interaction was postulated to stabilise 
the non-target strand of the targeted DNA site (Figure 1-3.E). More recently, protein engineering 
has been used to successfully modify amino acids at the interface between Cas9 and the DNA, 
which enhanced cleavage specificity [69, 70]. 
The modification enhanced targeting specificity by destabilising the non-specific interaction 
between the Cas9 protein and the DNA strand, rendering the binding more dependent on the base 
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pairing stringency between RNA and the DNA sequence (Figure 1-3.E). This approach led to 
unfavourable binding at off-target sites, due to the presence of sequence mismatches [69]. Recent 
evidence suggests that the Cas9 system varies from other types of nucleases in its binding kinetics, 
in that the protein remains bound to the targeted locus after cleavage [71, 72]. The number of 
cleaved DNA products induced by Cas9 reaches a maximum in one minute, with no further increase 
with time. This same trend was observed over a range of enzyme concentration (2.5 nM–100 nM), 
indicating that Cas9 is a single turnover enzyme that does not follow a Michaelis-Menten kinetic 
model [72]. 
Table 1-3: Comparison of the major characteristics of some commonly used nuclease 
platforms in genome engineering 
 
 ZFN TALEN Sp CRISPR-Cas9 
DNA recognition 
domain 
Protein Protein RNA+PAM motif 
Zinc fingers DNA binding 
motifs 
Transcription activator-like 
effectors 
 
Each motif recognises three 
bases 
Two amino acids in the repeat 
variable di-residue in the DNA 
binding repeat domain dictate 
the base preference 
Watson-Crick base pairing 
between DNA and crRNA 
Tuneable by changing the number of DNA binding modules Truncation of sgRNA to 
17 bp or appending 5′-GG 
may improve specificity 
Recognition 
sequence 
9–18 bp/monomer 14–20 bp/monomer 17–20 bp 
Nuclease domain Type IIS restriction enzyme 
FokI 
Type IIS restriction enzyme FokI Cas9 
Methods used in 
engineering the 
DNA binding site 
Protein engineering Complex molecular cloning Standard molecular 
cloning/cloning-free 
Type of DNA 
cleavage produced 
Cohesive ends: 5′ overhangs at cleavage sites Blunt ends (common) 
1 or 2 overhangs in vitro 
Nickase variant √ √ √ 
Sensitive to 
methylation 
Possible √  
Repurposed for gene 
regulation 
√ √ √ 
Used in clinical trial √   
 
Cas9 nuclease induces mostly blunt DSBs through the activity of two domains that independently 
nick the complementary strand (the NHN domain) and the non-complementary strand (the RuvC 
domain) [59]. Both domains are in the NUC lobe of the Cas9 protein. Interestingly, small overhangs 
were also reported during in vitro studies, which were attributed to exonuclease activity at the non-
complementary strand [59]. DSBs stimulate the cellular repair mechanisms (see Section 1.4 for 
details) through either NHEJ or homology-directed repair (HDR) in the presence of a donor 
template. 
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Figure 1-3: Schematic illustrating the process of inducing DSB at targeted DNA locus. A) 
Association of hybrid sgRNA to the Cas9-protein leading to conformational changes in the latter. 
B) The REC lobe of the formed ribonucleoprotein complex (sgRNA-Cas9) searches the DNA 
sequence and recognises a PAM motif, resulting in limited unwinding of the DNA duplex 
upstream of the PAM, forming a small bubble. C) A RNA-DNA heteroduplex is initiated; 
however, mismatches destabilise the structure leading to sgRNA-Cas9 dissociation (D). E) Upon 
base pair matching the loop is extended and the structure is stabilised by nucleotide base pairing 
and the non-specific interaction between the negatively charged non-target strand and the 
positively charged groove located between the HNH and RuvC domains. F) A proper base pair 
match occurs and loop extension induces a conformation change that activates the nuclease 
activity and introduces a DSB. The complex does not immediately dissociate from the binding 
site following cleavage. Figure adapted from [69, 72, 73]. PAM sequences are highlighted by red 
lines. 
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NHEJ is mostly an error-prone mechanism that results in mutagenic end joining, whereas HR leads 
to a defined and precise modification of a genomic DNA sequence dictated by the sequence in the 
donor vector. Consequently both types of DNA repair pathways have been exploited to facilitate the 
generation of gene knock-outs, gene or transgene knock-ins and point mutation. 
1.3.2.1.2 Off-target activity and strategies to enhance specificity 
Tolerance to several mismatches between guide RNA and DNA sequences raised concerns about 
undesired off-target cleaving that led to mutation as a result of repair through the NHEJ pathway, 
with possible undesired consequenses [58, 74, 75]. Remarkably, off-target activity was not limited 
to mismatches (base substitution). In fact, a DNA-RNA bulge formed as a result of the presence of  
insertions or deletions in the sequence of the off-target locus was also tolerated by Cas9 [76]. This 
non-specific activity potentially limits the utility of the Cas9 system for both basic research and 
therapeutic clinical translation. Although the determinants that govern the specificity of Cas9 are 
not fully characterised, various recommendations and strategies have been suggested to address this 
limitation. Details of these recommendations that include guide sequence properties and approaches 
to improve specificity will follow in the next section. 
Guide sequence properties that can play a role in modifying Cas9 specificity include:  
a) Unique target site selection: Li et al.[77] showed that enhanced specificity can be obtained by 
designing a sgRNA to target a DNA site with unique sequence. This study provided an analysis 
tool (software) that precluded sequences with mismatches by mapping all possible substrings of 
length sequence with less than 16 bases to the genome. The increased depth displayed by the 
mapped sequence reflects a possible unique target site (analysis of the HBB gene with the 
software provided is shown in Figure 1-4). Evidently, this strategy somewhat limits the selection 
of gRNA in gene correction studies as the placement of the DNA break relative to the intended 
modification site is critical for the efficiency of gene correction [78].  
 
Figure 1-4: Unique k-mer to identify a unique sequence in the HBB gene. 
(https://apps.cira.kyoto-u.ac.jp/igeats) [77]. 
13 
 
 
b) Selection of sequences with predicted off-target sites (DNA sequences with few mismatches) 
in a closed chromatin structure (heterochromatin with H3K27me3 mark) [76]: Although early 
studies indicated that the chromatin state does not inhibit the accessibility of Cas9 [58, 78, 79], 
recent evidence suggests that the chromatin environment may impact on Cas9 activity, as 
indicated by the fact that DNA in nucleosome structures was reported to be less prone to 
nuclease recognition and binding [80]. However, it should be noted that the dynamic nature of 
nucleosome occupancy and turnover during replication can render these DNA sites available for 
cleavage [80].  Nevertheless, others report that: (1) the search efficiency of Cas9 within 
heterochromatin regions displays slower kinetics in comparison to that in euchromatin regions 
[81]; (2) the genome-wide binding profile of Cas9, as revealed by Chip-seq analysis, shows that 
Cas9 displays a preference for open chromatin areas [82]; (3) discrepancies have been observed 
in the number of off-target sites identified in the cellular genomic context as compared to that in 
the in vitro context (no chromatin, Digenome-Seq) [83]. The number of off-target sites predicted 
using the in vitro approach were significantly higher than those captured in a cellular genomic 
context [54, 83, 84]. Yet, it is not clear if this is solely attributed to the differential chromatin 
state. Overall, the evidence supports a role for chromatin accessibility in Cas9 activity. Indeed, 
one of the recent bioinformatic tools for off-target prediction integrates information on the 
chromatin state into the analysis [85]. In the context of this thesis, it is important to note that 
pluripotent stem cells adopt an open chromatin structure that differs from that of somatic cells 
[86], implying that iPSCs may have a higher propensity for off-target activity.  Surprisingly, 
therefore, off-target Cas9 activity in iPSCs was reported to be low [87] or non-existent [88, 89]. 
However, it should be noted that Tan et al. [87] limited their screen to an analysis of 90 off-
target sites for 12 gRNAs, whereas Smith et al. [89] and Veres et al.[88] used whole genome 
sequencing in their study, for only a limited number of sgRNAs, in iPSCs. This implies that the 
interplay of various factors determines Cas9 activity, including cell-type specific parameters that 
influence off-target activity and can potentially explain these apparently discordant findings, as 
discussed in Section 1.4. 
c)  Modulation of the amount of sgRNA-Cas9 transfected: Off-target activity may be able to be 
reduced by limiting the amount of sgRNA-Cas9. One way to achieve this is by introducing a 
uracil-rich seed sequence (proximal to PAM) in order to decrease the abundance of sgRNA by 
affecting RNA transcription and thus improve specificity [82]. Similarly, titrating down the 
amount of sgRNA-Cas9 decreased non-specific cleavage in one study [58], but was not effective 
in changing off-target activity in another [74]. This latter observation was supported by a study 
by Frock et al. [90]who did not observe a change in either the qualitative (number of sites) or 
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quantitative (activity levels) off-target activity over a 10-fold range in the amount of sgRNA-
Cas9 (for a single locus). Evidently, the role that decreasing the amounts of Cas9 and sgRNA 
has in limiting off-target activity remains controversial possibly depending on guide sequence 
and locus context properties. 
d) Altering the stability of Cas9 binding: The GC content of the guide was also suggested to play 
a role in both off-target [74, 76], and on-target, activity [91]. A higher GC percentage is 
generally associated with higher activity. This was attributed to an increase in the stability of 
Cas9 binding associated with guide RNAs rich in GC nucleotides. Indeed, 28 per cent of the 
variation seen in Cas9 efficiency in inducing mutagenesis at the targeted locus was attributed by 
the melting temperature of the sequence (gRNA) [78]. The stability of binding may explain 
some of the differences observed between studies investigating the effect of titrating the amount 
of sgRNA-Cas9 on off-target activity; in other words, guides with high stability can produce 
higher off-target activity with little effect related to the available amount.  
e) Manipulation of the guide structure: Altering the guide structure by either decreasing the 
length of the guide (truncated guides) [92], or appending GG bases to the 5’ end of the guide 
[61], may promote specificity. The concept of decreasing the guide length was based on a 
thermodynamic model which predicts that shorter guides would be more prone to destabilization 
by nucleotide mismatches and thus increase the fidelity of the system [92].  
Alternatively, enhancing specificity can be achieved by using different forms or variants of Cas9: 
a) Transient expression: Transfection of Cas9 ribonucleoprotein was used instead of the plasmid 
form in order to avoid prolonged expression of Cas9 [93, 94]. This was based on the 
observation that the ribonucleoprotein was cleared from the cells within 24 hrs whereas 
plasmid-delivered Cas9 displayed continuous expression for ≈72 hrs.  
b) Engineer mutations in the Cas9 nuclease to generate variants with properties that limit off-
target activity: One strategy explored a cooperative model for DSB generation. (1) Converting 
the nuclease into a nickase variant (Cas9n) by introducing either D10A, H840A (or N863A) 
amino acid substitutions into the active site of the RuvCI or the HNH nuclease domains, 
respectively, effectively inactivating one catalytic domain [68, 95]. Inactivation of DNA 
cleavage at one strand thus allowed the introduction of an SSB, instead of a DSBs, at the 
targeted DNA site. Commonly, the Cas9D10A variant is used in conjunction with two guide 
RNAs to generate a composite DNA DSB on opposite DNA strands within a defined offset 
range at the targeted locus [96]. This so-called ‘paired nickase’ strategy aims to improve the on-
target cutting efficiency of the nickase by inducing a composite DSB at the targeted locus 
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(double nickase), while SSBs are induced at off-target sites by a single nickase. Mutagenesis at 
such off-target sites would be minimised because nicks are thought to be repaired through high 
fidelity repair mechanisms [96, 97]. (2) An alternative strategy involve the conversion of Cas9 
into a deficient nuclease protein (dCas9), which was accomplished by inactivating both cleaving 
domains (HNH and RuvC). The inactive Cas9 protein was next fused to non-specific wild-type 
FokI endonuclease. The specificity of this system is dictated by the synergistic interaction of 
two monomers of the fused protein (dCas9-FokI), where sgRNA directs the binding of dCas9, 
and the FokI endonuclease enables cleavage of the site upon dimerisation [98, 99]. The system 
is analogous to the ZFN or TALEN models. Of note, combining FokI-dCas9 nucleases with 
truncated guides has also been reported to further increase the specificity of DNA cleavage 
[100]. A second strategy aims to weaken the non-specific interactions between Cas9 and either 
the on-target strand (eSpCas9) [69] or the DNA phosphate backbone (SpCas9-HF1) [70] in 
order to destabilise the binding at non-specific targets. 
 Although the majority of the above-mentioned approaches were reported to enhance the specificity 
of DNA cleavage, the effectiveness of these approaches varied between different DNA loci and cell 
type. For example, while the truncated guide was reported to increase specificity of sgRNA-Cas9 
mediated DSB, as assessed by a genome-wide approach (Guide-seq) [65], another study reported 
persistent off-target activity with truncated guide RNAs, as well as the creation of new off-target 
sites compared to the full-length 20-mer counterpart [69]. Similarly, while the paired nickase 
strategy was proven to enhance the specificity of DNA cleavage in mouse embryos, and no 
mutagenesis associated with the monomeric nickase (Cas9D10A) was reported [101], other studies 
reported either low level of on-target activity associated with monomeric Cas9n in immortalised or 
transformed human cells lines [61, 98], or a tolerance of the RNA-DNA bulges at off-target sites 
[76]. It is clear, however, that nickase (or Cas9DN) certainly enhanced specificity when compared 
to Cas9WT [90, 96, 102]. As discussed previously, it remains difficult to perform a meaningful 
comparison between these different strategies as discrepancies may reflect differences in variables 
such as guide sequence properties [76, 91], differing states of local chromatin [80], the format of the 
transfected sgRNA-Cas9 (plasmid, mRNA, or ribonucleoprotein) [93, 94], the amount of both guide 
and Cas9 used, the sensitivity of the method used to detect mutagenesis (Surveyor, T7endonuclease, 
Digenome-seq, Guide-seq ect) and cell type. In this thesis, the double nickase approach was 
adopted and optimised for gene correction of the splice junction mutation in beta thalassaemia-
iPSCs. 
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 Repair mechanisms and pluripotent stem cells  
Cell type, cell cycle phase, the type of DNA damage, and chromatin state all influence a cell’s 
response to DNA damage [103, 104]. Pluripotent stem cells have certain unique characteristics that 
differ from other cell types; for example, different cell cycle phase lengths that are associated with 
the pluripotent state of the cell [105, 106], lack of some cell cycle checkpoints in response to certain 
types of DNA damage-inducing agents [107] and an open chromatin structure [86]. These 
properties may result in different repair kinetics for similar target sites in different cell lines. In the 
following sections, the major aspects of the DNA repair mechanisms and their relevance in 
resolving DNA breaks induced by nucleases in iPSCs will be outlined.  
1.4.1 Overview of DNA repair mechanisms 
The integrity of the genome is preserved by the concerted action of several cellular repair 
mechanisms commonly referred to as the ‘DNA damage response’ (DDR).  The DDR includes: 
nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR) and 
recombinational repair [108]. SSB breaks are mostly repaired through BER [97] while both SSB 
and DSB can be repaired via the recombinational repair pathways in the G2 phase of cell cycle [97, 
109]. The recombinational repair pathways include four pathways that fall into two different classes 
depending on the presence, or absence, of resection processing at the DNA break site (see Figure 
1-5). The resection-dependent pathways include alternative end joining (A-NHEJ, mutagenic), 
single-strand annealing (SSA/micro-homology-mediated end joining (MMEJ), mutagenic) and the 
homologous recombination pathway (HR, high fidelity). The resection independent pathway 
involves classical non-homologous end joining (C-NHEJ) and is mutagenic, but can also be error-
free [108, 109]. 
 Following detection of DSBs, the DNA site is marked by a molecular signal with subsequent 
recruitment of the repair machinery. In C-NHEJ, DNA resection is prevented by activating 
accessory factors that protect the break site [108]. Alternatively, in the resection-dependent 
pathways, nucleolytic degradation at the 5’ end of the DNA at the break site is stimulated [108, 
109]. As a result, ssDNA with 3’ overhangs is generated through the action of double-stranded 
DNA nuclease, exonuclease and helicase (see Figure 1-5 for further details on the mechanism). The 
resection is limited to 5-25 bp for A-NHEJ but is broader in HR and SSA [110]. The HR and BER 
pathways are considered high fidelity pathways that restore the integrity of the DNA sequence, 
whereas A-NHEJ, SSA, and C-NHEJ are generally considered to be error-prone pathways [108, 
109, 111]. Achieving high fidelity repair in nuclease-mediated gene targeting of PSCs relies on 
attenuating the mutagenic pathways and shifting the balance to high fidelity repair pathways (i.e. 
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HR and BER). Indeed, molecules that either inhibit NHEJ, or enhance HDR, were reported to 
enable more efficient and precise gene editing [112, 113]. Although many aspects of the regulation, 
mechanistic details, and repair pathway choices remain to be elucidated, several contributing factors 
that may play a role in coordinating the choice of repair path have been defined [109, 114].  
The cell cycle has been reported to be one of the factors determining the repair path followed 
(resection-dependent/independent) (Figure 1-5). Recent data indicates that HR is actively repressed 
during G1 phase [115]. This effect was mediated by preventing the assembly and localization of a 
protein complex (BRCA1–PALB2–BRCA2) required to promote HR at the DSBs during G1. HR 
predominates in the mid S/G2 cycle phases, where a homologous template is available [109]. On 
the other hand, data on the BER pathway are inconclusive. Caldecott [97] indicated that BER was 
active at all cell cycle phases, while Dianov and Hubscher [111] reported that it is only active in the 
G1 phase of the cell cycle. More recently, Mjelle et al. [116] analysed six transcriptome data sets 
from synchronised human cells, revealing that the expression of genes related to short patch BER 
are present throughout the cell cycle, while those associated with long patch BER were limited to 
the S phase. NHEJ was reported to be active throughout the cell cycle, with dominance in the 
G0/G1 phase, and is independent of homologous sequence [114]. Both cooperation and competition 
between HR and NHEJ may occur at cell cycle phases where both pathways are active; (i.e. G2-
phase), in a manner that maximises repair outcomes and genomic integrity (an outline of the major 
repair pathways and activities in a cell cycle context are shown in Figure 1-5)  [114].  
Different types of DNA breaks favour different repair mechanisms. DSBs and SSBs both lead to the 
stimulation of DNA repair. DSBs are mostly repaired through the recombinational pathway (NHEJ 
or HR) [109], while SSBs are thought to be predominantly repaired by dedicated pathways such as 
BER [97, 111]. However, SSBs encountered during DNA replication leads to the generation of  
DSBs due to collapse of the replication fork, and will thus shuttle the repair to DSB resection-
dependent pathways [97]. In this respect it is intriguing to note that HR at nicks introduced by 
nuclease variants does not seem to be triggered by the formation of DSB intermediates [117, 118]. 
In fact, various studies have indicated that nickase stimulates HR, yet the details of this mechanism 
remain to be elucidated [118, 119].  
Programmable nucleases, such as Cas9, induce either a DSB or a SSB depending on the protein 
variant used. The DNA termini (3' or 5') generated by Cas9 are not damaged and therefore may 
facilitate the restoration of the sequence by religation (i.e. C-NHEJ or BER) without end resection 
[97, 120]. Translocation through precise end joining was demonstrated for blunt end DSBs induced 
by Cas9WT [121]. Moreover, a recent study demonstrated a high percentage of precise end joining 
between two blunt end DSBs that generated genomic microdeletions in different cell types [120], 
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lending further support to the idea that blunt ends generated by Cas9WT can be repaired through 
error-free NHEJ. It should be noted, however, that in the study by Geisinger et al. [120] deletion of 
the intervening sequence would have prevented the iterative cycle of cleavage and repair induced by 
the nuclease [114]. Upon further examination of the data in that report, the range of precise ligation 
was higher in H9 pluripotent stem cells (>75 per cent, except for one guide RNA) than in HEK 293 
cells (which varied between 44 per cent and 90 per cent), despite a similar repair pattern in both cell 
types.   
It can be concluded that DNA breaks induced by CRISPR/Cas9 can be repaired through either 
error-free pathways that include BER, and HR, or error-prone pathways, but that the choice of 
pathway and its activity is dependent upon the locus, cell cycle, and the type of DNA break. 
Furthermore, As has already been discussed in the previous paragraph, NHEJ can result in an error-
free DNA repair [120]. 
1.4.2 DNA repair in pluripotent stem cells 
PSCs possess several unique cell and DNA repair characteristics. Mouse ESCs (mESCs) have been 
reported to favour HR [122] and exhibit a low level of NHEJ activity [123]. The majority of 
pluripotent stem cells exist in S phase, where resection-dependent mechanisms are active as 
opposed to C-NHEJ [106]. This may explain the observed decrease in mutation frequency in 
mESCs compared to their somatic counterparts [124]. A low expression level of some of the NHEJ-
related proteins was also found in mESCs [123]. 
Although species differences in PSC are well documented [121, 125], HR was suggested to 
predominate in hESCs, similar to mESCs [126]. When compared to other human cell lines, 
differentiated cells derived from hPSCs, hPSCs display an enhanced DNA repair capacity following 
exposure to various DNA-damaging agents. They also exhibit higher expression levels of genes and 
proteins involved in the repair mechanisms [127-129], and a lower level of NHEJ-mediated repair 
of DSBs [130]. Using human fibroblasts, a cell type in which C-NHEJ is the primary choice of 
repair mechanism [131], Shibata et al. [131] showed that the speed of repair influences the repair 
path chosen and that this depends on both the chromatin and DNA damage complexity, so that a 
slower repair may shuttle the repair through the resection-dependent pathway. Consequently, it is 
reasonable to infer that the relaxed chromatin environment in PSCs may predispose the cell to 
different kinetics for its DNA repair pathways [132, 133].   
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Figure 1-5: Schematic for the major repair pathways for SSB and DSB. (A) Specialised 
proteins are recruited at SSBs (depending on the type of DNA damage) and end processing of 
DNA termini ensues, followed by gap filling through either short patch or long patch repair and 
ligation. (B) SSBs that escape repair in G1 and progress to S phase lead to replication fork 
collapse and the possible formation of either one-ended or two-ended DSB. DSB are mostly 
repaired through accurate HR or through NHEJ. (C) During G1 phase DSB are mostly repaired 
through NHEJ, resulting in either precise or small deletions. NHEJ is active throughout the cell 
cycle (D); however, HDR and C-NHEJ compete in G2 phase, and the repair kinetics are mostly 
determined by the type of DNA damage and chromatin complexity. Upon activation of resection 
HR, SSA and A-NHEJ compete for DSB repair. Figure adapted from [97, 109, 134]. 
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A separate mechanism that maintains genome integrity and prevents the accumulation of DNA 
damage in PSC populations is apoptosis. In response to DNA lesions, PSCs display an increased 
propensity to activate apoptosis compared to that of somatic cells, and this propensity is lost 
following their  differentiation [135]. Activation of apoptosis following DNA damage, as opposed 
to activation of critical cell cycle phase checkpoints during replicative stress to enhance genomic 
integrity, constitutes a protective mechanism that prevents the accumulation of cells with genomic 
aberrations in some cell types (such as HSCs and PSCs) [134]. Indeed, in contrast to most cell 
types, both hESCs and hiPSCs undergo apoptosis and fail to activate the S phase checkpoint (G1/S, 
CHK1) following exposure to replication inhibitors and gamma radiation [107, 136]. At odds with 
these data, a functioning checkpoint was reported upon exposing pluripotent cells to DNA-
damaging ultraviolet radiation in the C range (UVC) light [137]. Overall, the preponderance of 
evidence indicates that the DNA repair response to the Cas9 system in PSCs is likely to lead to very 
different genomic integrity outcomes in iPSCs compared to other human cell lines.  
 Evidence for DNA repair at off-target sites in iPSCs 
Data regarding the resolution of DNA break induced by Cas9 at off-target sites in PSC vary greatly 
between studies. Whole genome sequencing revealed that Cas9WT showed a highly specific 
cleavage activity in pluripotent cells. Few off-target indels were identified, and none of them 
showed sequence homology with the targeted site or were recurrent between the screened clones 
[88, 89]. However, these studies were carried out on a limited number of clones using a small 
number of targeted sites. Further studies confirmed the absence of nonspecific activity by screening 
for cleavage activity at the most likely predicted off-target sites based on sequence homology to the 
guide RNA sequence [35, 36, 77]. Moreover, upon screening 624 and 717 potential off-target sites 
for 12 sgRNA in 293FT cells and iPSCs, respectively, a total of three sites were identified as being 
associated with two sgRNAs only [87]. On the other hand,  Xu et al. [138] showed clear off-target 
activity at seven out of 10 sites after targeting Intron 2 of the HBB gene, and reported a comparable 
level of off-target activity in 293FT cells and iPSCs. The discrepancy between these studies may be 
related to the sequence of the sgRNA used and the local environment of the targeted locus.  
 In conclusion, although the overall evidence points to possible high-fidelity repair of DSBs in 
PSCs, DSBs have the potential to be repaired via mutagenic repair pathways, with potential 
consequences resulting from off-target activity. The prediction of possible off-target activity is 
challenging, as it can be locus- and sequence (sgRNA) -dependent. Mutagenic end joining is rarely 
associated with SSBs or nicks. Evidence indicates that SSBs can predominantly stimulate HDR, 
albeit with markedly reduced efficiency compared to the DSBs introduced by the wild-type Cas9 
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nuclease [118, 119]. This strategy would be especially relevant for genes such as HBB, which has 
been reported to have a considerable propensity for off-target activity [139]. The number of studies 
that have investigated the validity of different strategies for enhanced specificity of gene correction 
in PSCs, and that have comprehensively analysed on-/off-target activity, is limited. This thesis 
attempts to address some of this deficiency.  
1.4.3 Gene editing in beta-haemoglobinopathies 
A number of studies have successfully used programmable engineered nucleases such as ZFNs, 
TALENs and RGNs for targeted repair of the disease-causing mutation in iPSCs derived from 
patients with monogenic disorders affecting the -globin gene, including sickle cell anaemia [140-
143] and thalassaemia [26, 35, 36, 38, 138, 144]. In contrast to ZFNs and TALENs, the Cas9 
system offers the advantage of a higher targeting efficiency using a cost-effective, flexible and 
versatile system [8].  The genotoxicity analyses in studies that used Cas9-based systems for gene 
correction of the beta thalassaemia mutation are mostly limited to a handful of computationally-
predicted potential off-target sites that bear high sequence homology to the on-target site. A high 
rate of off-target activity (7 sites with mutagenesis out of 10 screened sites) was reported in one of 
those studies [138]. Recent evidence suggests that bioinformatic methods may not accurately 
predict off-target sites, given the complex milieu of the factors determining functional off-target 
sequences [65]. Since precise genome editing is required to realise either the therapeutic or the 
disease-modelling potential of iPSCs, accurate quantification of off-target, as well as on-target 
mutagenesis by Cas9 remains an important issue in the field.  
As discussed above, any endonuclease that generates DSBs is associated with potential off-target 
activity that can compromise the specificity of the system. To reduce the potential for adverse 
mutagenic off-target activity by Cas9, a nickase variant (Cas9n) of Cas9 was developed. Because 
the nickase activity is reported to have low on-target efficiency, a double nicking strategy was 
devised that can improve this by inducing composite nicks [96]. Testing the applicability of the 
paired nickase strategy, which is predicted to have higher specificity compared to the native 
CRISPR-Cas9, for targeted gene correction of the HBB mutation is one of the main objectives of 
this thesis. Because the activity of the endonuclease (nickase or double nickase) and its induced 
HDR depends on different variables that include the targeted locus, gRNA sequence, and type of 
cells used [117, 145-147], it was expected that this strategy would require extensive optimisation. 
Furthermore, the effectiveness and fidelity of this system can also be influenced by the choice of 
nick sites relative to the mutation site or the insertion site [96, 145]. For instance, the design 
strategy can influence the occurrence of insertions/deletions at the targeted site, since the 
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continuous activity of the nuclease is likely to reduce the corrective editing rate [145]. Although the 
study [145] has suggested that physical separation of the guide pair by an insert can attenuate 
undesired on-target mutation following gene correction, this strategy has not been evaluated in the 
context of correcting a point mutation. Furthermore, testing of an alternative strategy that introduces 
a silent mutation designed to prevent repetitive cleavage cycles at the corrected allele was also 
carried out.  
 CRISPR/Cas9-mediated HBB activation 
Following gene correction in disease iPSCs, validation of the restoration of gene function is 
essential. However, if the gene is silent in iPSCs, directed differentiation to specialised cells that 
express the gene of interest is required. In the case of the haemoglobinopathies, this presents a 
challenge since little expression of either the -globin RNA transcript or protein has been reported 
following differentiation of pluripotent stem cells into the erythroid lineage. Furthermore, PSCs 
display defective haemoglobin switching, with incomplete erythrocyte maturation and dominant 
expression of the embryonic-foetal hemoglobin phenotype [148-152]. A low levels of -globin 
switching have recently been reported [143, 153]. This was partially attributed to the use of blood-
derived iPSCs that may have an improved differentiation potential towards the haematopoietic 
lineage because of epigenetic memory. Although, a recent study has shown otherwise [154]. To 
overcome this obstacle, Trakarnsanga et al. [155] deployed a strategy whereby erythroid cells 
derived from iPSCs were transduced with two developmental regulators of haemoglobin switching, 
KLF1 and BCL11A, and this was found to induce an adult level of -globin. Alternatively, DNA 
manipulation via null variants of RGN fused with an effector (activators, CRISPRa), could be used 
to facilitate the modulation of gene output, interrogation of biological processes and dissection of 
regulatory elements in mammalian cells without cleaving or inducing a mutation in the genome [56, 
156, 157]. In this thesis, this approach was explored in beta thalassaemia iPSCs. 
1.5.1 CRISPRa-platforms for gene activation 
Activation of a gene can be stimulated by various mechanisms. Activation can be mediated by 
recruitment of transcription factors or by epigenetic factors that facilitate forced DNA looping 
and/or recruitment of histone modifiers [156, 158]. The potent transcriptional activator domain 
(TAD) of VP16 (virus protein 16 from herpes simplex virus-1) was used in initial Cas9 studies [79, 
159]. The activator domain facilitates the assembly of the preinitiation complex at the promoter 
region of genes and thus upregulates gene expression. Tandem repeats of VP16(n) (TAD) such as 
VP48 (n=3), VP64 (n=4), and VP160 (n=10) are commonly fused to a DNA binding domain in 
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order to target the activator to the gene of interest and promote its transcription [156]. VP96 (n=6) 
and VP192 (n=12) have been used infrequently [160]. ZFN, TALEN and Cas9 systems attached to 
such tandem VP16 repeats have been successfully used for transcriptional activation of various 
endogenous genes [79, 161, 162]. The Cas9 system has the additional advantage that it permits 
multiplexing, achievable by co-expression of multiple gRNAs. Targeted transcriptional activation 
was successfully achieved by appending p65 [159] or VP16(n) [79, 163, 164] to the inactive Cas9 
protein. VP16(n) was used together with  multiple sgRNAs to direct the activation complex to the 
proximal promoter region of various targeted loci. Further, improved efficiency was achieved 
through recruitment of additional effectors such as the NF-κΒ, other hetero-effector domains or 
aptamers (see below) [165, 166]. To date, the Cas9-based system for gene activation can be broadly 
divided into two main classes depending on the nuclease activity of the Cas9 protein: 
The first class involves the use of the nuclease-dead Cas9 (dCas9) which is devoid of 
endonucleolytic activity. Nuclease null Cas9 can be obtained by inactivating both the catalytic 
domains (RuvC and HNH domains) of the enzyme [167]. The null variant retains its DNA binding 
ability which facilitates targeting to specific DNA sites. This modified protein is combined with 
engineered synthetic transcription factors to form a fusion protein product that is capable of 
activating the targeted genes. Significant activation of gene was achieved through:  
a) A single sgRNA (singleplex) coupled with: (1) A potent engineered chimeric or hetero-
activator domain such as dCas9-VP64-p65-Rta, tripartite activator [166], (2) the synergistic 
activation mediator that comprises VP64 bound to dCas9 and a hetero-effector domain 
MS2–p65–HSF1 bound to an engineered aptamer-modified sgRNA [165] and the SunTag 
array, which facilitated the recruitment of multiple copies of VP64 to the targeted site [168]. 
b) Multiple sgRNAs used in conjunction with VP16(n) (homo-activation domain) system. 
Multiplexing was used for tiling the proximal promoter region of the targeted gene. Tiling 
enhanced the low efficiency of gene activation as compared to a single guide [79, 163, 164]. 
The second class employs a shortened sgRNA in conjunction with an active Cas9 nuclease. The 
nuclease activity is attenuated by reducing the length of the targeted sequence to 14–15 bp while 
activation is achieved by appending the effector to either the ‘dead sgRNA’ [169] or to Cas9 
nuclease [170]. Dahlman et al. [169] achieved 10,000-fold activation for HBG1/G2 with Cas9-
sgRNA-MS2:P65:HSF1and Kiani et al. [170] reported 40 per cent of the expression level observed 
with dCas9-VPR-sgRNA (14nt) compared to full-length (N20) guide. 
Although using hetero-effector domains can mediate efficient gene activation with a single guide, 
using a VP16(n) system with multiple sgRNA may have the advantage of less off-target activation. 
In fact, using a single guide in conjunction with the dCas9-VP16(n) system was shown to have a 
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poor targeted activation efficiency unless it was coupled with tiling across the targeted region using 
multiple guides [79, 164]. Additionally, a single sgRNA used in conjunction with a potent 
transcriptional activation may cause off-target activity, as sgRNA has been demonstrated to bind to 
multiple genomic sites [95]. On the other hand, interrogation of a biological process that requires 
targeting of multiple genes or using a screening library would clearly benefit from an efficient 
system that requires only a single guide. More importantly, Cas9-mediated activation is not 
restricted by the chromatin state of the targeted locus [79]. Therefore, it was considered that this 
strategy had the potential to enable the assessment of the functionality of the corrected -globin 
gene in the absence of erythroid differentiation. Such recruitment of transcription factors to the 
proximal promoter region of the -globin gene has, to our knowledge, not been performed before, 
although targeted demethylation of specific CpGs in the promoter region by a TALE-TET1fusion 
protein was reported to increase HBB gene expression in K562 cells [171]. On the other hand, 
sgRNA-dCas9-mediated delivery of human acetytransferase p300 to the strong enhancer region of 
the -globin region (distal LCR) in HEK293FT with a histone modifier failed to activate HBB 
[172]. Instead, variable levels of upregulation of HBD, HBG, and HBE were observed. In this study, 
activation of the HBB locus with the CRISPR/Cas9 system in iPSCs was achieved by recruiting 
transcription factors using the VP16(n) system.    
 Project goals  
The recent explosive advances in genome engineering have provided powerful new tools that not 
only allow site-specific gene correction, but also, potentially, gene correction in vivo. A proof of 
concept of the latter was recently reported using a mouse model of Duchenne muscular dystrophy in 
three different studies [173-175]. However, in order to realise their full potential there is a need to 
explore and address the major challenges attached to the currently available genome editing tools. 
The establishment of efficient and highly specific gene correction strategies is one important hurdle 
to overcome. Secondly, the fidelity and off- and on-target effects of such strategies need to be 
carefully evaluated.   
The above discussion highlights evidence that PSCs may have a different on- /off-target profile 
compared to other cell types due to their unique characteristics. Indeed, review of the major repair 
pathways that are stimulated in response to DNA breaks indicates that Cas9-induced DNA damage 
can be repaired through multiple pathways that favour error-free modifications in PSCs. Based on 
the enhanced capacity of PSCs for repair and their increased sensitivity to apoptosis, it was 
reasoned that PSCs may have a better potential for either accurate repair or the removal of cells 
with altered genomes through apoptosis. In this study, it is hypothesised that strategies that convert 
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DSBs into SSBs, such as a DN strategy, would be more advantageous for precise modification in 
PSCs. As the efficiency of gene correction is influenced by various factors that include the strategy 
design, it was further hypothesised that preventing the iterative cycle of Cas9 activity by either 
separation of the guide pair that targets the locus of interest, or by introducing a synonymous SNP 
in the PAM motif, would be effective in limiting on-target mutagenesis. A further aim was to assess 
the applicability of Cas9 variants for stimulating gene expression of the inactive -globin locus in 
iPSCs and to explore the potential of this system for modelling the RNA processing defect of the 
HBB gene in beta thalassaemia and determine whether this was corrected following restoration of 
the wild type allele. 
To address these hypotheses, this study aimed to: 
1) Generate footprint-free iPSCs from fibroblasts with the beta thalassaemia mutation; 
2) Assess the applicability and efficiency of paired nickase strategy to correct the disease-
causing mutation; 
3) Evaluate the effectiveness and fidelity of two different design strategies for corrective gene 
targeting in iPSCs; 
4) Explore the applicability of the CRISPRa systems for inducing HBB transcription activation; 
and 
5) Validate the functionality of the corrected gene in terms of expression of the corrected -
globin gene using CRISPR-based technology. 
  
26 
 
 
 
 
 
 
CHAPTER II: 
MATERIALS AND METHODS 
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2 MATERIALS AND METHODS 
 Establishment of primary cell cultures 
Dermal skin punch biopsies (3 mm2) were obtained from three patients homozygous for a beta 
thalassaemia mutation and from one normal control. All primary samples were collected from 
donors by a trained physician after obtaining informed consent. The -globin gene mutation was 
confirmed using the -globin strip assay MED kit, from Vienna Labs, according to the 
manufacturer’s protocol. Briefly, the DNA was extracted from blood cells and used to amplify a 
specific region of the -globin gene in a single multiplex PCR. The biotinylated amplicons were 
hybridised to an array of probes immobilised on a membrane test strip, allowing the detection of 
mutant or wild type alleles by a visible enzymatic colour reaction. Two beta thalassaemic patients 
were siblings with a splice junction mutation (IVSII-1 G>A) that abolishes -globin chain synthesis 
(beta0) (Figure 2-1). The third patient had another type of splicing mutation that results in a severe 
decrease of -globin protein synthesis (beta+) (IVSI-110 G>A) (Figure 2-1).  
Fibroblast cultures were established from patient and control samples using the explant outgrowth 
method as described by Raya et al. [176] with minor modifications. Briefly, a scalpel was used to 
finely dice the skin punch biopsies. Small pieces were placed in a 60 mm diameter tissue culture 
plate, covered with a cover slip and cultured in a fibroblast medium consisting of Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, http://www.invitrogen.com) 
supplemented with 10 per cent heat-inactivated foetal bovine serum (HI-FBS), 1x sodium pyruvate, 
2 mM Glutamax, 50 U ml-1 penicillin and 50 mg ml− 1 streptomycin. Fibroblast outgrowths were 
passaged with TrypLE and expanded for two passages before cryopreservation at -80oC in a 
freezing medium that consisted of 80% FBS, 10 per cent complete DMEM and 10 per cent DMSO. 
 
Figure 2-1: Mutations leading to aberrant β-globin mRNA splicing in certain cases of beta 
thalassaemia. IVSI-110 leads to the formation of a new acceptor splice site whereas IVSII-1 
abolishes the splice donor site. 
 Maintenance of cell cultures 
Human embryonic kidney (HEK) 293FT cells (Life Technologies) were maintained in DMEM 
medium supplemented with 10 per cent FBS, 0.1 mM MEM non-essential amino acids, and 1 mM 
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sodium pyruvate. Cells were passaged every two days using TrypLE.  Pluripotent stem cells were 
either maintained on mouse embryonic fibroblast (MEF) feeder cells in KSR-hESC culture medium 
(DMEM Ham’s F-12 medium, 20% Knockout Serum Replacement, 1 per cent non-essential amino 
acids, 2 mM L-glutamine, 0.1 mM beta-mercaptoethanol, and 100 ng/ml basic fibroblast growth 
factor (all from Gibco, except for bFGF, which was from Invitrogen)) or on ECM Gel (from Sigma) 
in MEF-conditioned KSR-hESC medium, at 37°C with 5 per cent CO2. Subculture was performed 
on Day 7 using manual passaging of clones. 
 Derivation of iPSCs 
Reprogramming of fibroblasts into iPSCs was carried out as described by Yu et al. [45] using a 
total of 10µg of total plasmid from two different combinations of episomal vectors that expressed 
OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4, and SV40LT (plasmids were a gift from James 
Thomson, Combination 4; plasmid#20924: pEP4 E02S CK2M EN2L (7.3µg) and plasmid#20927: 
pEP4 E02S ET2K (Figure 2-2.A), and Combination 19; plasmid#20925: pEP4 E02S EN2K (3µg), 
plasmid#20927:pEP4 E02S ET2K (3µg) and plasmid#20926: pCEP4-M2L (2µg) (Figure 2-2.B) 
[45]. Clones were picked between Days 25-30 after transfection with the plasmids, screened for 
TRA-1-60 immunoreactivity and expanded for further analysis. After derivation, pluripotent cells 
were either maintained on MEFs in KSR-hESC culture medium or on ECM Gel in MEF-
conditioned KSR-hESC medium as described above. 
 Immunofluorescence assays 
The antibodies used were OCT4 (Millipore, MAB4401), NANOG (Cell Signalling, D73G4) TRA-
1-60 (Millipore, MAB4360), TRA-1-80 (Millipore, MAB4381), smooth muscle actin (Millipore, 
CBL171), alpha-fetoprotein (Millipore, 2004189) and nestin (Millipore, ABD69). Cells were either 
grown on chamber slides or coverslips. Cells were fixed in 4 per cent paraformaldehyde for 15 
minutes at room temperature before blocking with 5 per cent goat serum in 1X PBS. For 
intracellular or nuclear proteins, 0.2 per cent Triton X-100 was first used to permeabilise the cells at 
room temperature for 10 minutes before blocking with 5 per cent goat serum in 1X PBS. The 
blocked cells were incubated overnight at 40C with the primary antibody. This was followed by 
incubation with the appropriate secondary antibody at a 1:1,000 dilution. Slides were mounted with 
ProLong® Gold antifade mountant with DAPI (4',6-diamidino-2-phenylindole) to enable 
visualisation of the nuclei. An Olympus IX51 fluorescence microscope (Olympus, Tokyo, Japan, 
http://www.olympus-global.com) and Q-Capture Pro v6.0 software were used for image analysis 
and documentation. 
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Figure 2-2: Schematic diagram illustrating the episomal plasmids in Combination 4 or 
Combination 19 used in fibroblasts reprogramming. (A) Combination 4: OSKMNL and OSTK-
expressing plasmid. (B) Combination 19: OSTK, OSNK, and ML-expressing plasmid.  
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 Karyotype analysis 
Karyotype analysis (using standard G-banding) was carried out by Sullivan-Nicolaides Pathology 
(Taringa, Queensland, Australia, http://www.snp.com.au) to assess structural and numerical 
chromosomal abnormalities.  
 Functional assays of pluripotency 
Standard in vivo (teratoma) and in vitro (embryoid body, EB) assays were used to assess the ability 
of iPSCs to differentiate into all three germ lineages. To generate EBs, mechanical dissociation was 
used to harvest clumps of cells. The clumps were suspended in hESC medium without bFGF on a 
low-attachment plate, to allow the cells to aggregate into EBs, and cultured for 20 days. The 
medium was changed every other day. Subsequently, EBs were either lysed in TRIzol for RNA 
extraction or dissociated with TrypLE and transferred to gelatin-coated wells for immunostaining. 
For teratoma assays, iPSCs were grown on MEFs and sent to StemCore (StemCore, Australian 
Stem Cell Centre, St Lucia, Queensland, Australia) for injection into NOD/SCID mice as per 
standard protocols. Injections were performed in duplicate for each iPSC clone. After eight weeks, 
teratomas were paraffin-embedded and sections stained with hematoxylin and eosin and examined 
for the presence of tissues representing the three germ layers. 
 Vector construction 
2.7.1 The RGN plasmid 
Single expression vectors for both a chimeric single gRNA driven by the U6 promoter and a human 
codon-optimised Cas9 driven by the CBh promoter [Cas9WT: pSpCas9(BB)-2A-GFP (PX458) 
(Addgene plasmid # 48138)  or pSpCas9(BB)-2A-Puro (PX459) (Addgene plasmid # 48139) and 
Cas9n: pSpCas9n(BB)-2A-GFP (PX461) (Addgene plasmid # 48140) or pSpCas9n(BB)-2A-Puro 
(PX462) (Addgene plasmid # 48141, gift from Feng Zhang)] were used [177]. Guide RNA-
expressing vectors were constructed as outlined in Ran et al. [177], with slight modifications. 
Briefly, gRNA sequences with a sequence pattern GN19NGG encoding the targeted sequences 
(Table 2-1) were designed using the online CRISPR design tool (http://tools.genome-
engineering.org) [58]. A guanine residue was appended at the beginning of the gRNA sequence 
when the genomic sequence did not contain one. Complementary oligonucleotide pairs were 
ordered from Sigma. The annealed oligos formed overhangs compatible with ligation into the BbsI-
digested CRISPR-Cas9 plasmid backbone. The ligated vectors were transformed into competent 
cells and plated on agar plates containing carbenicillin (50 g/ml). Three clones were picked, 
inoculated into LB broth with 50 g/ml carbenicillin and incubated overnight at 37C on an orbital 
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shaker. The plasmid was extracted using the NucleoBond Xtra EF Kit (Macherey-Nagel). The 
presence of the insert was detected by PCR screening using the U6 forward primer and the 
complementary strand of sgRNA as a reverse primer. The correct insert sequence was further 
verified by Sanger sequencing. 
Table 2-1: Target sequences for CRISPR/Cas9. RNA guide sequences used either to induce 
DNA strand break or to activate the targeted gene. 
 Gene target Location gRNA Guide sequence GC% G 
DNA 
break: 
Cas9 
/Cas9n 
HBB ExonII/ 
IntronII 
1 AGCTCACTCAGTGTGGCAA 52.6 5 
3 GAACTTCAGGGTGAGTCTA 47.4 6 
4 AACTTAACCATAGAAAAGA 26.3 2 
5 TAGGAAGGGGATAAGTAAC 42.1 7 
6 AACAGGGTACAGTTTAGAA 36.8 5 
7 ACTTAACCATAGAAAAGAA 26.3 2 
8 TAAGTTCATGTCATAGGAA 31.6 4 
9 ACGAATGATTGCATCAGTG 42.1 5 
 
CRISPRa Gene target Location gRNA         Guide sequence                Position relative to TSS 
Gene 
activation: 
dCas9-
VP16(n) 
HBG1/HBG2 Proximal 
promoter 
1 GCTAGGGATGAAGAATAAA -26 * 
2 TTGACCAATAGCCTTGACA -101 * 
3 TGCAAATATCTGTCTGAAA -163 * 
4 AAATTAGCAGTATCCTCTT -209 * 
HBB 1 GGTTGGCCAATCTACTCCC -64  
2 CCTGTGGAGCCACACCCTA -84  
3 CCAAGAGATATATCTTAGA -189  
4 AGGGCTGGGCATAAAAGTC -23  
5 CCAATCTACTCCCAGGAGC -58  
6 TCACTTAGACCTCACCCTG -99  
7 CAATTTGTACTGATGGTAT -212  
8 CCCTGTGGAGCCACACCCT -85  
* Perez-Pinera et al. [79] 
2.7.2 The CRISPRa plasmid 
Gene activation was carried with vectors that simultaneously expressed the sgRNA and an inactive 
nuclease (dCas9) fused to a tandem repeat of the transactivation domain (TD) of the virion protein 
(herpes simplex virus) VP16 (four in VP64 and 10 in VP160). Cloning of the sgRNAs (Table 2-1) 
into the vectors was performed as described in the previous section, except that carbenicillin was 
replaced with kanamycin selection (at 50 g/ml) for plasmid #48226. Plasmids used for transient 
transfections included pAC152-dual-dCas9VP64-sgExpression (sgRNA-dCas9VP64; Addgene 
plasmid #48238), pAC154-dual-dCas9VP160-sgExpression, (sgRNA-dCas9VP160 Addgene 
plasmid #48240), and pAC94-pmax-dCas9VP160-2A-puro (Addgene plasmid #48226). Plasmids 
were a gift from Prof. Rudolf Jaenisch [164]. (Vector#48226 was used during optimisation as 
detailed in the Results section).  
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2.7.3 The donor vector 
To construct the donor vector for targeted correction, a 2,619 bp insert carrying a PGKpuroΔtk 
double selection cassette flanked by the ITR fragment was excised from the pMCS-AAT-
PB:PGKpuroΔtk plasmid (kindly provided by Dr. Allan Bradley from Wellcome Trust Sanger 
  
 
Figure 2-3: Schematic for cloning the PGKpuro-Δtk double selection cassette into the 
synthesised vector with the 5' and 3' homology arms. 
 
Institute, Cambridge, UK) [178] using NotI and NheI, and cloned into a digested donor plasmid 
 (synthesised by GenScript USA Inc, http://www.genscript.com) using the same enzymes (Figure 
2-3). The fragment from the donor plasmid carried the 5′ and 3′ homology arms (approximately 1 
kb each) and a segment of PB inverted terminal repeats to complement the fragment isolated from 
the pMCS-AAT-PB:PGKpuroΔtk plasmid. Isogenic sequences (to the parental beta thalassaemia-
iPSCs) were used to synthesise homology arms (Genscript). Primers used to sequence the HBB 
locus are shown in Table 2-6.Three base substitutions and two SNPs, as well as the substitution of 
the disease-causing mutation, were introduced in the donor template sequence (Figure 4-6). See 
Section 4.2.3.1 for further details on the introduced SNP. 
 Plasmid propagation, purification and quantification 
Ligated plasmid was transformed into chemically competent bacterial cells according to 
manufacturer’s instruction (DHα: Invitrogen or Bioblue: Bioline) and plated on agar plates 
containing the appropriate antibiotic. Clones were picked after 24 hrs, inoculated into 100 ml LB 
broth medium supplemented with the appropriate antibiotic and incubated overnight at 37C on an 
orbital shaker (200rpm). The plasmid was extracted using the NucleoBond Xtra EF Kit (Macherey-
Nagel). The plasmid was eluted using a minimum volume of elution buffer to obtain a final 
concentration of >1µg/µl. The plasmid yield and 260/280 ratios were quantified using a NanoDrop 
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1000 spectrophotometer (NanoDrop, Wilmington, DE, http://www.nanodrop.com). The presence of 
the insert was confirmed by sequencing.  
 Transfections of CRISPR/Cas9 plasmid  
Various method are currently available to introduce DNA plasmid into cells. The method of choice 
depend on the cell type and the objective of the transfection [179]. To deliver plasmid expressing 
CRISPR components into cells, nucleofection or lipid-based transfection are commonly used [78, 
94, 177, 180]. However, optimization of experimental conditions for both nucleofection and 
lipofection are needed in order to balance cell viability and efficiency of transfection. Optimization 
are further discussed in chapter 4 and 5 
2.9.1 RGN 
To induce DNA breaks in HEK293FT, the cells were cultured as previously described and seeded 
into a 12-well plate (about 130,000/well) one day prior to transfection. Unless stated otherwise, 1 
g of the dual sgRNA-Cas9-expressing vector or 500 ng of each of the pair of nickase plasmids was 
transiently transfected into 293FT cells using Lipofectamine LTX with the PLUS Reagent 
(Invitrogen) according to the manufacturer’s instructions. Medium was replaced after 24 hours.  
Nucleofection of iPSCs was carried out as described in Yang et al. [78]. Briefly, before 
nucleofection, cells were treated with 10 μM Y-27632 ROCK inhibitor for at least two hours. 2x 
106 iPSCs were collected by trypsinisation and resuspended in 20 l of Nucleofector mix that 
included P3 and supplement solutions (4D Nucleofector, Lonza, http://www.lonza.com). The mix 
was transferred to one well of a nucleovette strip that contained an equivalent of 1.5-2 g of the 
RGN expression plasmid or an equal mixture of plasmids for paired nickase (in a maximum volume 
of 2 µl). The cells were nucleofected using the CB150 programme. For HDR, 500 ng of the donor 
vector was added to the suspension mixture. Nucleofected cells were plated in one well of a 6-well 
plate on feeders in KSR-hESC medium supplemented with 10 μM Y-27632 ROCK. ROCK 
inhibitor was removed from the medium after 24 hours. Puromycin selection was started after 72 
hours post-transfection, using 1 µg/ml for three days, then maintained at 0.5 µg/ml for a minimum 
of 10 Days. 
2.9.2 CRISPRa 
HEK 293FT cells were cultured and transfected as previously described. Optimization of 
transfection conditions was performed as described in the Results section. In order to optimise 
transfection conditions, parameters including the total pDNA (amount of dCas9+gRNA), the 
amount of vectors carrying each sgRNA, and the charge ratio (Lipofectamine/DNA) were tested for 
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HBG using a previously published gRNA combinations [79]. Subsequently, optimised conditions 
were used to screen for the sgRNA mixture that displayed most robust activation of the HBB gene 
in HEK293FT. Multiple combinations were selected for further analysis in iPSCs. Nucleofection of 
iPSCs was carried using a P3 Primary Cell 4D-Nucleofector X Kit S (for 4D Nucleofector, Lonza, 
http://www.lonza.com). A total amount of 1.2-2 g of dCas9-based activation vectors was used. 
This amount was equally divided between multiple vectors targeting different sites in the proximal 
promoter region of the HBB gene. 
 Testing the functionality of single or paired guide RNAs in HEK293FT cells using the 
Surveyor assay 
Cells transfected with the specified vector or combination of vectors were collected by 
trypsinisation after 72 hours and the Surveyor assay was carried as descried by Ran et al. [177]. 
Briefly, DNA was extracted and amplicons that spanned the guide binding site were generated by 
PCR using various Surveyor primer pairs (Table 2-2).  
Table 2-2: Primer sequences used for Surveyor assays 
Primer name  Sequence Amplicon size 
S.V1 F GAGACTTCCACACTGATGCAAT 658 
 R AAGTCAGGGCAGAGCCATCTAT  
S.V2 F AGTAATGTACTAGGCAGACTGTG  616 
 R TGGGTTTCTGATAGGCACTGAC   
S.V3 F AAAGCAGAATGGTAGCTGGATTGT 969 
 R TACCCTTGGACCCAGAGGTTCT  
 
Figure 2-4: Schematics illustrating the location of the primer binding sites and Cas9 cleavage 
sites for various PCR-amplified products used in Surveyor assay. (A) The binding site for SV1, 
SV2, and SV3 primers.(B, C, and D) The predicted cleavage sites (red triangles) for sgRNA1/3 
and sgRNA4/5 in PCR fragments generated by using primer pairs (B) SV1, (C) SV2, and (D) 
SV3 that span the targeted site in the β-globin gene. 
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The amplicons were purified using the QIAQuick PCR purification kit (Qiagen). Heteroduplexes 
were formed by subjecting the purified amplicons to heat treatment following by gradual cooling to 
4oC. The normalised solutions were treated with Surveyor nuclease according to manufacturer’s 
instructions. Bands were resolved using 2 per cent agarose gels. Relative band intensity (volume 
intensity) was quantified using Image lab software (Bio-Rad) after subtracting background and 
adjusting the band limits to the band edges [181]. The percentage of indel mutation induced by 
Cas9 was calculated as indicated in Ran et al. [177] using the following formula: 
Indel (%)= 100 x [1-(1-fcut)
1/2 ] where     fcut =       (Sum of band intensity of digested products)  
                                                                  (Sum of band intensity of digested + undigested products) 
 RT-PCR and qRT-PCR expression analyses 
For RNA extraction, cells were lysed in TRIzol reagent (Ambion) followed by purification using 
the PureLink RNA Mini Kit (Ambion). One microgram of RNA was used for reverse transcription 
with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, http://www.bio-rad.com) according to 
the manufacturer’s specifications. Amplicons were generated from cDNA samples using PCR 
conditions specified in the next sections. Quantitative RT-PCR (q-PCR) analysis was performed in 
triplicate (or duplicate) using the CFX96 real-time PCR detection system (Bio-Rad) with Ssofast 
evagreen q-PCR mix (Bio-Rad). More than one housekeeping gene was used to normalise gene 
expression: GAPDH, EEA1F1 (eukaryotic translation elongation factor1 alpha1) and ACTB (beta-
actin). Expression data were either reported as relative gene expression (Ct) or fold change 
relative to a control (Ct). The former (Ct) was used when no expression of the gene of interest 
was detected in the control sample (for 40 cycles) in order to identify the combination of sgRNA 
yielding the highest increase in transcript abundance following activation. Sets of primers used to 
amplify the intended locus are listed in Table 2-6. 
 PCR amplification and sequence verification 
Genomic DNA was extracted using the NucleoSpin tissue kit (Macherey-Nagel), or ISOLATE II 
genomic DNA kit from Bioline according to the manufacturer’s instructions, and episomal DNA 
was isolated using the QIAprep spin miniprep kit (Qiagen), according to the manufacturer’s 
instructions. PCR reactions were performed using either Phusion high-fidelity DNA polymerase 
(New England Biolabs) for sequencing of the HBB locus, Herculase II fusion polymerase (Agilent 
Technologies) for sequencing of the targeted clones and for the Surveyor assay (Surveyor Mutation 
36 
 
 
Detection Kits), LongAmp Taq DNA polymerase (New England Biolabs) for the PCR-based 
screening for the targeted integration of the selection cassette, or Scientifix Taq DNA polymerase 
(TDP-500) for screening of the reintegration of the selection cassette. Touchdown PCR was mostly 
used to amplify the specified locus (25-30 cycles) according to the manufacturer’s instructions 
(depending on the Taq polymerase used). Sanger sequencing was used to verify the sequences for 
some samples and plasmids. Sequencing was performed by the Australian Genome Research 
Facility (AGRF, Brisbane node). Primer sequences are shown in Table 2-6. 
2.12.1 PCR-based screening of modifications in iPSC clones 
 Genotyping of puromycin-resistant clones 
Genotyping of puromycin-resistant clones was carried out as described by Yusa [182]. Briefly, cell 
lysate was prepared by cutting a small section from clones, suspending it in water with subsequent 
heat treatment for 10 minutes. This was followed by incubation for 1 hour with proteinase K. Cell 
lysate was used in multiplex PCR (Figure 2-5) in the presence of two sets of primers: one for 
genotyping the right arm and the other for the left arm (Table 2-3). Amplification was carried out 
using LongAmp Taq DNA polymerase as detailed in the Yusa’s [182] protocol. PCR amplicons 
were analyzed on a 1.5% agarose gel. Band pattern was used to screen for the absence or the 
presence of a possible targeting event at one or both alleles. DNA from the parental iPSC clone was 
used a positive control to screen for the unmodified original allele and also served as a negative 
control for the targeted allele.   
 
 
Figure 2-5: The genotyping strategy used to screen for the presence of the targeted allele 
and/or the original alleles in puromycin-resistant clones. Green and red arrows indicate primer 
sets used to screen for the presence of the original allele or targeted modification on the left arm 
and right arm, respectively.  
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Table 2-3: Primer sequences used for PCR-based screening of the left and right arms in 
resistant clones 
Primer name Sequence  
F2 TAGTAATGTACTAGGCAGACTGTG Left arm 
R2 TTGCAGATTAGTCCAGGCAGAAA 
P5* GCGACGGATTCGCGCTATTTAGAAAG 
F1 AAGGCTGAGAGATGCAGGATAAG Right arm 
R1 GTGGAGACAGAGAAGACTCTTGG 
P3* CGTCAATTTTACGCATGATTATCTTTAAC 
Multiplex PCR Targeted allele Original allele 
F1R1P3 1460 bp 1749 bp 
F2R2P5 1486 bp 1688 bp 
*Primers reported in Yusa et al. [182] 
 Screening for random integration 
Screening for on-target and random integration was performed simultaneously on the same cell 
lysate using the same PCR conditions described above. The sets of primers used are listed in Table 
2-4. Samples with positive bands at either arm were excluded from further analysis. 
Table 2-4: Primer sequences used in PCR-based screening for random integration of the 
donor vector 
Primer name Sequence DNA region Expected band size 
M13F97* TCGGTGCGGGCCTCTTCGCTATTAC Left arm 1,141 bp 
T3.1 GCGTCCCATAGACTCACCCTGAA 
M13R84* ACTCATTAGGCACCCCAGGCTTTAC Right arm 1,892 bp 
PurF* CTGCTGCAACTTACCTCCGGGATG 
*Primers reported in Yusa et al. [182] 
 Heteroduplex mobility assays 
Heteroduplex mobility assays (HMA) were used for allelic alteration screening at on- and off-target 
sites. The screen was carried out in puromycin-resistant clones with HR as described by Zu et al. 
[183], with minor modifications. To screen for on-target mutations, genomic DNA was extracted 
from both parental and puromycin-resistant iPSC clones at the same passage number. PCR 
amplicons for the DNA region flanking the Cas9 targeting sites were amplified from iPSC clones 
(resistant and parental clones) and the donor vector using three sets of primers. The first set was 
used to detect indel in the non-targeted allele, and the other two were used to screen the left and the 
right arms of the targeted allele (Figure 2-6). The primers sequences used are listed in Table 2-5.  
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Table 2-5: Primer sequences used to screen for the presence of allelic modifications in HMA 
 Primer 
name 
Sequence DNA region for 
indel screening 
Expected band 
size 
A. MA233R GTGCTCGGTGCCTTTAGTGAT Original allele 233 bp 
MA233F GCAATCATTCGTCTGTTTCCCATT 
B. P3 CGTCAATTTTACGCATGATTATCTTTAAC Targeted allele 
(right arm) 
130 bp 
MA233F GCAATCATTCGTCTGTTTCCCATT 
C. P5 GCGACGGATTCGCGCTATTTAGAAAG Targeted allele (left 
arm) 
249 bp 
MA233R GTGCTCGGTGCCTTTAGTGAT 
 
PCR products were assessed for the correct size on 2 per cent agarose gel. In order to generate 
heteroduplexes, PCR products from the control sample (BT-iPSCs or donor vector) were mixed 
with products from the tested sample at a ratio of 1:1 and subjected to denaturing and reannealing 
procedures. The annealed products were analysed by electrophoresis using 12 per cent native 
polyacrylamide gels. The gel mixture was prepared using acrylamide-bisacrylamide (29:1, w/w), 1x 
Tris-borate-EDTA (TBE), ammonium persulfate, and tetramethylethylenediamine (TEMED). 
Samples were loaded into wells and subjected to a constant voltage of 120V/cm for ≈2 hours. The 
gel was immersed in diluted SYBER Gold solution for 35 minutes before visualisation using the 
Geldoc XR1 Imaging System (Biorad). The allelic alteration was identified by comparing samples 
to a control homoduplexes. The genotype of selected samples was further validated with Sanger 
sequencing.  
 
Figure 2-6: Strategy for screening for allelic alteration at specific DNA regions using HMA. 
A) PCR amplicons used to screen for possible DNA alterations introduced by the Cas9 nickase at 
the on-target locus in the original allele compared to that from BT-iPSCs. B) Two PCR 
amplicons were used to screen for the targeted allele compared to that from donor vector.  
indicates PCR amplicons with their relative position to the paired nickase used to stimulate the 
gene targeting event. 
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For off-target screens, the same steps as described in the previous section were followed using the 
primer listed in Table 2-6. 
 Excision of the selection cassette 
Excision of the selection cassette was carried by transfecting targeted iPSCs with a 2 µg of a 
plasmid expressing the HA-tagged hyperactive piggyBac transposase (kindly provided by Dr. Allan 
Bradley) using the above-mentioned transfection conditions in iPSCs [184]. FIAU selection was 
ineffective, as demonstrated by the high survival of a negative control (biallelic targeted clones). A 
stepwise enrichment procedure, as shown in Figure 2-7 was adopted. This procedure is detailed in 
the Result section of Chapter IV. Multiplex PCR-screening was carried using the primers listed in 
Table 2-5A. and B to screen for the restoration of the TTAA site and the presence of the targeted 
selection cassette, respectively. 
Absence of reintegration was confirmed in the selected clones using a PCR-based method with a 
primer pair located inside the puromycin selection cassette. 
 
Figure 2-7: Outline of the strategy used to enrich and isolate iPSC clones with a restored 
TTAA site after excision of the cassette. 
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Table 2-6: Primer sequences 
 
Primer name 
 
Sequence band size bp 
Transgene 
     
 
EBNA F TTTTCGCTGCTTGTCCTTTT 883 
PCR/RT-
PCR 
  
R TTCCAACCCGAAATTTGAGA 
  
 
Lin28 
IRES2-
SF 
TGGCTCTCCTCAAGCGTATT 245 
PCR/RT-
PCR 
  
Lin28-
SR 
GCAAACTGCTGGTTGGACAC 
  
 
KLF4 
IRES2-
SF 
TGGCTCTCCTCAAGCGTATT 253 
PCR/RT-
PCR 
  
Klf4-SR GTGGAGAAAGATGGGAGCAG 
  
 
OCT4 
Oct4-
SF1 
AGTGAGAGGCAACCTGGAGA 657 
PCR/RT-
PCR 
  
IRES2-
SR 
AGGAACTGCTTCCTTCACGA 
  
 
NANOG (exo) 
Nanog-
SF2 
CAGAAGGCCTCAGCACCTAC 732 
PCR/RT-
PCR 
  
IRES2-
SR 
AGGAACTGCTTCCTTCACGA 
  
 
GAPDH F GTGTGGCTCCCTTGGGTATATG 351 
PCR/RT-
PCR 
  
R ATACTTCTCATGGTTCACACCCA 
  
 
NANOG (endo) F TTTGGAAGCTGCTGGGGAAG 194 
PCR/RT-
PCR 
  
R GATGGGAGGAGGGGAGAGGA 
  
Selection 
cassette 
PURO F CTGCTGCAACTTACCTCCGGGATG 323 PCR 
  
R CCAATCCTCCCCCTTGCTGTCCTG 
  
EB 
GATA4 F GCGGTGCTTCCAGCAACTCCA 138 q-PCR 
 
R GACATCGCACTGACTGAGAACG 
  
MAP2 F CAGGTGGCGGACGTGTGAAAATTGAGAGTG 186 q-PCR 
 
R CACGCTGGATCTGCCTGGGGACTGTG 
  
PAX6 F CAGCACCAGTGTCTACCAACCA 67 q-PCR 
 
R CAGATGTGAAGGAGGAAACCG 
  
SMA F ACGTGGGTGACGAAGCACAG 135 q-PCR 
 
R GGGGAACACGAAGCTCATTGT 
  
Brachyury-T F TCAGCAAAGTCAAGCTCACCA 102 q-PCR 
 
R CCCCAACTCTCACTATGTGGATT 
  
GAPDH (exon) F GTGGACCTGACCTGCCGTCT 152 q-PCR 
 
R GGAGGAGTGGGTGTCGCTGT 
  
SOX17 F GGCGCAGCAGAATCCAGA 61 q-PCR 
 
R CCACGACTTGCCCAGCAT 
  
 
SOX2 F CCACCTACAGCATGTCCTACTCG 123 q-PCR 
  
R GGGAGGAAGAGGTAACCACAGG 
  
 
OCT4 F CGTGAAGCTGGAGAAGGAGA 91 q-PCR 
  
R CTTGGCAAATTGCTCGAGTT 
  
 
GAPDH F ACCCACTCCTCCACCTTTGAC 100 q-PCR 
  
R TGTTGCTGTAGCCAAATTCGTT 
  
 
EEF1A1 F CCCCAGGACACAGAGACTTT 120 q-PCR 
  
R GCCCATTCTTGGAGATACCA 
  
 
B-Actin F GCCGGGGACCTGACTGACTAC 101 q-PCR 
  
R TTCTCCTTAATGTCACGCACGAT 
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Table 2-6 Continued  
 Primer name  Sequence band size bp 
 HBD F ATCCTGAGAACTTCAGGCTCTT 161 q-PCR 
  R AAACAGTCCAGGATCTCAATGGT   
 HBG F GGACAAGGCTACTATCACAAGC 193 q-PCR 
  R GGAAGTCAGCACCTTCTTGC   
 HBB1 F GGCACCTTTGCCACACTG 132 q-PCR 
  R CACTGGTGGGGTGAATTCTT   
 HBBS F TGCACGTGGATCCTGAGAACT 79 q-PCR 
  R AATTCTTTGCCAAAGTGATGGG   
 HBB3 F CTCATGGCAAGAAAGTGCTCG 181 q-PCR 
  R AATTCTTTGCCAAAGTGATGGG   
 NANOG F TTTGGAAGCTGCTGGGGAAG 194 q-PCR 
  R GATGGGAGGAGGGGAGAGGA   
     
Off-target analysis Primer name  Sequence Band size bp 
sgRNA1 G1-11-S1F F ACTCTCAAAATCCCACTGCTGAA 365 PCR 
 R AGTCTCCTGGTTGTCTACCCAT   
G1-8-S2F F ATCTCTGAGAAGCTCAAGGCTC 335 PCR 
 R AGAACTGAAGGCAGAAGAAGTGT   
G1-4-S3F F GTGTCTGCCTAGACTGTGTTAGA 370 PCR 
 R AGGATCTCAATAGCCCTGAGTG   
G1-1-S4F F CTGGAGCACGCTTTAGACCAG 333 PCR 
 R CCCTGAAATGGCTCCTTAGAGAC   
G1-13-S5F F GAACACGAGTAGGAGTGTTGTG 374 PCR 
 R CCTGGCAAATGAACTGTCACT   
sgRNA3 G3-2-S1F F GGCGCCCTATACTCCATTCTTCA 314 PCR 
 R ACGGTTTCATGCTGGGATTCCATA   
G3-8-S2F F GTACTTGGGCTCCGAGTTTCTG 342 PCR 
 R CACCTCCTTACTTGAAGCAGCA   
G3-6-S3F F GTGTTTGGGTATTTACTCCCCCT 343 PCR 
 R AGGAAAACTGACACAGGAAATGC   
G3-X-S4F F ATGTACATGTCCCACGGCTC 318 PCR 
 R TTCGGCTTGCTAAACACCCTG   
G3-12-S5F F CTTGGCTTTCCTTGCCCTATAC 336 PCR 
 R TGCAATCCAGATTCCATCCTGA   
sgRNA4 G4-8-S1F F CCAATAATGCCCTTCTGGTCTG 330 PCR 
 R ATGCCAACTGTGTAACAAGGAC   
G4-X-S2F F AAATTGCAATGCATGTCCTCACC 372 PCR 
 R CAGGTCGATTCTGGTGGCAAGAT   
G4-2-S3F F GTTTGATTTTAGCCGCAGAAACTG 309 PCR 
 R CGTCATTAATATCTCACAGGCAGAA   
G4-6-S4F F GTATGATTAGCTGAAGGGAGCTGG 337 PCR 
 R GCAAACCAAGCCACAGGAAACT   
G4-12-S5F F TCAATTCTAGAGCACACAGGCT 307 PCR 
 R GCAATGGTCGATCTAAAGCTGC   
sgRNA5 G5-10-S1F F ACCTCAAGCCTTTTCCTGATTCT 327 PCR 
 R TGCTCTGCTGGGATGTAATGAAT   
G5-2-S2F F AGAACCTAATTTCCAAGGGAGCC 339 PCR 
 R CCGAAGAGACTTTGGAATGAAAATC   
G5-5-S3F F CCCTACATGTGACAGGATAGCTG 348 PCR 
 R AGCAGGCATTGCAAGAGATAAA   
G5-14-S4F F CTTCCTGATGAGCCAGTAACCC 327 PCR 
 R TCTTCTCATCAAGAGCACAGGT   
G5-2-S5F F AGTCCGTCTGCTGTAGGAACAC 304 PCR 
 R AACGAAAGGAGCACATCAGAGAT   
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Table 2-6 Continued  
Sequencing HBB 
locus 
     
HBB PCR primers A F ACGGCTGTCATCACTTAGAC 1457 PCR 
 B R AAGAGGTATGAACATGATTAGC   
 C F GTGTACACATATTGACCAAATC 1213 PCR 
 D R CAGATTCCGGGTCACTGTG   
 T3.9F F CCATCACTAAAGGCACCGAGCAC 1324 PCR 
 T3.9R R AGACCTTTTCCCCTCCTACCCCTA   
Sequencing primers T3-ABS-F F CAAAGGACTCAAAGAACCTCT   
 T3ABS-R R GAGAAGATATGCTTAGAACCGA   
 ABS F F TAATGTACTAGGCAGACTGTG   
 ABS R R CAGAGCCATCTATTGCTTACA   
 ABS2 F F GACTCAGAATAATCCAGCCTT   
 ABS2 R R CATGTCATAGGAAGGGGATAAG   
 CDS F F TTCATGAGGACAGCTAAAACAA   
 CDS R R GTGATAATTTCTGGGTTAAGGC   
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CHAPTER III: 
THE GENERATION OF TRANSGENE-FREE INDUCED PLURIPOTENT 
STEM CELLS WITH A BETA THALASSAEMIA MUTATION 
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3 THE GENERATION OF TRANSGENE-FREE INDUCED PLURIPOTENT STEM CELLS WITH A BETA 
THALASSAEMIA MUTATION 
 Introduction 
Beta thalassaemia is an umbrella term for a group of inherited blood disorders that are characterised 
by an absence, reduction, or otherwise abnormal synthesis of the haemoglobin subunit beta (-
globin chain, HBB gene), mostly brought about by point mutations, or small deletions, in the -
globin gene causing defective transcription, splicing or translation of -globin mRNA. Beta 
thalassaemia is a relatively frequent genetic disorder, with an estimated 5 percent of the world 
population being carriers [1]. Patients with beta thalassaemia major are homozygotes or compound 
heterozygotes for a severe type of HBB mutation and display severe anaemia and 
hepatosplenomegaly. They require regular blood transfusions as a supportive therapy, with the only 
currently available effective treatment being an allogenic HSC transplant. Given the incidence of 
the disease, and the shortage of suitable HLA-matched donors, engraftable autologous cells derived 
by ex vivo manipulation of the patient’s HSCs, through the directed differentiation of gene-edited 
patient-specific iPSCs, or the direct conversion of gene-edited somatic cells into HSCs, offers an 
alternative de novo source of cells with the potential for clinical applications [24].  
Although recent evidence has suggested that ex vivo targeted gene correction in HSCs is achievable 
[6], this approach limits the number of cells available for gene therapy due to the inefficiency of 
gene targeting in these cells and their poor expandability in vitro; thus, a successful therapeutic 
effect can only be achieved through introduction of a gene that confers a survival advantage [5, 8]. 
Conversely, iPSCs present a practical alternative that allows careful verification, enrichment and 
expansion of gene-edited cells with subsequent haematopoietic differentiation capacity. Provided 
engraftable HSCs can be generated from iPSCs, this approach may allow for the generation of 
therapeutic levels of isogenic HSCs. However, to be clinically relevant, the genetic defect should be 
precisely corrected, preferably using non-integrating methodologies so as to maintain the integrity 
of the genome.  
Several integration-free methods are available for the derivation of footprint-free iPSCs. Footprint-
free methods can involve the use of a plasmid, minicircles, episomes, mRNA or the Sendai-virus to 
achieve transient ectopic expression of reprogramming factors [18]. Alternatively, cells can be 
transduced with the reprogramming factors in the protein form [42, 43, 185]. Episomal-based 
reprogramming of somatic cells has been reported to be a more reliable method for iPSC derivation 
from fibroblasts in comparison with mRNA, result in a rapid and passive loss of the transfected 
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vector in comparison to Sendai virus-based reprogramming, and more importantly, iPSCs may be 
more appropriate for potential therapeutic use [186].    
 Therefore, this study aimed to generate iPSCs from beta thalassaemia patients using episomal-
based reprogramming. While the generation of iPSCs from the fibroblasts of beta thalassaemia 
individual [26-28, 35-37] and amniotic fluids cells [38] has previously been reported [28, 187] he 
production of footprint-free iPSCs from fibroblasts derived from patients with the Mediterranean 
mutation IVSII-1(G>A) of beta thalassaemia has not been reported to date (Table1-1). IVSII-
1(G>A) is a splice junction mutation that affects the 5′ splice site leading to a severe form of beta 
thalassaemia in the homozygous state. Restoration of the normal splice site in gene-edited cells can 
be verified by assessing the formation of the normally spliced product (mRNA) generated upon 
HBB gene activation.  
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 Results and discussion 
3.2.1 Establishment of fibroblast cultures and derivation of iPSCs 
All primary samples were collected from donors by a trained physician after obtaining informed 
consent. Punch biopsies were acquired from the inner arm of three patients homozygous for beta 
thalassaemia mutations: siblings with the IVSII-1 (G>A) mutation (a 9-year old female and a 10-
year old male, referred to as T3 and T2, respectively) and one patient with the IVSI-110 (G>A) 
mutation (16-year old male, T1), as well as from a control individual (29-year old male, N4). While 
IVSII-1 (G>A) results in the absence of -globin production (beta0 thalassaemia), the IVSI-110 
(G>A) mutation leads to a substantial reduction in the synthesis of -globin (beta+ thalassaemia). 
The former mutation affects the donor splice site abolishing normal splicing at this location [188], 
while the latter introduces an alternative acceptor splice site that results in a significant reduction in 
the correctly spliced product [189]. Fibroblast cultures were established using the explant outgrowth 
method as described by Raya et al. [176] with minor modifications. At Days 4-5 of culture, cells 
with a morphology consistent with that of keratinocytes were observed in some explants (Figure 
3-1.A, B, C and D). Fibroblasts emerged later and dominated the culture surface except in the small 
area where keratinocytes emerged from the skin specimen (Figure 3-1.C and D). Keratinocytes 
stopped proliferating, presumably due to unfavourable culture conditions, as the fibroblasts were 
cultured in a medium with a high calcium concentration and in the absence of keratinocyte growth 
factors. Keratinocytes became more phase-dense and remained on the culture plates after the 
fibroblasts were passaged with TrypLE. After passaging, the morphology of the cells was almost 
entirely consistent with fibroblasts (Figure 3-1.F). Primary fibroblast cultures were verified to be 
free of transmissible pathogens (including mycoplasma) and cryopreserved at Passage 2. The 
presence of the mutation was confirmed in the fibroblasts derived from the three beta thalassaemia 
patients using the -globin strip assay MED kit (Vienna Lab) (Figure 3-1.G). 
Next, fibroblasts were transfected with episomal plasmids as described by Yu et al. [45]. 
Transfection was carried-out using either Combination 4 (C4) or Combination 19 (C19). C4 is 
composed of two vectors: the first vector expressed OCT4, SOX2, KLF4, C-MYC, NANOG, and 
LIN28 (OSKMNL) under either the strong elongation factor alpha (EF) or cytomegalovirus 
(CMV) promoter, and the second expressed OCT4, SOX2, SV40LT and KLF4  (OSTK) under the 
EF1 promoter, whereas C19 is composed of three vectors that express the same set of transgenes 
(OSTK, OSNK, ML) except for differences in their arrangement and the type of promoter used for 
some of the transgenes (Figure 2-2). Transfected cells were seeded onto irradiated MEF feeders and 
adapted from fibroblast medium to hESC medium between Days 4 and 6. From Day 9 onwards, 
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MEF-conditioned medium supplemented with 100 ng/ml b-FGF was used until around Day 25-30 
(Figure 3-2.A) [190]. 
 
 
 
Figure 3-1: Establishment of fibroblast cultures and characterisation of the -globin gene 
mutation using reverse hybridisation. Skin punch biopsies were sliced into small pieces, 
covered with cover slips and cultured in a fibroblast medium. (A, B, C, D and E) Two different 
types of cells were observed between Days 4–7; the first were cells with a morphology consistent 
with that of keratinocytes (red arrows) while the second were cells with a morphology consistent 
with that of fibroblasts (black arrows). (F) Fibroblast cells became dominant in subsequent 
passages. (G) Beta thalassaemic mutations were confirmed in fibroblasts derived from beta 
thalassaemia patients using reverse hybridisation: 1) homozygous for IVSI-110 G>A, 2) normal 
control, 3 and 4) homozygous for IVII-1 G>A. 
Emerging colonies were picked for further passaging. Colonies with a high nuclear-to-cytoplasmic 
ratio and compact edges were considered as possible iPSC clones. More colonies were obtained 
from the C19 than the C4 combination of episomal vectors (Table 3-1). TRA-160 immunostaining 
was used to discriminate between putative iPSCs and pseudo-iPSCs (Figure 3-2.B). A total of 
11/138 and 19/91 of the screened clones were positive for TRA-160 in cells reprogrammed with the 
C4 and C19 combinations of vectors, respectively (Table 3-1). More iPSC clones were obtained 
when the three-vector combination (C19) was used, which is in agreement with Yu et al.[191]. The 
difference in proportion of iPSC clones generated by different vector combinations was statistically 
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significant (p=0.031, Fisher exact test). This indicate that the type of vector combination used is 
associated with a better rate of reprogramming to pluripotency. 
 
Table 3-1: Number of iPSC clones generated from each patient using C4 and C19.  
  R 1 R2  
 Plasmid combination 4 (C4) Plasmid combination19 (C19) C4 
  Sample 
type 
No. cells 
transfected 
No. 
clones 
picked 
No. 
TR160+ 
clones 
No. cells 
transfected 
No. 
clones 
picked 
No. 
TR160+ 
clones 
No. 
TR160+ 
iPSCs 
No. clones 
for further 
analysis 
1 T1 BT   
IVSI-110 1x10
6
 0 0 1x10
6
 1 0  
0 
2 T2 BT 
IVSII-1 1x10
6
 65 0 1x10
6
 30 2  
2(C19) 
3 T3 BT 
IVSII-1 1x10
6
 24 1 6x10
5
 30 5 1 
3(C19), 
2(C4) 
4 N4 Control 
1x10
6
 49 10 6x10
5
 30 12  
3(C19) 
 Total 
 
138 11 
 
91 19 
 
10 
R1: transfection 1, R2: transfection 2 
 
Figure 3-2: Timeline for iPSCs derivation from primary fibroblasts. (A) Colonies were 
observed on Day 10 after transfection and picked around Day 25–30. Rare colonies assumed an 
iPSC-like morphology before passaging, while the majority required passaging before they 
appeared to be characteristic of iPSCs. Most of the iPSCs generated during the course of the 
experiment for this study emerged between Passages 1 and 2. (B) TRA-160 staining was used to 
discriminate between putative iPSCs (b) and pseudo-iPSCs (c) and (d). 
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While these data show that the generation of footprint-free beta thalassaemia iPSCs from fibroblasts 
is possible, some patient fibroblast cultures were more refractory to reprogramming than others. 
This may be related to the age of the individual, the quality of the biopsy, genetic or epigenetic 
variability or may require further optimisation of the reprogramming conditions (e.g. increasing the 
amount of SV40LT and/or use L-MYC). For example fibroblasts from Patient T1, with the IVSI-110 
mutation, repeatedly failed to reprogramme with either of the two plasmid combinations used 
(Table 3-1). Moreover, fibroblasts from Patient T2 (IVSII-1G>A) failed to reprogramme with the 
C4 combination; however, two clones were generated from this patient using the C19 combination. 
A total of seven putative iPSC clones were obtained from Patient T3 (IVSII-1G>A): two using the 
C4 combination and five from C19. Twelve and ten putative iPSC clones were generated from the 
control patient (N4) using the C19 and C4 combination, respectively. A maximum of 10 iPSC 
clones were selected from the normal line and all clones generated from beta thalassaemia patients 
fibroblast were expanded and cryopreserved. 
Following the expansion of selected clones for seven to eight passages (Table 3-1), karyotype 
analysis revealed that both clones from Patient T2 displayed genetic abnormalities with a balanced 
reciprocal translocation involving the long arms of chromosomes 4 and 11 for one clone, and a 
translocation between chromosomes 13 and 15 for the other (Figure 3-3.A). One of the clones from 
the control subject, N4, showed monosomy for 8p and partial trisomy for a material of unknown 
origin (Figure 3-3.A). All karyotypically-abnormal clones were excluded from the study. Thus, 
further characterisation was performed on the five clones from beta thalassaemic patient T3 and 
three clones from the control subject, N4. The presence of the beta thalassaemia mutation in the T3-
derived clones was verified by DNA sequencing confirming that iPSC clones were indeed derived 
from T3 beta thalassaemia cells (Figure 3-3.B).  
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Figure 3-3: Characterisation of iPSCs: Karyotype/presence of the mutation.  (A) Assessment 
of structural and numerical chromosomal abnormalities using standard G-banding karyotype 
analysis. (B) The presence of the beta thalassaemia mutation was verified in iPSC clones derived 
from beta thalassaemia patient T3 by DNA sequencing. 
3.2.2 Assessment of the pluripotency of the iPSC clones 
Both the T3 and N4 clones displayed robust expression of cell surface markers TRA-1-60 and 
TRA-1-81, as well as the pluripotency markers OCT4/POU5F1 and NANOG, as determined by 
immunocytochemistry (Figure 3-5). They also expressed endogenous NANOG and OCT4 mRNAs 
at levels comparable to control H9 hESCs (Figure 3-4). Although a significant reduction in SOX2 
expression was observed in two iPSC clones (N4C9 and N4C007) compared to hESCs, the parallel 
reduction in NANOG and OCT4 expression may indicate the observed decrease was caused by the 
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presence of differentiated cells. In fact, some clones were difficult to maintain at early passage 
numbers and improved at a later passage (p15). 
 
 
 
 
Figure 3-4: Expression of pluripotent marker genes in iPSCs. Fold change in expression of 
endogenous pluripotent cell markers A) OCT4, B) NANOG, C) SOX2 genes for the indicated 
clones relative to H9 (normalised relative to GAPDH) by q-PCR. (Data represent mean±SEM, 
n=3). * p<0.05, ** p<0.01. 
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Figure 3-5: Immunocytochemical detection of the pluripotency markers OCT4, NANOG, 
TRA-1-81 and TRA-1-60 in control and beta thalassaemia iPSCs. 
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However, the robust expression of the pluripotency marker genes at the protein level (Figure 3-5) 
supports the notion that the previous observation most probably reflects the presence of 
differentiated cells at the time of collection. Next, spontaneous differentiation of iPSCs was 
assessed by transferring clumps of cells into a low-attachment cell culture platform in the absence 
of b-FGF in order to form EBs.  EBs from all the tested clones expressed GATA4, SOX17, SMA, 
Brachyury, PAX6 and MAP2 at different levels (Day 23), indicating the pluripotency of the iPSC 
clones (Figure 3-6).  
 
Figure 3-6: Expression of various lineage-specific genes in D23 EBs. Fold change in (A) 
endodermal (GATA4 and SOX17), (B) ectodermal (MAP2 and PAX6) and (C) mesodermal 
(Brachyury and alpha smooth muscle actin) markers during EB differentiation of clones from 
iPSCs lines (Data represent the mean±SEM, n=2). 
Moreover, the expression of alpha smooth actin (SMA, mesoderm), alpha-fetoprotein (AFP, 
endoderm) and nestin (NESTIN, ectoderm) was detected using immunofluorescence in Day 23 EBs 
(Figure 3-7). AFP was not detected in one of the clones. However, pluripotency of all six clones 
was confirmed by their ability to form teratomas containing cell types representative of the three 
C. 
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germ layers following intramuscular injection into NOD-SCID mice (Figure 3-8), which indicates 
that the lack of the endodermal marker AFP was due to technical, rather than biological, reasons. 
 
 
Figure 3-7: Immunostaining for lineage-specific markers in Day 23 EB after dissociation and 
plating on coverslips. Markers assessed were: alpha smooth muscle actin (mesoderm), alpha-
fetoprotein (endoderm) and nestin (ectoderm) with DAPI nuclear staining for the indicated iPSC 
clones. (Alpha-fetoprotein was not detected in clone T3C1). 
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Figure 3-8: Teratomas demonstrating the trilineage competence of the iPSC lines. 
Haematoxylin and eosin histology images of derivatives of the three germ layers found in 
teratomas formed after injection of control and beta thalassaemia iPSCs into 
immunocompromised NOD-SCID mice. 
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3.2.3 Analysis of vector integration and persistence 
To assess the absence of integration or persistence of the episomal reprogramming factors, PCR and 
RT-PCR analysis was performed on genomic DNA and RNA isolated from the iPSCs using 
transgene-specific primers. Episomal plasmid DNA could not be detected in five of the six iPSC 
lines, while transgene expression could not be detected in any of the clones (after excluding clone 
N4C007). The presence of amplicons for EBNA, OCT4, and KLF4 in the absence of a positive band 
for NANOG and LIN28 in one clone derived from the control fibroblasts indicates the OSTK 
plasmid was integrated in the genome (Figure 3-9.A, C007). The faint band for EBNA in the 
absence of the expression of reprograming factors in one clone may indicate a DNA contamination 
(Figure 3-9.C, C007). Although, most of the clones were integration-free, this finding highlights the 
importance of careful screening of the clones for the presence of a random integration. Of note, the 
presence of GAPDH amplicon in the sample of plasmid extracted from Day 15 transfected 
fibroblasts (positive control: PC1 and PC2) indicates contamination of the extracted samples with 
genomic DNA (Figure 3-9.A, and B).  
 
Figure 3-9: Presence and expression of transgenes as assayed by PCR analysis of genomic 
DNA and RNA isolated from the iPSCs using transgene-specific primers. Episomal DNA 
could not be detected in (A) 2/3 N4 iPSCs clones and (B) 3/3 T3 iPSCs clones, (C) while 
transgene expression was not detected in 5/6 clones. The presence of an amplicon in Lane 3C 
(C007) possibly indicates a low level of DNA contamination as no amplification was detected 
after treating the sample with DNase. (M: Marker, PC1: Plasmid DNA extracted from Day 15 
transfected fibroblasts (T1), PC2: Plasmid DNA extracted from Day 15 transfected fibroblasts 
(T2), B: Blank control (no DNA), PLS: plasmid). 
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Thus, it is possible to generate bona fide high quality iPSCs from adult fibroblast samples from 
control and beta thalassaemia patients using episomes; however, there is a high attrition rate due to 
karyotypic abnormalities and some loss due to low-level transgene integration. Moreover, some 
patient samples are much more difficult to reprogramme than others, for reasons that are not 
immediately obvious.   
 Conclusion 
This chapter describes the generation and full characterisation of footprint-free iPSCs from 
fibroblasts of individuals with and without beta thalassaemia using two different combinations of 
episomal vectors. More partially-reprogrammed iPSC clones emerged using C19 compared to C4. 
This difference can be attributed to variation in transgene arrangement that may impact their 
expression levels with subsequent consequences on the reprogramming processes [45, 192] as both 
vector combinations carry the same number and type of transgenes. Furthermore, even though 
episomal vector-based reprogramming is generally considered an integration-free process, careful 
screening of clones is needed to confirm the absence of transgenes in the genomic DNA, in 
agreement with previous reports [45, 46]. This is important since the transgenes that were silenced 
in iPSCs, as shown by RT-PCR, can be reactivated upon differentiation, which may limit the 
developmental potential of iPSCs and present further complications for future clinical applications 
in particular [193].   
The nature of the vectors used to express the reprogramming factors is of critical importance for the 
generation of safe iPSCs. Despite the fact that reprogramming with episomal vectors is limited by a 
relatively low efficiency of reprogramming compared to other integrative methods, it only requires 
a single transfection followed by passive removal of the vector by continuous passaging. More 
importantly, this approach has been shown to generate iPSCs that are less immunogenic than those 
produced by retroviral delivery of the reprogramming factors after syngeneic transplantation of 
iPSC-derived cells in non-human primates [33]. It was also associated with a reduced incidence of 
teratoma formation by iPSC derivatives compared to clones produced by retroviral transduction 
[31]. This finding may be attributed to a greater presence of cells with a defective ability to 
differentiate (Type I phenotype) in retrovirally transduced cells as compared to those transfected 
with episomes.  As such, the generation of adult fibroblast-derived footprint-free patient-specific 
iPSCs using episomes, as performed here, is another essential step towards a cell-based therapy for 
beta thalassaemia patients.  
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MUTATIONS IN BETA THALASSAEMIA INDUCED PLURIPOTENT 
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4 DOUBLE NICKASE-MEDIATED SEAMLESS REPAIR OF HBB MUTATIONS IN BETA 
THALASSAEMIA INDUCED PLURIPOTENT STEM CELLS 
 Introduction 
Recent advances in genome engineering provide powerful gene-editing tools that enable site-
specific DNA modification through the exploitation of the intracellular repair machinery [8]. 
Similarly, iPSCs constitute a powerful platform for providing a renewable source of cells with 
patient/disease-specific genetic backgrounds. Combining both tools and achieving site-specific 
editing in PSCs holds great potential for exploring the pathological processes associated with 
genetic disease, devising novel and effective therapeutic strategies and generating edited cells with 
potential therapeutic utility [8, 194]. However, achieving highly precise genome editing with 
engineered nucleases remains a challenge.  
Type II CRISPR/Cas9 is one of the most prevalent nuclease systems that is widely adopted for 
genome engineering. It is characterised by the ease of its design, its efficiency and the possibility of 
repurposing this system to carry additional molecular functions [156]. The system is dependent on a 
modular short guide sequence to direct the nuclease domain to cleave its DNA target site provided 
that a PAM motif sequence site is located downstream of the protospacer sequence [59]. As a result 
of the induced DNA break, the DNA repair mechanisms are stimulated and either the error-prone 
NHEJ, or the HDR pathways predominate, depending on the gene editing strategy employed. In 
fact, in the presence of an ectopic donor plasmid, the repair can be guided to tailor the DNA 
modification through HDR [195]. Subsequently, insertions, deletions, and point mutations can be 
formed at the targeted site with various consequences including, gene disruption, gene correction, 
transgene insertion or a combination of simultaneous modifications. However, unwanted on-target 
[145, 196] and off-target induced mutagenesis [58, 65, 74, 84] are frequently associated with Cas9 
activity. On-target mutagenesis is caused by the iterative cycles of Cas9 activity after the 
introduction of the desired genetic modification (i.e., unwanted specific activity), whereas off-target 
mutations are mostly caused by the tolerance of Cas9 to sequence mismatches which, results in non-
specific mutagenesis (i.e. non-specific activity). The target sequence properties, the type of nuclease 
variants, and targeting strategy, are all factors that influence the repair pathway activated (i.e. 
accurate or mutagenic pathways).   
To limit off-target activity, an approach that biases the resolution of DNA breaks through high 
fidelity repair pathways has been suggested [95, 96], that is induced by the nickase variant of Cas9 
and is supposed to be quickly and efficiently repaired through either the faithful BER mechanism 
[97] or error-free HDR [58, 63, 118, 119], while reducing the frequency of the error-prone NHEJ 
[101, 119]. However, nickase-induced HR has also been reported to display inefficient activity that 
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can be sequence- and locus-dependent [117, 145]. Further improvement of nickase efficiency was 
achieved by adopting a ‘paired nickase’ strategy. This strategy has been suggested to favour a more 
effective on-target modification (compared to a single nickase), while reducing off-target effects 
[95, 96]. This was based on the notion that paired nicks induce a composite DSB at the targeted site, 
while only a SSB is induced at off-target sites. However, HDR and NHEJ compete and cooperate to 
repair the composite DSB and thus are thought to lead to undesired on-target modifications 
following gene correction [118, 197]. To address this concern, a donor strategy design was 
suggested that converts a DSBs to a SSBs at the targeted allele following HR. This was achieved by 
designing a donor template that inserted a selection cassette at either a one of the guide-binding 
sites (inactivating one guide) or between the guide-binding sites of a pair (both guides-binding sites 
are intact but the DNA nicks are not closely spaced) [145, 198]. However, for this strategy to be 
effective, the nicks closely positioned in the targeted allele must be resolved by a high fidelity 
repair mechanism.   
The data on the mutagenicity of monomeric nickases are inconsistent at present. Moreover, the 
majority of the studies on nickase activity to date have been carried out in transformed, or 
immortalised, cell lines and limited data are available on the efficiency and safety of this strategy in 
the context of gene correction in human pluripotent stem cells. The prevalence of on-target indel 
levels (NHEJ) induced by a single nickase was reported to range between undetectable [96], 
measurable (low activity) in HEK 293 cells [58, 61] and U2OS cells [98] or considerable activity in 
HEK 293 cells [71]. Although these studies indicate that the type of repair can be sequence- and 
locus-dependent, they also indicate that SSBs can be repaired through an error-prone pathway at 
some guide-binding sites, which is clearly of concern when using this method for precise genome 
editing.  
Different cell types can use different pathways for the repair of DNA lesions resulting in different 
outcomes. Generally, iPSCs exhibit a low off-target mutation load with Cas9WT as assessed by 
whole genome sequencing [88, 89] or screening of the top predicted off-target sites [35, 36, 77, 87]. 
However, this was disputed when researchers targeted Intron 2 of the HBB gene [138]. Similar 
inconsistencies were observed with monomeric Cas9n (single guide), which showed undetectable 
mutagenesis rates in bulk iPSC populations [58], whereas a high variability of monomeric nickase 
activity at the targeted allele was evident in iPSCs obtained after positive selection but not in bulk 
cell populations [145]. Interestingly, despite the high activity of nickase observed at some loci, 
these authors showed that abolishing the binding site for one guide, or separating the DNA nick 
sites by a selection cassette in the context of a double nickase strategy can considerably reduce on-
target mutagenesis in iPSCs. 
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Assessing strategies based on a DN approach with respect to gene correction of a disease-causing 
mutation in human iPSCs is particularly relevant for a gene like HBB, which has been reported to 
have a considerable propensity for off-target activity for some sgRNA sequences [138, 139]. In this 
study, it was hypothesised that a Cas9-DN approach for HBB gene correction would benefit from 
strategies that: (1) convert DSBs to nicks at the target allele as this limits unwanted mutagenicity; 
(2) generate bi-allelic targeting, considering that the untargeted site will be vulnerable to NHEJ-
mediated mutagenic events; and (3) approaches that allow for both positive and negative selection 
mode, so as to facilitate the identification of targeted clones and permit subsequent seamless 
excision with the aim of preserving genomic integrity. Therefore, the present study sought to assess 
the applicability of a DN approach to achieve biallelic seamless gene correction of a disease-
causing mutation in iPSCs derived from patient with beta thalassaemia major (homozygous), and 
evaluate and compare on-target mutagenesis in iPSCs using two different design strategies for 
corrective gene targeting. In both strategies, the double nickase activity on the targetted allele was 
eliminated following HR by designing a donor template that either introduced a SNP in the PAM 
sequence at the binding site for one of the guides (sgRNA1) of the first pair set (sgRNA1/3), or by 
inserting a large selection cassette flanked by the piggyBac transposon inverted repeat (>3 kb) at the 
binding site for another guide (sgRNA4) in the second pair (sgRNA45).  
The results revealed that biallelic seamless gene correction of a beta thalassaemia-causing mutation 
is possible, and that the vast majority of the monoallelically targeted clones (after excluding random 
insertions) possess an indel at the guide binding site of the untargeted allele (original allele), 
indicating a high level of on-target activity that can be attributed to either double, or in some cases a 
single nickase activity. Upon further investigation of the effect of this approach on reducing on-
target activity at the targeted allele, it was found that there was no indel associated with the targeted 
allele obtained through modification of the PAM sequence, and destroying the binding site for one 
guide/separating the guides in the other pair did abolish the DN activity but was unable to fully 
eliminate DNA modification as revealed by the presence of an indel at the binding site of the 
second guide of the pair in 5 out of 26 of the screened clones, strongly suggesting existence of an 
unexpected nickase-induced activity associated with one guide.  
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 Results and discussion 
The following sections will present and report on: 
1) The strategy used to design various gRNAs to target exon/intronII of the HBB gene, the 
validation of this approach in HEK293FT cells using Cas9WT, the assessment of the 
functionality of the first guide pair (sgRNA1-Cas9WT and sgRNA3-Cas9WT), and the 
evaluation of the paired nickase activity of five multiple pairs (sgRNAA/B-Cas9n) in 
HEK293FT cells. 
2) Optimisation of the iPSC transfection conditions, using sgRNA1-Cas9WT-EGFP, to 
maximise the transfection efficiency (via GFP-positive cells quantifications) relative to cell 
viability. 
3) Targeting the HBB gene with a piggyBac-based donor construct and Cas9DN using two 
different strategies that convert DSBs into SSBs upon targeting: a sgRNA1/3-Cas9n+ donor 
(inactivation of PAM motif for sgRNA1) and the sgRNA4/5-Cas9DN+ donor (separation of 
the guide pair by inserting the selection cassette). 
4) Screening for HR events and on-target mutagenesis after positive selection with puromycin. 
5) Validation of the correction of the disease-causing mutation by sequencing. 
6) Assessment of off-target activity at five top predicted off-target sites per guide. 
7) Assessment of the restoration of the wild type allele after seamless excision of the selection 
cassette. 
8) Evaluation of the pluripotent state and karyotype analysis of the corrected cells. 
4.2.1 Gene targeting of the HBB locus with Cas9 or Cas9n in HEK293FT 
 Design of guide RNA pairs for genome editing using a double nickase approach 
The efficiency of DNA modifications (through NHEJ or HDR) in response to composite DNA 
breaks induced by paired nickase is affected by the sequence context, the offset distance between 
pairs of guides used to target the intended region, and the distance of the nicks relative to the 
intended modification [96, 145, 146]. The intended DNA modifications in the current study involve 
a corrective substitution of the disease-causing mutation and an insertion of an excisable dual 
selection cassette using the piggyBac transposon-based approach described in Yusa et al. [182]. 
Therefore, multiple pairs of sgRNAs were designed to screen for efficient guide pair capable of 
introducing DNA breaks at different distances relative to either the insertion or the targeted 
mutation. Some of the pairs were designed to introduce a DNA nick close to the HBB mutation site 
whereas other pairs introduced the break upstream to the TTAA insertion site (for piggyBac). The 
offset distance for different pairs varied between -7 to 51 bp (Figure 4-1.B). Vectors with dual 
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expression of sgRNA and Cas9 nuclease (or Cas9-D10A nickase) were used because this ensures 
concomitant expression of both components in transfected cells. 
 
Figure 4-1: Schematic illustrating the HBB gene and the location of multiple pairs of sgRNA. 
Guides with a different offset (dashed line) were designed to either target the region around the 
mutation site () or the TTAA site (dark red box). The first sgRNA of the pair was cloned in an 
EGFP expression vector (green), while the second was cloned in a puromycin-expressing vector 
(blue). The PAM sequence is indicated by the red box. 
 Assessment of the efficiency of sgRNA-Cas9(n) targeted genome modification in 
HEK293FT cells 
To assess if the system could generate indels at the HBB locus, the efficiency of inducing indels at 
the gRNA binding sites was initially evaluated for one pair of guides using a Cas9WT nuclease-
expressing vector (Figure 4-2.C). Guides for the first pair (gRNA1 and gRNA3) were cloned into a 
vector co-expressing a human codon-optimised Cas9WT nuclease and puromycin (PX459). One 
guide (gRNA1) was also cloned into a sgRNA1-Cas9WT-EGFP (PX458) expressing vector to 
assess the transfection efficiency [177]. Vectors were independently transfected into HEK 293FT 
cells using Lipofectamine LTX. Cells transfected with the PX459 vector were subjected to 
puromycin selection for 48 hrs. Transfection was determined as being efficient as >80% of the cells 
were GFP-positive as identified by GFP-positive cells using fluorescent microscopy (Figure 4-2.A). 
DNA was extracted 72 hours post-transfection to assess the rate of targeted DNA modification. The 
indels resulting from NHEJ were analyzed with the Surveyor assay using PCR amplicons amplified 
with SV1 primers (Table 2-2). The size of the fragment generated by the Surveyor nuclease 
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corresponds to an indel at the expected Cas9WT cutting site (Figure 4-2.E). The efficiency of indel 
frequency (as quantified using Imagelab software, BioRad) induction by NHEJ was 28.78 per cent 
in the absence of selection. However, this value increased two-fold with drug selection, reaching 
51.97 and 58.3 per cent for sgRNA1 and sgRNA3, respectively (Figure 4-2.C).  
 
Figure 4-2: Functional analysis of guide RNAs using Cas9 or Cas9DN systems in HEK293 
cells. (A) Transfection of HEK293FT cells with sgRNA-Cas9-EGFP-expressing vector (B) or 
co-transfection of both sgRNA-Cas9n-EGFP and sgRNA-Cas9n-puromycin-expressing vectors 
resulted in efficient GFP expression as displayed by fluorescent microscopy (b and e). Phase 
contrast image is shown in a and d and merge image in c and f. The transfection resulted in 
efficient on-target modification as demonstrated by the Surveyor assay for (C) Cas9WT (D) and 
Cas9 double nickase systems for the indicated guide pair. (E) Schematic illustrating the location 
of the Cas9 cleavage sites of guide1 and guide3 (red triangle) for primer SV1 and the predicted 
size from the Surveyor nuclease (F) and the predicted cleavage sites for both sgRNA1/3 and 
sgRNA4/5 for primer SV2. Primer pairs SV1 and SV2 were used in C and D, respectively.  
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This observation possibly indicates that Cas9WT did not result in mutagenesis in nearly 40 per cent 
of the transfected cells (puromycin-resistant cells mostly expressing GFP).  
Different sgRNAs can have different activities [146]. This is of relevance when a composite DNA 
break is needed. Therefore, for the paired nickase approach to be effective, both guides forming the 
pair should ideally have comparable activity to efficiently form a staggered composite double DNA 
break. All five pairs were next assessed for their ability to induce indels at the targeted site (Figure 
4-2.D). Two different expression vectors were used to clone guides for each pair; PX461 (EGFP) 
and PX462 (puromycin). This strategy facilitated monitoring of the transfection efficiency while 
allowing for drug selection. The effect of paired Cas9-nickase dosage on the indel efficiency was 
also explored using either 600 ng or 1000 ng of total plasmid. Transfected cells were subjected to 
drug selection (for two days) starting at 24 hours post-transfection. The majority of puromycin-
resistant cells were positive for GFP, as observed under a fluorescence microscope (24 hours after 
selection) (Figure 4-2.B). This observation indicates that efficient co-transfection of the vectors was 
achieved. The induced indel efficiencies obtained for vectors expressing sgRNA45, sgRNA46, 
sgRNA78 were 57.3, 55.67 and 43.34 per cent for 600 ng of pDNA and 46.66, 33.55 and 33.6 per 
cent for 1 g of pDNA, respectively. These values indicate that increasing the plasmid did not 
increase the efficiency. It is likely that the decrease in efficiency observed at 1 g pDNA reflects a 
loss of transfected cells due to either plasmid load-induced toxicity or suboptimal transfection 
conditions. These results may also have been affected by the low sensitivity, low signal-to-noise 
ratio [199] and accuracy of the Surveyor assay. Moreover, differences in sample loading in different 
lanes or experimental variability associated with transfection condition can also bias the results. The 
cutting efficiency was not normalised to transfection efficiency as the transfection efficiency was 
consistently high in HEK293FT as judged by fluorescence microscopy. Moreover, the plasmid 
dosage effect was likely to differ in iPSCs, as they are a different cell type and require different 
transfection conditions (lipofection/nucleofection).   
Upon further analysis, multiple bands were observed for sgRNA13 and sgRNA79. It is highly 
unlikely that this pattern would be the result of 5′ exonuclease activity of the Surveyor nuclease 
[200] as the band pattern (for the additional band) seems to be proportional to the offset distance 
between the pair of guides (Figure 4-3.B). In fact, diffuse PCR amplicons were observed for 
sgRNAs 46, 13 and 79 with an offset of 21, 28, and 51, respectively, and this was not observed for 
the offset of -7 and +5 bp (Figure 4-3.A). At first glance this band pattern may indicate a 
subpopulation of cells with indels resulting from the repair at a single nick. However, this 
hypothesis is highly unlikely as the bands generated with the single nickase are barely detectable 
above the background levels (Figure 4-2.D, G9). A similar observation was reported in another 
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study using paired nicks with offsets greater than 100 bp [61]. They reasoned that the DSB occurred 
in a region between the nicks during the process of repair which was resolved through a head-to-
head strand replacement resulting in deletion [61]. Interestingly, in that study, a parallel band 
pattern was obtained with paired Cas9WT (compared to Cas9DN) which indicated the occurrence 
of a large deletion of the intervening sequence (confirmed by sequencing). Contaminants or 
spontaneous reversion of the D10A mutation in the RuvC I-Cas9 domain was ruled out after 
sequencing the Cas9n vectors in the current study. 
 
 
Figure 4-3: Band pattern for PCR amplicons, generated using SV2 from transfected HEK293 
cells (Cas9DN), and their Surveyor nuclease treated products. The band pattern possibly 
indicates a large deletion that seems to be proportional to the offset distance between the pair of 
guides as indicated by: (A) The diffuse band for PCR products for offset distances of 28 and 51 
bp (red arrows), (B) and the products after digestion with Surveyor nuclease for the indicated 
guide pairs. The gel in B was cropped and rearranged from (Figure 4-2.D). 
Moreover, repair through the formation of a DSB intermediates was recently demonstrated for a DN 
strategy with an offset of less than 100 bp [118]. Thus, it was concluded that the overhang length 
may be a factor that possibly dictates a type of utilised repair mechanism at the composite break 
sites. The band pattern suggests the presence of two defined processes that resolve the composite 
break. 
4.2.2 Optimisation of iPSC transfection conditions 
 Liposomal-based transfection of iPSCs 
To deliver the sgRNA-Cas9WT-EGFP plasmid liposomal delivery approaches that do not require 
cell suspension for transfection, were explored using commercially available lipid-based 
transfection reagents. The reagents tested included Lipofectamine 3000 (Life Technologies), 
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Fugene HD (Promega), TransIT-LT1, and TransIT-2020 (Mirus Bio's). A low survival and very low 
transfection efficiency was observed upon transfecting iPSCs with Lipofectamine 3000 despite the 
fact that adherent iPSCs (single cell format) were used as opposed to cell suspensions (in 
nucleofection). Next, transfecting colonies as opposed to single cells was tested in an effort to 
improve the transfection efficiency. Transfection of colonies was carried out as per the 
manufacturer’s instructions using two different charge ratios (1.5X and 3X) of Lipofectamine3000 
to pDNA and 1g of pDNA in 12 well plates.   
 
Figure 4-4: Liposomal-based transfection of iPSC clones with the sgRNA1-Cas9WT-EGFP-
expressing vector. (A) Transfection efficiency for clones with the indicated reagent. (B) The 
calculated efficiency for on-target modification as assessed with Surveyor assays was 4.3 per 
cent (Lane 3), 7.3 per cent (Lane 6) using SV1 primers, and 6.1 per cent (Lane 11) using SV3 for 
TransIT®LT1, Lipofectamine 3000 (3X), and Fugene HD, respectively. (C) A toxic effect was 
observed on Day 5 for some clones. IPSC controls: Lanes 9 and 10. 
Notably, fluorescence was visible between 24-72 hours post-transfection, and decreased 
considerably from Day 4 onwards. This finding indicates a short, transient expression of EGFP. 
After trialling all liposomal transfection reagents, it was found that transfection Fugene HD yielded 
the highest number of GFP-positive cells (as observed under a fluorescence microscopy) (Figure 
4-4.A). Fluorescence-activated cell sorting (FACS) was not used to estimate the percentage of 
fluorescent cells, as a measurement of the efficiency of the induced indel at the targeted site can be 
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a more relevant indicator for downstream applications than estimating transfection efficiency by 
FACS. Thus, Surveyor nuclease assays was carried out to compare the transfection efficiency of the 
various reagents. Estimated induced indel efficiencies of 7.3, 4.3 (using SV1 primers), and 6.1 per 
cent (using SV3) were obtained for Lipofectamine 3000 (3X), TransIT®LT1 and Fugene HD, 
respectively, under the reported experimental conditions and transfection with sgRNA1-Cas9WT-
EGFP (Figure 4-4.B). The discrepancy between the observed fluorescence and induced indel 
efficiency for Fugene HD and for Lipofectamine 3000 may reflect the loss of transfected cells, as 
cell toxicity was observed in a subset of transfected iPSC clones (Figure 4-4.C). It may also reflect 
the high signal-to-noise ratio that influences the estimation of band intensity. No bands were 
observed for Lipofectamine 3000 (1.5X) and TransIT-2020, possibly indicating that the activity was 
below the detection limit of the assay. It was concluded that both Fugene and Lipofectamine 3000 
can be used as transfection reagents for the delivery of the sgRNA-Cas9 plasmids. Further 
optimisation of experimental conditions regarding the amount of plasmid used and the charge ratio 
relative to cell density will be necessary to improve the observed indel efficiencies. 
 Optimisation of nucleofection conditions 
For CRISPR-Cas9-mediated gene correction, induced PSCs that had been adapted to single cell 
feeder-free culture conditions were used. Despite trialling different programmes that included 
CB150 and CA137 (common stem cell-specific programmes) to nucleofect 5x105–1x106 cells with 
1 g sgRNA1-Cas9WT-EGFP vector (P3 buffer, 4D Nucleofector), the iPSCs continued to exhibit 
low viability after transfection (less than 25 per cent viable cells), as estimated by trypan blue 
exclusion, when seeded under feeder-free conditions. This was coupled with a very low transfection 
efficiency, as judged by the number of GFP-positive cells. Similar findings were obtained using a 
different buffer (Ingenio Electroporation buffer) with two different transfection programmes, B016 
or A023 (Nucleofector II, Amaxa) [201]. However, seeding the cells on MEFs after transfection 
yielded promising results. In fact, extracellular matrix (ECM) and irradiated MEFs were tried for 
plating cells subjected to nucleofection with sgRNA1-Cas9WT-EGFP. Cell survival improved with 
an increased plating density for cells seeded on ECM (Figure 4-5.B). However, a significant 
improvement in cell viability was observed when a layer of irradiated MEF was used to plate cells 
on after transfection, as judged by the number GFP-positive cells (Figure 4-5.A) and by the number 
and the morphology of clones that formed after seven days compared to ECM alone, even at a low 
plating density. Therefore, irradiated MEFs were used for plating transfected iPSCs. Further 
optimisation attempts were made using different cell density to total pDNA ratios, nucleofection 
programmes and seeding densities after nucleofection, as follows: 
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a) Programme for nucleofection: Cells (5x105) were subjected to six different nucleofector 
programmes that varied in strength and centred on CB150 (suggested by the manufacturer’s 
instructions; weak CA137<CA-150<CB-141<CB-150<CD-150<DE-150<DE-148 strong) in 
16-well nucleovette strip format with 1 g pDNA. Transfected cells were plated on 
irradiated MEF plates (12-well) in the presence of ROCK inhibitors. Programme CB150 had 
a higher count of GFP-positive cells as observed by fluorescence microscopy (Figure 
4-5.A). 
b) Cell density to pDNA ratio: The CB150 programme was used to transfect 1–2x106 cells 
with a range of pDNA concentrations (1–4 g). Although transfecting 2x106 cells with 2 g 
of pDNA produced the highest number of GFP-positive cells, the resulting indel efficiency 
(as assessed by Surveyor assays) was not significantly different compared to transfection 
with 4 g/2x106 cells, which produced lower numbers of fluorescent cells. This may 
indicate that the system is tolerant to a range of conditions and that GFP expression does not 
necessarily correlate with indel efficiency. The modest difference in indel efficiency did not 
result from experimental or measurement artefacts, as it was consistent between two 
different PCR amplicons generated with two different set of primers (SV1 and SV3) from 
the same sample DNA. The observed indel efficiencies using 2 g and 4 g of pDNA were 
10.6 and 9 per cent (with SV1 primers) and 7.07 and 5.77 per cent (with SV3 primers), 
respectively (Figure 4-5.C). The difference in the absolute values of indel activity between 
both primer sets from the same sample indicates that this assay can be affected by many 
variables, including the background of cleavage, especially at a low rate of mutation. Based 
on results from the observed GFP-positive cells and indel efficiency, 2 µg of plasmid was 
used to transfect 2x106 cells. Overall, the indel efficiency achieved in HEK293FT cells was 
2.8-fold higher than that observed in iPSCs for the same sgRNA-Cas9 vector. 
Having optimised the parameters for iPSCs nucleofection, the next step was to assess the indel 
efficiency induced by paired nickase using guide pair 1 and 3 with two set of primers (SV1 and 
SV2). Although a band of the expected size was detected, the signal-to-noise ratio was high (Figure 
4-5.D), preventing the estimation of the cutting efficiency. 
These data suggest that the guides designed were functional in both the Cas9WT and Cas9 paired 
nickase strategies, as judged by the presence of indels at the targeted site of the HBB gene in iPSCs. 
It appears that under these experimental conditions Cas9WT is more efficient at inducing an indel at 
the targeted locus compared to Cas9DN. This finding does not concur with an earlier report, which 
showed a similar efficiency for both strategies (Cas9WT and Cas9DN) in HEK293 cells [96]. This 
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can perhaps be attributed to the difficulty in ensuring equal co-delivery of two vectors (each 
expressing one guide). A dose-dependent effect has been reported to reduce the activity of the 
endonuclease in various studies [58, 74, 145].  
 
 
Figure 4-5: Analysis of on-target modifications following nucleofection of iPSCs with 
sgRNA1-Cas9-EGFP or paired Cas9n vectors. (A) Cells transfected with 2 g of vector/2x106 
cells. (B) Effect of plating density of transfected cells on cell survival (ECM). (C) Efficiency of 
on-target modification using the Surveyor assay for the cells transfected with 2 g/2x106 (Lane 
1) and 4 g/2x106 (Lane 2) sgRNA1-Cas9WT-EGFP using two different PCR amplicons. (D) 
Efficiency of indels for cells transfected with sgRNA1/3-Cas9DN using two different primers 
(SV1 and SV2) that span the expected indel site (Lanes 1 and 3) compared to untransfected 
control (Lanes 2 and 4). The red arrows indicates the band location for the digested product. 
In conclusion, these data indicate that different approaches can be used to transfect iPSCs with the 
sgRNA-Cas9-expressing plasmid. Although lipid-based transfection of plasmid DNA has been used 
in iPSCs [180], in this study this approach was not highly successful in these difficult-to-transfect 
cells [94]. Nucleofection has been reported to have a superior efficiency of plasmid delivery in 
pluripotent cells [94]. Although a comprehensive optimisation of both systems is needed for a 
proper comparison, the data from this study support the idea that nucleofection is slightly more 
efficient. More importantly, nucleofection is an approach that has been validated in maintaining 
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stem cell properties. Therefore, nucleofection was selected for the subsequent gene targeting 
experiments. 
4.2.3 Gene correction of disease-causing mutation in iPSCs 
Having established conditions for transfection of iPSCs with a beta thalassaemia mutation (BT-
iPSCs), the efficiency of HDR using different design strategies to prevent further modification of 
the targeted allele brought about by the continuous activity of Cas9 was assessed. The effect of 
placing the cut site at a different location relative to the mutation or insertion site for the selection 
cassette on HDR efficiency was also examined using different guide pairs. 
 Strategy for gene correction 
Although strategies for site-specific repair in the absence of drug selection are available, such as 
those using ssODN templates [78, 202], they can be limited by the low frequency of targeting of 
certain genomic loci and low transfection efficiency or cloning inefficiency in some iPSCs lines. 
Enrichment by FACS [78] or by the combination of droplet digital PCR and sib selection methods 
[203] has been suggested to facilitate the identification of transfected cells or those with on-target 
DNA modifications. However, such an enrichment strategy is complicated by the need to 
cryopreserve the cells in a 96-well format which is associated with a very low recovery rate in this 
laboratory. It was thought that efficient antibiotic selection followed by seamless excision [182] 
would offer a more practical alternative that avoids multiple rounds of sib selection aimed at 
enriching for low-frequency events [203]; this was therefore chosen as the method of choice. 
The rate of HDR can be improved by using a donor plasmid with isogenic sequence and increasing 
the length of the homology arms [204, 205]. Therefore, isogenic sequences to those of parental beta 
thalassaemia-iPSCs were used to synthesise homology arms (Genscript). Three base substitutions 
that include two SNPs in addition to the correction of the disease-causing mutation, were introduced 
into the donor template sequence (Figure 4-6). The first synonymous SNP was introduced in the 
PAM sequence by converting the NGG sequence into NCG for one guide of the first pair 
(sgRNA1/3) [59].  A change in the PAM sequence was surmised to eliminate the recognition site 
for one guide (sgRNA1) and prevent modification in the repair template as closely spaced DNA 
strand breaks cannot be efficiently generated (Figure 4-7). Although the second guide of the pair is 
still active, the generation of a single nick has been reported to be highly inefficient in inducing 
NHEJ in pluripotent stem cells [58]. This was attributed to the activation of the BER mechanism 
[97, 111], although data from a recent study challenged this notion [145]. To assess if this exonic 
modification had a functional consequence, the variant effect predictor (VEP, Ensemble) analysis 
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tool was used to exclude any possible consequences of this variant introduction on gene function or 
mRNA processesing. 
 
 
Figure 4-6: Schematic of the location of the SNPs introduced in the piggyBac donor template. 
Three SNPs were introduced in the donor template; (1) one in the PAM sequence of sgRNA1 to 
prevent Cas9 from nicking the donor template or the corrected allele when sgRNA1/3 is used 
(SNP1, green); (2) a polymorphic SNP variant present in the RefSeq to validate that the 
modification occurred through gene correction (SNP2, green); (3) and the substitution of the 
disease-causing mutation (A>G, red arrow). Black arrow indicate a polymorphic SNP variant. 
A similar strategy was thought to be irrelevant for the second pair as a selection cassette was 
inserted at one of the guide-binding sites, which theoretically should reduce the efficiency DSB 
generation (Figure 4-7). Inserting the selection cassette at the sgRNA4 binding site would result in 
four consecutive 5’mismatches to the guide sequence at the targeted site. A second SNP in the 
intron region downstream of the mutation site (a common polymorphic SNP variant absent in beta 
thalassaemia-iPSCs) was also introduced. 
 
 
Figure 4-7: Schematic of the strategies used to prevent the formation of closely spaced SSBs. 
The PAM sequence was inactivated in the first pair (green pentagon) in the donor template by a 
SNP, while the selection cassette will destroy the first guide in the second pair (red pentagon). 
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The efficiency of HDR using a double nicking strategy can also be affected by other factors, such as 
the distance of the nicks relative to the insertion site of the selection cassette or the gene correction 
site (alteration site) [96]. Therefore, two different targeting strategies to correct the disease-causing 
mutation were assessed. Two pairs of sgRNA with the highest scores reflecting lowest likelihood of 
off-target activity (CRISPR design tool [58]) were selected after functional validation in 
HEK293FT. One guide (sgRNA3) in the first pair (sgRNA1/3) was designed to direct Cas9n to 
induce a nick 6 bp downstream of the mutation site whereas in the second pair (sgRNA4/5) one 
guide (sgRNA4) was designed to induce a single DNA break 9 bp upstream from the insertion site 
(TTAA) of the selection cassette and 38 bp downstream from the mutation site. The distance 
between the mutation and insertion sites is 47 bp (Figure 4-7). 
 Optimisation of gene targeting in iPSCs 
Four independent experiments were performed using sgRNA1/3 and sgRNA4/5, as illustrated in  
Table 4-1. Two different forms of donor vector were used: circular and linear. In the initial 
experiment (A), a handful of GFP-positive cells were observed under fluorescence microscopy 
indicating a low transfection efficiency. The low number of GFP-positive cells observed may have 
been due to the decreased amount of the GFP-expressing vectors used in the transfections as the 
total mass of the plasmid was equally divided between the two sgRNA-expressing vectors (GFP- 
and puromycin-expressing vectors). Increasing the total amount of the sgRNA-expressing vectors to 
3 g did not, however, improve the fraction of observable GFP-positive cells. A Surveyor assay 
was carried out to verify if the transfection was associated with nickase activity for one of the pairs 
(sgRNA1/3, Table 4-1.A1). Faint bands of the expected fragment size were observed indicating the 
presence of a possible indel at the guide binding sites, which is consistent with our initial 
optimisation experiments (Figure 4-5.D). Again, it was not practical to calculate the cutting 
efficiency due to the high background and low sensitivity of the assay. Given these findings, it was 
thought that increasing the number of transfected cells would increase the GFP-positive proportion 
of cells. Therefore, 8x106 cells were transfected with a total of 8 g pDNA expressing sgRNA4/5-
Cas9DN (Table 4-1.C1). However, even at a high cell density, GFP-positive cells were still rare. 
Unexpectedly, the number of resistant clones obtained after two weeks of positive selection for 
targeted events using puromycin did not correlate with the number of observed GFP-positive cells. 
In fact, there were 39 and 15 clones each for cells initially transfected with sgRNA4/5 and 
sgRNA1/3, respectively (Table 4-1.A6 and A5).  
The overall low targeting efficiency in iPSCs is in agreement with Merkle et al. (0.75x10-5 and 
1.9.5x10-5 for sgRNA1/3 and sgRNA4/5, respectively) [145]. Too many resistant clones to count 
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were obtained from the high cell density transfection (Table 4-1.C1), despite the disproportionate 
number of observed GFP-positive cells. No resistant clones were observed for cells transfected with 
either the donor vector alone or a plasmid expressing non-specific sgRNA-Cas9n with a donor 
vector indicating that both a donor and a DNA cleaving components are required to induce a gene 
targeting events. Importantly, 7.5-fold more resistant clones were generated by using the circular 
form of the targeting vector compared to the linear form (2 clones only) (Table 4-1).   
 The presence of a targeting event in the absence of a proportionate number of GFP-positive cells 
may indicate that the fluorescence signal intensity (low GFP) was undiscernable from background 
(autofluorescence) by microscopy, the CBh promoter driving the expression of Cas9-EGFP is too 
weak in iPSCs, and/or may indicate a proportion of targeted events were induced by a single 
nickase activity (Cas9n-puromycin).   
. 
Table 4-1: Experimental design and number of puromycin-resistant clones observed 
 Paired guide used Donor vector Resistant clones Comments 
A 2x106 cells/2 g vector, 500 ng donor Few GFP+ cells 
1 sgRNA 1/3 - - - Control/indel efficiency calculation 
2 Control sgRNA-Cas9n + Circular 0 HR/non-specific integration 
3 - + Circular 0 HR 
4 sgRNA 1/3 + Linear 2 
Compare form of targeting vector 
5 sgRNA 1/3 + Circular 15 
6 sgRNA 4/5 + Circular 39 Compare different pairs of guide 
B 1x106 cells/500 ng donor Few GFP+ cells 
1 sgRNA 1/3 + Circular 4 pDNA: 2 g 
2 sgRNA 1/3 + Circular 6 pDNA: 3 g 
3 sgRNA 4/5 + Circular 16 
C 3µg each sgRNA-Cas9n + 2 µg donor Few GFP+ cells 
1 sgRNA 4/5 + Circular Too many to count 
 
 Genotyping of puromycin-resistant clones 
4.2.3.3.1 Agarose gel-based genotyping 
To investigate the efficiency of various strategies for mediating HR events, a total of 60 puromycin-
resistant clones were selected from three different transfection experiments (A4-6, B1 and C, Table 
4-1) to screen for correctly targeted alleles. Two clones from patient iPSCs transfected with 
sgRNA1/3 and a linear donor vector, 17 clones with sgRNA1/3 and a circular donor, and 41 clones 
with sgRNA4/5 and a circular donor were included in the analysis. Multiplex PCR was used to 
screen for the presence of the targeted allele and/or the original alleles. The screening was carried 
out using two sets of primers for both 5′ and 3′ homology arms as suggested in Yusa et al. [182]. 
Each primer set included a forward primer annealing outside the targeted homology arms and two 
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reverse primers, one located across the insertion site and the other at either the 5′ and 3′ ITR of the 
transposon (insertion specific primer) (Figure 4-8.A). 
 
Figure 4-8: Screening strategy for the correctly targeted allele and validation. (A) Primer sets 
used to screen the 5′ (green arrows) and the 3′ regions (red arrows) of the homology arms. (B) 
Validation of each set of primers using BT-iPSCs and a clone targeted at both alleles (after 
confirmation by sequencing). 
This multiplex PCR strategy facilitated rapid genotyping of the clones by enabling the simultaneous 
screening for the presence of the original and/or the targeted allele. Each primer pair set was 
validated for the amplification of the proper fragment size using either the BT-iPSCs or 
homozygous clones identified during the screen as positive controls and verified by sequencing 
(Figure 4-8.B). 
Ten clones were excluded due to poor growth characteristics or difficulties in maintenance. Cell 
lysates were used for the screening of the remaining 50 clones [182]. No band for the targeted allele 
was observed in clones generated with a linear donor indicating that their drug resistance was 
acquired through random integration of the selection cassette (Figure 4-9). Almost half (52.08 per 
cent) of the clones obtained using a circular donor vector had one targeted allele (heterozygotes), 
and 16.67 per cent had a possible targeting event at both alleles (possible homozygous or 
hemizygous) after excluding clones with random integration (31.26 per cent) (Details provided in 
the next section; Figure 4-10 and Table 4-2). The probability of obtaining a targeting event at one or 
two alleles was dependent on the pair of guides used (p=0.011, Fisher’s exact test). Thus, this 
suggests that the efficiency of HDR can be influenced by the efficiency of the guide pair, the 
location of the nick sites relative to the insertion site or by sequence-dependent factors. Of note, the 
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analysis (Fisher’s exact test) was performed by including all the targeted events (with or without 
random integration).  
 
Figure 4-9: Screening of puromycin-resistant clones by multiplex PCR at both left (top gel) 
and right (bottom gel) arms. The band sizes for amplicons generated by untargeted and targeted 
alleles differ by 200–300 bp, which facilitates genotyping. Lanes 5, 10 and 17: clones targeted at 
both alleles, Lanes 6, 7, 8, 9, 11, 13, 14, 15, 16: clones targeted at one allele; Lanes 3, 12: 
targeting at one arm, while Lane 4 represents large deletions at one arm. L: linear donor; C: 
circular donor; N1, 3, 4, 5: sgRNA(NANB)-Cas9n. 
Of the 48 clones targeted with circular donor vector, four clones showed a targeting event in the 
right arm, coupled with no amplicons in the left arm (Figure 4-9: Lane3, and Lane 12) which may 
indicates a deletion occurring at this site that abolished the primer binding site. Furthermore, an 
irregular band pattern, in terms of band size, was observed for amplicons obtained from the original 
allele, which may indicate an on-target indel-induced by the Cas9DN at this allele. For instance, the 
band pattern for the right arm (bottom panel, Figure 4-9) in Lane 9 indicates that the clone may 
contain a large deletion in the original allele. Overall, 81.5 per cent of the resistant clones 
(regardless of random integration) included in the screening had at least one targeted allele 
(52.08+16.67+6.25+6.25), which indicates that this strategy can enables efficient gene targeting in 
iPSCs. 
4.2.3.3.2 Screening for the presence of random integrations 
The screening for random integration was carried out using a PCR-based strategy. The primer pairs 
were designed as suggested by Yusa et al. [182] where each primer set is designed to bind to a 
DNA region that spans the junction site between the homology arms (left and right arms) and the 
plasmid backbone (Figure 4-10.A). Both a negative (beta thalassaemia-iPSCs) and a positive 
control (donor plasmid) were used to validate the assay. A total of 33/48 (25 heterozygous, and 
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eight homozygous) clones were identified that were devoid of random integrations. Interestingly, 
the screen revealed a higher number of random integrations associated with sgRNA1/3 (42.8 per 
cent) compared to sgRNA4/5 (20.59 per cent) (Table 4-2). However, this difference was not 
statistically significant (p=0.145, Fisher’s exact test) likely indicating that the process is not directly 
associated with the sgRNA-Cas9DN activity.  
 
 
Figure 4-10: PCR-based screening for random integration for both left and right arms using 
whole cell lysate. (A) Schematic indicating the binding sites of primer pairs used in screening for 
random integration at both left and right arms. (B) Analysis of amplicons obtained by PCR using 
1.5 per cent agarose gel. Bands in Lanes 2, 7, 15 and 17 indicate the random integration of both 
arms, Lanes 4, 9, 11 indicate integration for one arm. Lane 19: donor plasmid used as positive 
control. 
Interestingly, some clones carried a random integration for one arm of the vector (e.g., Lane 11), 
while others showed integration at both arms (e.g., Lane 2) (Figure 4-10.B). The observed 
difference in the band intensity can be attributed to the difference in the DNA amount as crude cell 
lysate was used for the analysis, or a copy number of integrated transgenes. All positive clones 
(random integration) were excluded from further analysis. 
Table 4-2: Frequency of clones with correctly targeted alleles in puromycin-resistant clones 
  Screened Excluded Total 
  Excluded  Included 
targeted allele 
Total 
screened 
  
Guide 
pair 
Donor 
form 
R M R+M HT+R HO+R HT HO  Growth 
characteristics 
 
N1N3 Linear  2      2  2 
            
N1N3 Circular 3 1 2 1 - 6 1 14 3 17 
%  21.43 7.14 14.29 7.14 - 42.86 7.14    
N4N5 Circular 2 1 - 2 3 19 7 34 7 41 
%  5.88 2.94 - 5.88 8.82 55.88 20.59    
 Total  Circular 5 2 2 3 3 25 8 48   
%  10.42 4.17 4.17 6.25 6.25 52.08 16.67    
       
Total  L+C 17 33 50 10 60 
R: Random integration; M: different band size (compared to control), indicating either deletion 
or insertion or targeting at one arm, HT: one allele targeted, HO: both alleles targeted, L: linear, 
and C: Circular. 
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4.2.3.3.3 Sequence verification of selected clones 
After excluding clones with random integration, the sequence of both the left and right arms of 
some selected clones was verified by Sanger sequencing (Figure 4-11.A and B). The sequence 
analysis of the left arm confirmed the correction of the disease-causing mutation and the 
introduction of the intended two SNPs upstream and downstream of the correction site indicating 
that gene modification occurred through HR (Figure 4-11.A). Notably, no on-target modification 
was detected at the DNA binding site for either sgRNA1 or sgRNA3. Surprisingly however, 
sequencing of the right arm revealed the presence of a deletion at the binding site for one of the 
guides in one clone. Evidently, separating the guide by insertion of the selection cassette did not 
completely eliminate indel formation at the targeted site. A recent study demonstrated that the on-
target indel frequency was reduced to 0.5 per cent ±0.4 per cent upon physical separation of the 
binding site of the guide pair with an insert in conjunction with Cas9DN [145]. The latter value was 
obtained by screening 188 clones at eight targeted sites. It was reasoned that on-target indels would 
be found to be a rare occurrence if a wider screen with a larger number of targeted clones was 
carried out (see below). Nevertheless, the presence of DNA modification at one guide binding site 
(sgRNA5) suggests that DNA nicks can be repaired through mutagenic pathways.  
Notably, the identified clone with the on-target mutagenesis was a compound heterozygote with 
different deletions occurring at both the targeted allele and the non-targeted allele (Figure 4-11.C). 
Sequencing of the original allele in heterozygotic clones (n=3) confirmed the earlier observation of 
abnormal band patterns at the original allele and revealed the presence of a DNA modifications in 
all the sequenced clones (n=3) (Figure 4-12). Merkle et al. [145] reported a high frequency of on-
target modifications at the untargeted allele, with a mean value of indel frequency of 26 per cent 
using the Cas9DN strategy. Therefore, it was postulated that it would be possible to identify clones 
with no indel at the original allele if more clones were screened. This is supported by the 
observation that sequencing revealed an intact original allele in two monoallelically targeted clones 
that were excluded because of the presence of random integration of the donor vector. 
Consequently, all the clones identified with monoallelic targeting (n=25) were screened for the 
presence of indel at the original (or untargeted allele) in addition to both left and right arm DNA 
regions of the guide binding sites at the targeted allele.  
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Figure 4-11: Sequencing of the DNA region around the targeted site in the corrected clones 
identified by PCR screening. (A) Sequencing of the left arm of the targeted allele revealed the 
correction of the disease-causing mutation and the presence of both SNPs. (B) Sequencing of the 
right arm identified the presence of a deletion at the gRNA5 binding site in one clone. (C) 
Sequencing of the original allele for the clone with possible nickase activity in (B) revealed the 
presence of an indel at both the targeted and the untargeted alleles. PB/ITR: piggyBac inverted 
repeat region. BT: beta thalassemia-iPSCs. 
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Figure 4-12: Sequencing of the original allele in clones targeted at one allele revealed the 
presence of indels in each of the selected clones. 
Screening the untargeted allele will provide a more comprehensive analysis of the on target 
mutagenesis at the original allele as a result of the activity of either dual or single Cas9n. Screening 
the targeted allele will specifically assess the frequency of indel generation as a result of nickase 
activity, as one of the guide pairs is either inactivated (due a mutation in the PAM motif) or 
destroyed by the insertion of the selection cassette. To assess this, the HMA was recently put 
forward as an efficient high-throughput method for screening for Cas9-induced allelic alterations 
[183]. A genotype screen was therefore carried out using HMA and the results verified by 
sequencing random samples. 
4.2.3.3.4 PAGE-based genotyping (HMA) of nickase binding sites 
PAGE-based genotyping was used to further characterise on-target alterations mediated by either 
nickase or paired nickase. Three sets of primer pairs that spanned the predicted indel sites were used 
to amplify short amplicons around the Cas9n binding site at both arms of the targeted insertion and 
in the original allele. Each primer set included a forward gene specific primer coupled with either a 
reverse gene-specific (untargeted allele) or insertion specific (targeted allele) primer. To screen for 
alteration at either the original or the targeted allele, PCR amplicons generated from the BT-iPSCs 
and the donor plasmid (or one homozygous targeted clone verified by sequencing) were used for the 
formation of DNA duplexes, respectively. Heteroduplex mobility is slower due to the formation of 
the open angle at the site of the mismatch [183], resulting in a different band migration patterns in 
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native PAGE for homoduplex and heteroduplexes as well as for heteroduplexes with a different 
type of mutation mismatch. The variability in the band pattern was assessed relative to a control 
homoduplex formed by hybridisation of PCR product from the control sample (e.g. BT-iPSCs) to 
rule out artefacts produced during PCR amplification.  
(A) On-target modification at the original allele in heterozygous clones (due to Cas9n or Cas9DN 
activity): 
The large variability in the size of PCR amplicons across clones was discernible by agarose gel 
(Figure 4-13.A). However, HMA revealed the complex composition of the PCR products obtained 
from a single clone. In fact, multiple heteroduplex bands were observed for some clones (Figure 
4-13.B and C: Lane2, 18 and 19), indicating that those clones were heterogeneous. The 
heterogeneity may have resulted from a possible mosaicism due to non-unicellular source, or may 
indicate modification in a subset of cells as a result of continuous nuclease activity as suggested in a 
previous study [145]. The data also indicate that indels were present at the untargeted allele in all 25 
potential heterozygous clones included in the screen. Notably, the high rate of indels at the 
untargeted allele was irrespective of the guide pairs (sgRNA1/3 and sgRNA4/5) used to target the 
locus. Moreover, PAGE-based analysis also showed that different types of mutations had been 
introduced as revealed by the distinct, and unique band patterns observed for each clone (Figure 
4-13.B, C and D). 
Three samples were randomly selected for sequencing. Sequence analysis provided further evidence 
that indels occurred at the sgRNA binding sites with complex allelic alteration patterns that 
included insertions, deletions and substitutions on the same allele (Figure 4-13.E, and F). 
Remarkably, the introduction of a single base substitution (G>A) was observed at position 16 of the 
binding site for one of the guide (sgRNA5) in two out of the three sequenced clones (Figure 4-13.E 
and F: L4 and L17). To achieve a more comprehensive understanding of the mutation pattern 
induced by Cas9-DN strategy, additional heterozygous clones were sequenced. Sequencing data 
revealed a mutation spectrum that consisted of a deletion range that varied between 5 and 54 bp, 
affecting the intervening sequence (offset sequence) between the guide binding sites (Figure 4-13.G 
and H, and Figure 4-14.A). The latter was observed in all the untargeted alleles analysed (Figure 
4-14.A). 
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Figure 4-13: Detection of undesired mutagenesis at the original allele in heterozygous clones. 
(A) Band patterns of PCR products obtained by amplifying a short DNA region that spans the 
guide RNA binding site, resolved on 2 per cent agarose gel. (B, C, D) PAGE-based genotyping 
of the original allele in heterozygotes clones revealed a Cas9-DN- or Cas9n-mediated indel at the 
original allele in all heterozygote clones screened. (E and F) Validation of the HMA results by 
sequencing three randomly selected clones (Lanes 4, 10 and 17) obtained by sgRNA4/5 and the 
mutation pattern observed. (F) The red triangle indicates the nick site, dashed line: deletions, red 
bases: insertions and green bases: substitutions. (G) Sequencing result of additional clones (9) 
targeted by sgRNA4/5. (H) Sequence result of untargeted alleles in four clones obtained by 
targeting with sgRNA1/3. The sequence revealed a pattern that includes small deletions, deletion 
+ insertion and deletion + inversion + insertion. (I) analysis of the complex mutation (deletion, 
insertion, and insertion) observed in one clone (C3/1). 
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The active guide binding site (minimum 17 bp [92]) remained intact in 7/12 and 2/4 alleles of cells 
targeted with sgRNA4/5 or sgRNA1/3, respectively. Short microhomology regions (2-4) flanking 
the deleted sequence were identified in 67 per cent of the clones verified by sequencing 
(sgRNA4/5) (Figure 4-14.A and B) [206]. Usually, this pattern of deletion is associated with the C-
NHEJ DNA repair pathway [110]. 
 
Figure 4-14: Mutation patterns observed at the original allele in heterozygous clones targeted 
with sgRNA4/5-Cas9DN. Micro-homology sequence flanking the deleted region varied between 
2–4 bp in 8/12 clones. (B) the observed frequency of clones with the indicated micro-homology 
sequence size. (C) The mutation pattern included deletions or mixed (deletions, insertions, and 
substitutions), the frequency of clones identified with the indicated size range is shown. sgRNA 
sequences are highlighted in grey flanked by the PAM sequence in red, micro-homology 
sequences are underlined, deleted sequence flanked by micro-homology are in red, and the 
deleted sequences in the remaining clones (4) are in green, insertion is in blue, and substitutions 
in lower case. 
Intriguingly, an inversion with deletion and an insertion of 17 bp was detected in two clones 
targeted with sgRNA1/3 (Figure 4-13.H and I). These data suggest that the length of the overhang 
may play a role in determining the mechanism of repair. In fact, different mutation patterns have 
been reported for ZFNs and TALENs, which were also attributed to the differences in the spacer 
size [207]. However, the small number of clones analysed for sgRNA1/3 guide pairs does not allow 
proper and reliable analysis. The repair speed and the local DNA environment can also affect the 
repair path [131]. The targeted site for sgRNA1 may be located in a region of nucleosome 
occupancy (PSC track not available) which may impact the speed of repair, resulting in a different 
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mutation pattern compared to that of sgRNA4/5 (Figure 4-15). Interestingly, nucleosome 
positioning has recently been implicated in restricting Cas9 activity [80]. 
 
 
Figure 4-15: Nucleosome occupancy for the DNA region targeted by sgRNA1/3-Cas9DN in 
two different cell lines. The targeted region for sgRNA1/3 is shown as a black solid box. 
The unexpectedly high rate of on-target mutagenesis observed at the untargeted allele can perhaps 
be attributed to the amount of plasmid used as current evidence suggests that increasing the plasmid 
dose can increase the on-target mutation frequency [74, 145]. Indeed, an on-target indel frequency 
of 26 per cent at the original allele was reported by Merkle et al. [145] upon using 1 g of the 
vector (3-6 x106 cells) whereas 2 g (2x106 cells) was used in the current study, resulting in 25/25 
clones with monoallelic targeted events that carried a mutation. However, it should be noted that 
despite the difference in the amount of plasmid used, the majority of the targeted clones (20/25) did 
not carry multiple alleles, as judged from their band patterns and confirmed by sequencing (for 
limited clones), whereas Merkle et al.[145] identified multiple alleles possibly as a result of 
continuous plasmid expression which was reasoned to lead to the formation of multiple types of 
indels in a subset of cells within the same clone. These data can be interpreted as meaning that 
while on-target mutation can certainly be influenced by the vector dosage, locus-dependent 
characteristics can also play a role in modulating this activity.  
(B) On-target modification at the guide binding site in both left and right arms (Cas9n activity) 
No mutation were detected at either the sgRNA3 or the sgRNA4 binding sites. Remarkably, the on-
target allelic modification was identified at sgRNA5 in the right arms of heterozygote (Ht) and 
homozygous (Ho) clones (3/19 Ht and 2/6 Ho) (Figure 4-16.A: Lane 4, 12, 18 and C: Lane 3 and 7) 
targeted with sgRNA4/5, despite the separation of the guide pair. This indicates that indels most 
likely resulted from the activity of a single nickase.  
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Figure 4-16: Screening for DNA modification at the guide binding site on the right arm in 
DNA obtained from targeted clones. PCR amplicons of (A) 19 clones with one targeted allele 
(Ht) (C) or in clones with biallelic targeting (Ho) were separated on 2 per cent agarose gels. 
Three bands with deletions were observed in Ht and two in Ho clones. (B, C) HMA confirmed 
the presence of the deletion. Arrows with similar colours indicate the same clones and asterisks 
indicate the heteroduplex band location. Hybridisation was carried using unpurified PCR 
products. (E) Sequence analysis of the sgRNA5 binding site for identified clones (Lanes 4, 12 
and 18 in Panel A). Lane11: homozygous clone verified by sequencing (biallelic targeted clone: 
BT-T). 
Table 4-3: Frequency of on-target mutagenesis observed at the sgRNA5 binding site in mono- 
and bi-allelic targeted clones obtained using a strategy that destroy the binding site for one 
guide of the pair sgRNA4/5 . 
sgRN4/5       
Original allele   No. of 
clones 
analysed 
Indel Clone intact 
at original 
allele 
 
Heterozygous  19 19 0  
 
Targeted 
allele 
  No. of 
clones 
analysed 
Indel No. of 
targeted 
alleles 
Indel allelic frequency at 
the targeted allele 
 Heterozygous  L/arm 19 0 19 15.79% 
 R/Arm 3  
Homozygous L/Arm 7 0 14 14.29% 
 R/Arm 2  
mean     15.04% 
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In contrast to the findings of Merkle et al.[145],  these observations suggest that this design strategy 
can also result in a relatively high frequency of on-target mutagenesis as a result of nickase activity 
associated with one of the guide (gRNA5). In this study, the on-target indels induced by sgRNA5-
Cas9n at the targeted allele with a mean allelic indel frequency of 15.04 percent (Table 4-3).  
The presence of indels was further confirmed using HMA (Figure 4-16.B and D). The faint band 
observed for the heteroduplex bands may be the result of the disproportionate amount of PCR 
product used to form the mix. In fact the intensity of the band for the control (homozygous clone 
verified by sequencing) (Figure 4-16.C: Lane 11) indicates a higher PCR efficiency for the control 
clone compared to other tested samples (the intensity was more than two-fold higher, as calculated 
by Image Lab software). This highlights the importance of using normalised amounts in the mix if 
one wishes to reliably detect the heteroduplex.  
On the other hand, the analysis of bands for the left arms revealed an abnormal band pattern in only 
one clone which suggests a possible deletion at one allele and an insertion at the second allele 
(Figure 4-17.B: a lane2). However, a similar band pattern was also observed at the original allele 
(Figure 4-13.A: Lane 2), which may indicate a duplication or a heterogeneous clone (clone 
excluded from further analysis). Although it was possible to identify six correctly biallelic targeted 
clones from eight homozygous clones (for both sgRNA1/3 and sgRNA4/5), all the heterozygous 
clones carried an indel at the untargeted allele. 
 
Figure 4-17: Screening for DNA modifications at the guide RNA binding site on the left arm 
of DNA extracted from targeted clones. (A) PCR band patterns resolved on 2 per cent agaros 
gels indicating that the clone in Lane 2 has both a deletion and insertion at this site, Lane 2 2–15: 
targeted clones, Lane 18: positive control (donor plasmid), Lane 16: negative control (BT-iPSCs) 
and Lane 17: PCR blank control. (B) PAGE-based genotyping indicating the absence of 
heteroduplexes with the exception of the sample in B (a) Lane 2 (same clone in A, Lane 2). 
Overall, these data suggest that nickase activity could also be associated with mutagenesis, possibly 
by single break conversion to DSBs with subsequent stimulation of the repair mechanism through 
the error-prone NHEJ pathway [208]. The majority of the reported studies on nickase activity were 
performed in immortalised or transformed cell lines such as HEK293, K562, Hela and U2OS cells 
[58, 61, 96, 98, 209], and described an activity that varied between minimal to absent, whereas in 
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PSCs the activity was reported to be undetectable [58]. However, a more recent study observed an 
indel frequency of 4 per cent at the guide binding site at the original allele (untargeted allele in 
targeted clones) induced by a monomeric nickase activity in iPSCs  [145]. The mean calculated 
allelic frequency in the current study is 15.04 per cent associated with one guide only (sgRNA5), 
while no mutagenesis was associated with sgRNA3 or gRNA4. Although the indel frequency in 
iPSCs seems to be higher than that reported by either Tsai et al. [98] of 1.02 per cent (0.0048 per 
cent to 3.04 per cent) or Hsu et al. [58] of 1.1 per cent in transformed cell lines, the indel frequency 
in both the current study and that of Merkle et al. [145] was not estimated in the bulk cell 
population. In fact, in the present study, the double nickase strategy that displayed a 100 per cent 
indel frequency in the targeted clones was below the detection limit of the Surveyor assay in the 
bulk cell population. 
Upon further examination of the data reported by Merkle et al. [145], the frequency of indels 
induced by Cas9n varied across different loci and over a wide range under the same experimental 
conditions (plasmid-based expression, amount of plasmid used, ratio to donor template, transfection 
conditions etc), at the targeted allele (mean=4 per cent). This may indicate that the sequence context 
of the targeted site can be a determinant of either the repair mechanism [131] induced by the DNA 
nick or the activity of the guide. The latter has been demonstrated to be affected by the sequence 
content [210]. Furthermore, although the Merkle et al. [145] study reported a total mean indel 
frequency for Cas9WT that is higher than Cas9n (10-fold difference for the untargeted allele), the 
distribution pattern of the data was similar. In other words, both the Cas9WT and the nickase 
variant can have high and low frequencies of mutagenesis depending on the locus, which was 
particularly obvious at the targeted allele. Remarkably, the average frequency of mutagenesis at one 
locus (HCRT-C2) was higher for Cas9n (compared to Cas9WT). 
It is likely that the relatively high rate of on-target indels (at the targeted and untargeted allele) in 
the current study can be attributed to a combination of factors in the strategy used. For example, 
these factors include the use of plasmids for transfection, as plasmids have been demonstrate to 
produce sustained expression of Cas9 protein over several days, which can expose cells to 
continuous activity of the enzyme, as opposed to using Cas9 protein, which is cleared from cells in 
less than 24 hours [93, 94]. Moreover, the amount of plasmid used for transfection can affect the 
efficiency of endonuclease activity [58, 74], while chromatin factors at the targeted locus, the 
sequence of the targeted site and the donor template strategy [145] have been reported to affect the 
targeting efficiency and activity of the Cas9 protein. A recent report described a loss of blue 
fluorescent protein (BFP) signal, reflecting a NHEJ event, from a BFP reporter upon transfection of 
cells (HEK293) with the ribonucleoprotein form of Cas9N and ssDNA donor [71]. Similar 
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observations under different experimental conditions may indicate that mutagenesis with nickase is 
a consistent finding that can be obtained with Cas9N delivered either as a plasmid [145] or as a 
ribonucleoprotein [71] at certain loci. Whatever the precise mechanism, nickase is clearly 
associated with mutagenesis at a rate that is sequence- and/or locus-dependent [145]. The dual 
nickase approach was suggested to maintain the targeting efficiency of Cas9WT while reducing the 
potential for adverse mutagenic off-target activity [61, 96]. This was based on the hypothesis that 
SSBs are mostly resolved through the efficient housekeeping process that removes SSBs [97]. 
However, the results of the present study shows that undesired on-target indels can be avoided for 
some guide whereas the presence of an indel at the binding site of another guide binding site 
suggests that nickase can use an error-prone repair mechanism, which casts doubt on the suitability 
of this approach for producing safe, precisely edited iPSCs destined for clinical applications. A 
better understanding of the factors and conditions that determine the choice of repair path following 
DNA nicks is needed to design foolproof strategies that permit efficient and specific gene targeting 
in iPSCs.  
4.2.4 Assessment of off-target activity for gRNA 
 
Figure 4-18: Screening of five potential off-target loci for each gRNA in three different 
targeted clones. Cropped image of PAGE gels for hybridised PCR products obtained by mixing 
amplicons from the parental clone (BT-iPSCs) and the indicated targeted clone using five pairs 
of primers. Primers were used to amplify the DNA fragment across the potential off-target site 
(P1–5) for clones transfected with either (A) sgRNA1/3 or (B) sgRNA4/5. Two bands are shown 
for each site; the first is for the hybridised products of BT-iPSCs (control), and the second is for 
the hybridised products obtained after an equimolar mix of PCR amplicons derived from BT-
iPSCs with the targeted clone. 
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To examine the possibility of off-target mutagenesis induced by Cas9n, the five top-scored genomic 
sites that bore high sequence homology to the sgRNA-targeted region were screened for the 
presence of mutations. Ten potential DNA sites for each guide pair (five sites per sgRNA) were 
screened using 10 different primer pairs that span the intended genomic site in three different 
clones, one generated using the sgRNA1/3 and two using the sgRNA4/5 guide pairs. PCR 
amplicons obtained from the selected clones were mixed with amplicons obtained from the BT-
iPSCs, and the hybridised product was analysed using native PAGE [183]. The presence of 
heteroduplex bands was used to indicate the presence of allelic mismatches (relative to the BT-
iPSCs parental line) at the screened DNA site. No off-target activity at the selected loci was 
detected as evident from the presence of only a single band, indicating that only homoduplexes 
were formed between amplicons (Figure 4-18).  
 
 
Figure 4-19: Verification of selected off-target sites by Sanger sequencing. A representative 
sequence of one off-target site for (A) sgRNA1/3 and (B) sgRNA4/5, showing the sequence in 
the parental clone (BT-iPSCs, upper) and that of the targeted clones (lower). (C) The sequence at 
the P2 site for potential off-target sgRNA4 indicates possible heterozygosity present in the both 
the parental (BT-iPSCs) and targeted clones. 
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The presence of four heteroduplexes and the absence of a homoduplex at one site (P2) for sgRNA4 
in both screened clones does not suggest off-target activity, as a similar pattern was observed in BT-
iPS clones. Rather, the pattern suggests heterozygosity at this locus.  
The sequence was further verified by Sanger sequencing for three randomly selected off-target sites 
(P1-5) for each gRNA, including the DNA site for off-target 2/sgRNA4 (Figure 4-19.A and B). 
Sequence analysis confirmed the heterozygosity of the BT-iPS clones at this locus and the absence 
of DNA modifications in the targeted clones (Figure 4-19.C). The sequence was further 
deconvoluted using Surveyor mutation software by SoftGenetics (Pennsylvania, USA). This finding 
highlights the importance of including the parental line as a control to detect heterozygosity at the 
analysed DNA sites. The presence of unique SNPs in some cell lines raises potential concerns about 
the limited reliability of the currently available in silico predictive tools that identify potential off-
target sites based on homology to the consensus genomic sequence. 
4.2.5 Seamless excision of the selection cassette in the corrected clones 
 Excision of the selection cassette 
The main rationale for using the piggyBac transposon system in gene correction is that it affords 
eventual seamless excision of the selection cassette upon transfection with transposase. Enrichment 
of cells that have lost the expression of the viral thymidine kinase (truncated version,  HSV-TK in 
this case) marker can be achieved through negative selection with 1-(2-deoxy-2-fluoro-beta-D-
arabinofuranosyl)-5-iodouracil (FIAU) [182].  In the presence of FIAU, a nucleoside analogue, the 
active expression of tk driven by PGK leads to production of a toxic metabolite that kills the cells 
that express the gene. In order to establish an optimum dose of FIAU suitable for negative selection 
of the corrected iPSCs with a restored allele, a dose response curve was generated using 
biallelically-targeted cells. Interestingly, a high background was observed over a wide range of 
FIAU concentration (0.2-50 M) using positive control cells (BT-T: homozygous targeted cells) 
plated either on either MEF or feeder free on ECM. The low efficiency of the FIAU selection 
possibly indicates that the cassette was silenced, perhaps because it is inserted into an inactive locus 
(HBB) not expressed in iPSCs.  
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Figure 4-20: Schematic of the screening strategy used to identify gene-corrected clones with 
excision of the selection cassette insert and its validation. (A) Two sets of multiplex primers 
were assessed. Each primer set include three different primers: (1) a common gene-specific 
primer upstream or downstream of the insertion site (), (2) insertion-specific primers () 
and (3) a reverse gene-specific primer (). This strategy allows simultaneous amplification of 
the corrected allele that excised the selection cassette and the targeted allele if present. (B) 
Amplicons obtained by using the gene-specific primer pair (red arrows) in the presence (A1) and 
absence (A2) of the insertion-specific primer P3 (ITR region of piggyBac) in iPSC lines with a 
beta thalassaemia mutation (BT-iPSCs: Lanes 2 and 6), WT-iPSCs (Lanes 4 and 8) and two 
biallelic targeted line (BT-T iPSCs: Lanes 3, 5, 7 and 9). 
A similar observation was reported in a study where a different (hygromycin) selection cassette 
driven by PGK promoter was inserted into the first intron of the HBB gene in iPSCs. These authors 
attributed the decrease in transgene expression to epigenetic factors after expansion of the cells in 
the absence of selection for a few passages [141]. Despite these caveats, we set out to test if the low 
efficiency of the FIAU selection would be sufficient for the enrichment of the restored allele in the 
corrected clones. Two biallelically-targeted (A, and B) and two monoallelically-targeted (C, and D) 
clones, were initially transfected with a plasmid expressing HA-tagged hyperactive piggyBac 
transposase. The expression of the transposase was driven by a CMV promoter. Transfected cells 
were passaged on Day 3 (in the absence of puromycin) and plated at low cell density before 
subjecting them to FIAU selection for eight days. Clone screening was carried out using a set of 
primers that included a common primer located upstream or downstream of the excision site and 
two additional primers, either a gene-specific or an insertion-specific primer (Table 2-5.A and B). 
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Each primer set was designed to generate amplicons with different sizes to indicate the presence or 
absence of the selection cassette (Figure 4-20.A) [182]. 
 
Figure 4-21: Screening for the restored allele following transposase transfection and selection 
with FIAU. Band patterns obtained using the screening strategy shown in Figure 4-20 upon 
transfecting (A) a biallelic targeted clone with transposase, followed by FIAU selection. The 
pattern indicate that the excision of the selection cassette occurred in a small subset of cells of 
the identified clone (Lanes 7, 11, 31, 37 and 39); (B) whereas none was detected in either clone 
B (biallelic targeted clone) or clone D (monoallelic targeted clone) and one in clone C 
(monoallelic targeted clone, B: Lane 20). PCR band size of 233 bp (red arrows) indicate a 
restored allele and PCR band size of 130 bp (black arrows) detect the presence of the insert. The 
size of the amplicons generated by the untargeted allele in the monoallelic targeted clones (MT-
T) displayed deletions that were different from that obtained for the restored allele (green and 
blue arrows). The deletions resulted in either a small shift in the band (clone C, 213 bp) or a 
different band size (clone D, 179 bp). 
The band pattern was used to genotype the DNA region spanning the TTAA site. The screening 
strategy was validated using the BT-iPSCs and cells carrying a biallelic integration of the cassette 
(Figure 4-20.B). Eight clones derived from clone A and one from clone C (from  48 screened 
clones) displayed a band pattern that indicated possible excision of the cassette, whereas none was 
detected in clones derived from B and D (Figure 4-21). Of note, the size of the amplicons generated 
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by the untargeted allele in the heterozygous clones displayed deletions that were different from that 
obtained for the restored allele. The deletions resulted in either a small shift in the band (clone C) or 
a different band size (clone D). To overcome this hurdle an alternative strategy for enriching and 
isolating iPSCs with rare events was adopted. The approach was adapted from McCormick et 
al.[211] and Miyaoka et al. [203] where the former proposed enrichment by fractionation with a 
simultaneous use of an assay to detect the presence of the modified gene, while the latter applied the 
approach in conjunction of droplet digital PCR in iPSCs [203, 211]. Therefore, in order to avoid 
screening of hundreds of cells, the applicability of using a stepwise approach that involved: (1) 
FIAU selection to eliminate cells expressing tk (inefficient), (2) a sequential fractionation of the 
positive cell pools that displayed a positive band (screening with PCR) for the restored allele to 
enrich for cell populations with positive events, (3) plating cells at low density with subsequent 
screening and isolation of clones with the restored allele by limiting dilution (details are provided in 
the Material and Method) was assessed. The PCR strategy used to detect excised events (positive 
cells) is shown in (Figure 4-20.A).   
Cells from two different biallelic targeted clones (E, and F) were transfected and passaged on Day3 
for two cycles (instead of one), with subsequent plating at low cell density into two different plates 
(pool 1 and 2) before subjecting them to FIAU selection for eight days [182]. The cells were 
dissociated and divided into two fractions. The first fraction was plated at low density and the 
second fraction was used for DNA extraction and screened using multiplex PCR (Figure 4-22). Two 
bands were observed in both fractions indicating the presence of alleles with an excised cassette. 
 
Figure 4-22: Screening of pools of iPSCs to identify the fraction with the highest percentage 
of alleles with an excised selection cassette. Screening for cassette excision was carried out 
using two primer sets (SV3+P5 and MA233FR+P3) in cell pools collected at Passage 2 after 
transfection with transposase and subjected to FIAU selection for eight days. Two cell pools 
from each clone were screened (Clone E: 1E and 2E, Clone F: 1F and 2F). The pool with the 
highest proportion of excised events was selected for further screening after plating cells at low 
density. Bl1 and Bl2 are blank controls for the different primer sets. 
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The fraction with the highest percentage of the restored allele (Figure 4-22: Lane 2E and 2F) was 
used for subsequent culture. The variable band intensity between the different primer sets most 
likely reflects differences in primer efficiencies. Nevertheless, both primer sets indicated that the 
restoration of the original corrected allele occurred in a subset of cells. Clones obtained from the 
low-density plating were further screened for biallelic excision. A mixed band pattern was observed 
in the majority of the clones (Figure 4-23.A and B). 
 
 
Figure 4-23: Screening of clones for biallelic excision of the selection cassette. (A and B) 
Band patterns observed upon screening clones obtained by plating cells with the highest 
proportion of excised events for two clones with biallelic targeting. (C and D) Band patterns 
observed upon screening clones obtained by deriving single cell-based clones by limiting 
dilution in a 96-well plate. The C1 clones were derived from Clone E, Lane 23, C2 clones were 
derived from Clone F, Lane 25 and C3 were derived from Clone E, Lane 8. 
Most of the clones were either negative for the excision or contained heterogeneous cells, as 
indicated by the disproportionate band intensity of the amplicons. Satisfyingly, few clones 
displayed a biallelic excision in the bulk cells population (Figure 4-23.A: clone E: Lane 4 and clone 
F: Lane 3 and 30) as indicated by the prominent band observed for the restored allele. 
Consequently, clonal isolation by limiting dilution was performed for selected clones followed by a 
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second round of screening (Figure 4-23.C and D). Two cycles of plating enriched cells followed by 
screening enabled us the purification and isolation of clones with biallelic excision as indicated by 
the presence of a single band. Remarkably, while the band pattern for some clones indicated that 
they mostly formed from cells with either biallelic excision or no excision (Figure 4-23: C, D: clone 
C2), other clones displayed a pattern that indicates monoallelic excision Figure 4-23: C, D: clone 
C3). It should be noted that some wells contained more than one clone which explains the 
disproportionate intensity of bands in some lanes (Figure 4-23: Lane 23, 28 and 32). 
 Screening for random reintegration of the cassette 
Although transposase allows precise excision, the enzyme activity can be associated with 
reintegration of the excised insert into the genome. To assess this, the clones were screened for the 
presence of reinsertion of the cassette using a primer pair that detects the presence of the puromycin 
insert. Some clones (e.g., 5/7 for colonies derived from one parental clone: BT-T iPSCs) displayed 
a puromycin-specific band, while others did not (Figure 4-24.A). The sequence of the amplicon 
obtained from the gene-corrected clones confirmed the precise biallelic restoration of the TTAA site 
after excision (Figure 4-25) and an absence of cassette reinsertion was confirmed by puromycin 
resistance gene-targeting PCR (Figure 4-24.C). 
 
 
Figure 4-24: Screening for the excision of the selection cassette and the absence of 
reinsertion. (A) Amplicons obtained from colonies derived by limiting dilution from the same 
iPS clone indicate the absence of reinsertion in 2/7 clones screened (Lanes 7 and 8); Lane 2, 
negative control (BT-iPS clone); Lane 3, positive control (clone with targeted allele). (B) 
Analysis of amplicons obtained by multiplex PCR from selected clones indicates selection 
cassette excision in clone C1, C2, C5 derived from clones T1, T2, and T5. Analysis of amplicons 
obtained with puromycin resistance gene-targeting PCR indicates the absence of reinsertion of 
the selection cassette in biallelic (c-BT-C1 and C2) and monoallelic ( c-MT-C5) gene-corrected 
clones following transfection with transposase and single cell cloning  by limiting dilution (from 
original targeted iPS clones BT-T1, BT-T2, and MT-T5). BT-T1, BT-T2, and MT-T5: Parental 
targeted iPSCs, BT : beta thalassemia iPSCs, and WT: wild type iPSCs control.  
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Figure 4-25: Restoration of the TTAA site after excision of the cassette. (A) The sequence of 
the corrected allele showing three SNPs at the designed location: a SNP in the PAM sequence, 
correction of the disease-causing mutation, and a SNP introduced in the intron. (B) Enlarged 
section of Figure (A) displaying the sequence of the mutation and TTAA sites in BT-iPSCs, and 
corrected iPSCs after excision of the insert.. 
4.2.6 Characterisation of gene-corrected iPSC clones 
Three clones were selected for further experimentation and validation (gene activation). Two clones 
that are seamlessly corrected at both alleles and one clone that was heterozygous with one allele 
carrying an intron II 20bp deletion were subjected to karyotype analysis (Figure 4-26). Each of 
these clones displayed a normal karyotype and expressed pluripotent markers that include OCT4, 
and TRA-1-60 (Figure 4-26).    
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Figure 4-26:  Characterization of the corrected iPSCs.   
(A, and B) Representative karyotype analysis of two gene-edited iPSC lines with uniform 
expression of pluripotent stem cells markers that include (A1-A3, and B1-B3) OCT4 and (A4-
A6, and B4-B6) TRA1-60. 
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 Conclusion 
This chapter describes the successful seamless site-specific gene correction of a beta thalassaemia 
causing mutation (IVSII-I G>A) in iPSCs using the double nickase (Cas9-DN) approach [95, 96]. 
In agreement with a previous study, the efficiency of the targeting events in the bulk iPSC 
population was low [145]; however, both biallelic and monoallelic modifications were achieved. 
Six out of 33 correctly biallelically targeted clones without random integration were obtained using 
two gRNA pairs sgRNA1/3 and sgRNA4/5. Genotyping of the guide binding site at the original 
allele (untargeted allele) in heterozygous clones revealed a considerable frequency of on-target 
mutagenesis that occurred at a rate that is higher than that reported by Merkle et al. [145]. It is 
known that the efficiency of Cas9 activity can be affected by the amount of vector used [58, 74, 
145] and it may therefore be possible to isolate clones with unmodified original alleles by titrating 
down the sgRNA-Cas9n vector concentration. However, this will also reduce the efficiency of HR-
mediated repair.  
To improve the editing rate (prevent on-target activity at the targeted allele) following HR, two 
different design-strategies that prevent generation of the on-target DSBs in the donor vector and 
targeted allele were implemented [145, 198]. No on-target mutagenesis was observed for clones 
targeted with the guide pair with the inactivated PAM site. However, unlike the Merkle et al.[145] 
study, which suggested that separating the guide binding sites can abolish on-target mutagenesis, 
the result of the current study indicate that the indel allelic frequency at the targeted allele remained 
relatively high for one guide. It is not unlikely that the mitigating effect reported by Merkle et al. 
[145] following the separation of the nick site in the context of the DN strategy is attributable to the 
reduced load of sgRNA compared to Cas9n as the amount was divided between the guide pairs. 
This inference is based on the observation that mutagenesis was associated with monomeric Cas9n 
strategies (4 per cent at the original allele), whereas no indel was reported for monomeric Cas9n in 
the context of nick site separation in the DN strategy. Unfortunately, the Merkle and colleagues’s 
study [145] did not provide data on the utility of this strategy with guides that display the highest 
on-target activity at the targeted allele.  
Even though the number of guides and loci evaluated in the current study are limited, the data 
appear to indicate that mutagenic activity of monomeric nickase can be sequence-dependent rather 
than reflecting a design strategy. In other words, the paired nickase approach is not a true dimeric 
approach; in fact, monomeric nickase retains some activity that can be guide sequence- or locus-
dependent [98, 145]. Clearly, inactivating one guide will reduce on-target mutagenesis at the 
targeted allele, but the rate will depend on the activity of monomeric sgRNA-Cas9n. In fact, guide 
sequence composition can play a role in forming stable structures that have been associated with 
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efficiency of activity using Cas9WT [210]. Guide 5 had the highest number of guanine bases and is 
likely to generate more stable DNA/Cas9n complex. Moreover, a difference in the mutation patterns 
was observed at the original allele for clones targeted with sgRNA1/3 and sgRNA4/5. The offset 
distance (28 and 5 bp) differed, generating longer overhang with sgRNA1/3 which may explain the 
more complex pattern of deletions, inversions and insertions. However, in contrast to Kim et al. 
[207] the larger overhang was associated with a larger insertion. Interestingly, the sgRNA1 binding 
site resides in a high nucleosome occupancy area, which has been reported to restrict Cas9 activity 
[80]. However, it is not clear if this will also impact on the mechanism of repair as the speed of 
repair have been reported to determine the repair path in the G2 phase of the cell cycle [131]. 
 Despite the unexpected mutagenesis with one of the sgRNA, this strategy was effective at limiting 
on-target mutagenesis as evidenced by the large difference in the indel frequency observed between 
the targeted and untargeted alleles. Indeed, using this strategy, it was possible to identify clones 
with correct biallelically targeted events. Although the data did not reveal off-target activity upon 
screening the top predicted site based on sequence homology, nicks can be occasionally repaired 
through error-prone pathways, as evidenced by the presence of on target-mutagenesis [71, 98, 145]. 
To restore the integrity of HBB locus following gene targeting, the piggyBac-based donor design 
that facilitates seamless excision of the selection cassette was adopted [182]. Despite the fact that 
negative selection was inefficient, perhaps due to possible silencing of the cassette [141], clones 
with restored wild-type sequence were isolated at both alleles by implementing a stepwise approach 
for enrichment and screening, followed by clonal isolation by limiting dilution. This strategy was 
adapted from Miyaoka et al. [203] and McCormick [211]. HMA-based genotyping was also 
validated as an effective and reliable approach for screening for the on/off-target changes in 
genomic DNA [183]. For this assay, including a control to identify heterozygosity in the parental 
cell line reduced false positive results, while using an equimolar amount of the hybridised products 
ensured a reliable and sensitive assay in the absence of PCR product purification. Thus, with careful 
design of the targeting strategy and determination of the right balance between Cas9-DN activity 
and gRNA design, this method should be able to be used to improve editing rate for the seamless 
correction of any gene mutation in iPSCs, provided this is combined with careful screening and 
analysis of both alleles in putative corrected clones and verification of the absence of transposon-
mobilised cassette reintegration. 
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CHAPTER V: 
TARGETED TRANSCRIPTIONAL ACTIVATION OF THE β-GLOBIN 
GENE 
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5 TARGETED TRANSCRIPTIONAL ACTIVATION OF THE β-GLOBIN GENE 
 Introduction 
To demonstrate the restoration of the wild type phenotype in gene-corrected disease iPSCs, the 
corrected cells are commonly differentiated into specialised cell types that express the edited gene 
[77, 212]. However, differentiated iPSCs mostly fail to adopt a mature phenotype, and this 
evidently limits the functional analysis of the corrected allele for genes that are associated with 
mature phenotypic characteristics. This is particularly relevant for correction of disease-causing 
mutations in the -globin gene, such beta thalassaemia major [35, 141]. Indeed, the -globin gene is 
only expressed during the late stages of erythropoiesis and is considered an adult attribute (HbA). It 
has been shown that erythroid cells, derived by the currently available methods for directed in vitro 
differentiation of iPSCs, mostly adopt an embryonic phenotype with variable expression of foetal 
globin and failure of efficient globin switching to -globin [154]. To circumvent this problem, in 
this study an alternative approach was considered, which takes advantage of CRISPR-mediated 
transcriptional activation of the endogenous gene [156] to assess the restoration of adult gene 
expression following gene correction of a mutation associated with a loss of function in monogenic 
disease. 
Using the null Cas9 variant as a targetable programmable protein to direct a single VP16(n) [79, 95, 
163] or multiple TDs (VP64-p65-Rta and VP64 +MS2–p65–HSF1) to cis-DNA elements in the 
proximal promoter region of genes [165, 166] has been shown to be sufficient to modulate gene 
expression in a range of cell types, such as HEK293 and iPSCs. Activation of transcription through 
this technology is achieved by recruiting various chromatin remodelling and transcription factors to 
the targeted sites, which facilitates the assembly of the preinitiation complex [213, 214]. This 
approach can also be adapted to mediate gene activation by directing epigenetic regulators to the 
enhancer regions of specific loci [172]. Although variability in the potency of gene activation 
between different targeted gene regions was observed [160], the activation level was sufficient to 
enable the replacement of reprogramming factors (OCT4) [160] in iPSC generation or to induce the 
differentiation of hiPSCs [160, 166, 215]. For some loci, gene expression levels can be achieved 
that approach those of native tissue, provided enhanced activation systems are used [166]. Notably, 
the activity of some guide combinations has been reported to be cell-type dependent (under some 
experimental conditions). For example, guides targeting the promoter region of the HBG1 gene 
increased the expression of this gene in HEK293 cells, yet failed to do so in human dermal 
fibroblasts [216]. In the case of epigenetic modulation of the HBB gene with programmable 
proteins, variable outcomes have been reported. Targeting the LCR region of the -globin locus 
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with the epigenetic regulator Cas9p300core did not result in HBB gene activation in HEK293 cells 
[172], whereas targeted demethylation of specific CpGs (TALEN-TET1) in the promoter region 
strongly upregulated -globin gene expression in K562 cells [171]. To the best of the researcher’s 
knowledge, the effectiveness of programmable dCas9-VP16(n) for transcriptional activation of the 
-globin gene has not yet been evaluated in iPSCs. 
To date, different transfection approaches have been evaluated for delivery of Cas9 activators, 
including both transient non-integrative vector (dCas9-activator) expression [79, 95, 163, 164] or 
integrative approaches with stable or inducible dCas9-effector expression [166, 215, 216]. Although 
both systems were effective in achieving gene activation, transient transfection is usually used for 
achieving specific gene activation at a given DNA locus with limited number of guides, whereas 
stable cells lines are ideal for genome-scale screens with large gRNA libraries [165]. To screen for 
dCas9-gRNAs able to trigger specific target activation either singly or in multiplex, transient 
transfection with either liposomal (Lipofectamine) or non-liposomal (Fugene HD)-based 
transfection reagents in HEK293 cells is commonly used. However, the transfection conditions and 
amount of vector used relative to cell density vary widely between different studies. 
Here, it was hypothesised that a dCas9-based approach would facilitate modelling of the RNA 
processing defect in cells with beta thalassaemia (IVSII-I G>A) and enable the assessment of the 
restoration of gene expression in iPSCs following gene correction. Thus, it was necessary to: (1) 
optimise a transfection protocol that would allow for screening of sgRNA activity in HEK293FT 
cells using pre-validated sgRNA combinations that target the promoter region of the HBG gene (2) 
assess if a similar strategy (synergistic effect of multiple guides) would enable transcriptional 
activation of the -globin gene in HEK293FT cells, (3) evaluate the effectiveness of the strategy of 
HBB gene activation in iPSCs, and (4) compare HBB gene expression in beta thalassaemia iPSCs 
before and after gene correction. 
Data indicated that at the cell density used in this study, the transfection of 1 µg of total vector 
(expressing gRNA-dCas9-activator) at a 3x charge ratio (Lipofectamine LTX) in HEK293FT 
yielded the maximum level of HBG gene induction (using a combination of pre-validated guides). 
The same strategy was applied to mediate gene activation of the HBB gene with either the 
dCas9VP64 or the VP160 system; however, increasing the TD tandem (VP16) repeat to a total of 
10 repeats did not result in an increase in gene activation. This chapter also presents data that shows 
that this system can be applied to iPSCs, although in this cell type nucleofection enables a higher 
induction of gene expression than lipid-based transfection methods. Importantly, manipulating HBB 
expression with this system can model the splicing defect in beta thalassaemia iPSCs, as evidenced 
by the lack of normally spliced product upon gene activation in iPSCs with the beta thalassaemia 
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RNA processing mutation. Furthermore, this activation system can also be used to assess the 
restoration of the normal splicing process in gene-corrected iPSCs. 
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 Results and discussion 
5.2.1 Activation of globin genes (HBG and HBB) in HEK293FT cells using lipid-based 
transfection 
 Gamma globin gene activation 
Several methods are available for transient transfection of cells with dCas9-expressing plasmids. 
They include chemical methods, like cationic liposomes [79], and non-liposome [164] or physical 
methods, such as electroporation [160]. However, cell viability and transfection efficiency varies 
with each transfection method [94, 217]. Efficient delivery is critical since in most cases robust 
dCas9-mediated gene activation requires the synergistic action of multiple guides. Indeed, single 
guides in conjunction with dCas9-VP16(n) systems are rarely associated with a considerable increase 
in gene expression [79, 164]. Transfection conditions reported in the literature varied widely (Table 
5-1). It was therefore necessary to optimise the liposomal transfection conditions and screen for the 
guide combination that would achieve a sizeable HBB activation with dCas9-activator system in 
HEK293 cells. Four previously validated guide RNAs spanning the proximal promoter region of the 
HBG1 and HBG2 genes were initially assessed, using Lipofectamine LTX-based transfection 
essentially as described by Perez-Pinera et al. [79]. 
 
Figure 5-1: Schematic of the HBG1 and HBG2 genes and their proximal promoter regions. 
Grey boxes indicate the location of the targeted DNA sites, and the numbers indicate their 
position relative to the TSS. The guide sequences were reported in Perez-Pinera et al. [79]. 
 
Table 5-1: Transfection conditions used in some gene activation studies 
Study No. of transfected cells Total plasmid Charge ratio Transfection 
reagent 
Maeder et al. 1.6x105 0.5 µg 5x Lipofectamine LTX 
Konermann et al. 0.2x105 0.3 µg 2x Lipofectamine 2000 
Mali et al. 4×105 4 µg NM Lipofectamine 2000 
Chavez et al. 0.5x105 0.210 µg NM Lipofectamine 2000 
Hu et al. 2.4x105 1.6 µg NM Lipofectamine 2000 
NM: not mentioned, charge ratio: transfection reagent/DNA ratio. 
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5.2.1.1.1 Activation of the HBG gene with sgRNA-dCas9-VP64-expressing vectors 
Differences between this initial approach for lipid-based transfection and that published by Perez-
Pinera et al. [79] are illustrated in Table 5-2. Principally, these researchers used two separate 
expression vectors; one for sgRNA, driven by the U6 promoter, and the other for dCas9-VP64, 
driven by the CMV promoter, with a mass ratio of 1:3, whereas in this study, the double-stranded 
oligonucleotide pairs of the gRNA were cloned into the BbsI site of a single vector expressing a 
sgRNA driven by the U6 promoter and a codon-optimised nuclease-deficient Cas9 fused to the 
VP64 acidic TD driven by the CBh promoter (addgene plasmid#48238) with a molar ratio of 1:1. 
The molar ratios of the expression plasmids in both studies are equivalent. 
Table 5-2: Experimental conditions used in the current study compared to that reported by 
Perez-Pinera et al. [79] 
 Perez-Pinera et al. [79] Current 
Cells HEK293T 293FT 
sgRNA Four sgRNAs:G1, G2, G3, G4 
Format NM 12 well 
Lipofectamine(Lp) 2000 LTX/PLUS 
Liposome/DNA ratio NM 2.5:1 
Total plasmid NM approximately 1 g 
No. of vectors used Two (sgRNA and dCas9-VP64) One (dual expression) 
dCas9/gRNA 3:1 mass ratio (1:1 molar ratio) 1:1 molar ratio 
q-PCR primer used Span Intron 2 Span Intron 1 
NM: not mentioned. 
Although using a single vector with dual expression (sgRNA-dCas9VP64) has the advantage of 
ensuring the concomitant transfection of both components needed for gene activation, this approach 
does limit the manipulation of the levels of the individual elements. Consequently, three different 
experiments (A, B, and C) were initially carried out in order to screen for conditions that produced 
high gene expression levels using different guide combinations (Figure 5-2). The charge ratio of 
Lipofectamine to DNA ratio used was 2.5 to 1, as this permitted a high transfection efficiency as 
judged by GFP expression under fluorescence microscopy (Chapter IV, Section 4.2.1). In the first 
experiment (Experiment A) the total amount of plasmid DNA (pDNA) was kept constant at ≈1 g. 
This amount was equally divided among multiple plasmids co-expressing dCas9VP64 and different 
sgRNAs, in order to study the effect of targeting multiple loci within the HBG promoter while 
keeping the total amount dCas9VP64 constant. In order to avoid wide variation between different 
conditions in terms of the total DNA amount or total gRNA, the transfection with the three and four 
guide combination was carried out at 1.2 g total pDNA (≈300–330 ng per sgRNA-dCas9VP64 for 
3 and 4 vectors multiplex vs 500 ng for two vectors). In Experiment (B) the amount of vector 
expressing individual sgRNAs (G1–G4) was kept constant (500 ng for each sgRNA(n)-dCas9VP64) 
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as opposed to holding the total amount of pDNA constant and varying sgRNA(n) (Experiment A). 
The amount of the vectors used in Experiment (B) was replicated in Experiment (C) in the presence 
of a vector expressing a stronger activation domain (500ng dCas9-VP160, Addgene plasmid 
#48226). In the following sections G(n) will be used to denote sgRNA(n). 
 
Figure 5-2: Schematic of the experimental design for gRNA-dCas9VP64-based HBG gene 
activation. Solid colours indicate the amount of individual gRNA-dCas9VP64 vector transfected 
relative to the total amount of the vectors used for transfections in Experiments A, B, and C. The 
total amount of dCas9VP64 is represented by the dashed arrows, while the amount of each guide 
is represented by the solid arrows. 
 
Figure 5-3: Activation of gamma globin gene expression in HEK293FT cells. The indicated 
vector or combination of sgRNA-dCas9VP64 vectors was used (A) with keeping a constant total 
of pDNA (~1 µg/well); (B) or by holding the amount of each sgRNA-dCas9VP64 constant (500 
ng) in the presence (solid bars) or absence (pattern bars) of 500 ng of dCas9VP160. Primer 
efficiencies for GAPDH (C) and gamma globin (D) were 102.4 and 97.5 per cent, respectively. 
Data are shown as the mean for technical repeat±SEM. 
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Surprisingly, in Experiment (A), only a modest increase in gene expression (3.7-fold) was observed 
when the four sites were used to target the promoter region of the gamma globin genes (HBG1 and 
HBG2), which is in contrast to the extent of activation (more than 100-fold change) reported by 
Perez-Pinera et al. [79]. A 40-fold increase was obtained upon targeting two sites at -163(G3) and -
209(G4) from the TSS of the HBG genes (Figure 5-3.A). Similar data were obtained when different 
housekeeping genes (EEF1A1/GAPDH) were used for data normalisation. The primer efficiency 
was high, at 97.5 and 102.4 for HBG and GAPDH, respectively (Figure 5-3.C and D). Moreover, 
the levels of activation of gene expression between biological repeats was highly reproducible and 
displayed a consistent pattern, ruling out inconsistencies in transfection efficiencies (Figure 5-3.A 
and B). Indeed, the transfection efficiency of HEK293FT cells transfected with a GFP-expressing 
vector under similar conditions was consistently high, as assessed by fluorescence microscopy. The 
only possible difference between this study and that of Perez-Pinera et al. [79] is the cell line used; 
indeed, HEK293 clones are known to vary widely at both the genetic and epigenetic levels. 
Using a single guide to target HBG did not result in substantial gene expression compared to 
multiplex guides (Figure 5-3.A and B), which is in agreement with previous studies on gRNA-
dCas9-mediated gene activation [79, 95, 164]. Upon increasing the concentration of individual 
vectors expressing different sgRNA (sgRNA/dCas9-VP64) from 300 ng (Figure 5-3.A) to 500 ng 
(Figure 5-3.B) an increase in gene activation was observed, indicating a possible dose-dependent 
effect, which is consistent with other studies [163, 164]. The combination G2-4 increased gene 
expression from 2.4 (A) to 14.4 (B) and the combination G1-4 from 3.7 (A) to 13.9 (B) (Figure 
5-3). However, it is uncertain whether this is due to the relatively higher levels of sgRNA, 
dCas9VP64, or both. Somewhat unexpectedly, a consistent decrease in gene expression was 
observed when the purportedly stronger activation domain (dCas9-VP160) was added to the 
combination with G34, G234, and G1234-dCas9VP64 (Figure 5-3.B). It is possible that this is due 
to increased toxicity of this plasmid, steric hindrance at the promoter, or DNA toxicity. Activation 
of the gamma globin gene was not due to generally increased transcription of the entire locus, since 
no mRNA expression for the beta or delta globin gene was detectable upon HBG gene activation. 
5.2.1.1.2 Optimisation of the transfection conditions 
(A)  Amount of individual vector relative to total mass of plasmid 
To further explore the previous observations, the guide combination (G34) that induced the highest 
level of increased HBG transcription was used to study the effect of varying the total amount of 
sgRNA and/or the total amount of pDNA on HBG expression levels. The level of gene activation 
was assessed using three different amounts of vector expressing individual sgRNAs (200 ng, 350 ng 
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and 500 ng) at three different levels of total pDNA (1 g, 1.5 g, and 2 g), as illustrated in Figure 
5-4.A. The manufacturer’s recommendation for Lipofectamine LTX is between 1 µg and 1.5 µg for 
the plate format used in these experiments. 
  
Figure 5-4: The effect of varying the amount of G34 and/or the total pDNA on HBG gene 
expression levels. (A) Schematic of the experimental design, where the solid bars indicate the 
mass of individual vectors expressing single sgRNAs transfected and patterned bars indicate the 
mass of empty vector NsG used to bring up the total to either 1 g, 1.5 g, or 2 g, (B) RNA 
expression of HBG gene with the indicated amount of vector used. Data are shown as the mean 
for technical repeat±SEM. 
The non-specific (non-binding) sgRNA-dCas9VP64 (NsG) vector or empty sgRNA was used to 
bring the amount of total pDNA to the desired constant value. In each of the conditions, the molar 
ratio of sgRNA relative to dCas9VP64 was kept identical. This experimental design facilitated the 
assessment of gene induction levels over a range of sgRNAs, while maintaining a constant amount 
of dCas9VP64 (constant total mass of plasmid). It also allowed the assessment of the effect of 
varying the total pDNA on the activity by holding the mass of vector expressing a specific guide 
constant. The experimental design should further reveal the maximum DNA amount tolerated by 
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the system, as DNA toxicity can be an issue with lipid-based transfection. The ratio of liposomal 
transfection reagent to pDNA was kept at 2.5 to 1. 
The dose-dependent effect of sgRNA on gene expression activation is evident from the increase in 
expression within each subset of total pDNA used (Figure 5-4.B). This indicates that the apparent 
failure of combination G1234 to induce HBG gene expression as compared to combination G34 in 
Experiment (A) (Figure 5-3.A) was likely influenced by the reduced amount of sgRNA used; i.e., 
300 ng vs 500 ng. Figure 5-4.B further shows that the activity induced by a similar mass of vectors 
expressing the most potent pair of gRNAs (G34) dropped sharply as the total amount of pDNA 
increased. For example, the change in HBG expression at 1 g of G34 decreased by more than six-
fold, from 51 to 7.7 when the total pDNA was increased from 1 g to 2 g. This observation may 
thus also explain the decrease in gene expression upon adding dCas9VP160 in Experiment (C) 
(Figure 5-3.B) at the specified charge ratio of liposome/DNA and indicates an apparent toxicity of 
higher plasmid loads, but does not rule out steric hindrance at the promoter. 
(B) Charge ratio relative to total amount of plasmid 
Selection of the charge ratio of 2.5:1 was based on GFP expression upon co-transfection with the 
GFP expression vector. To further investigate the potential effect of the charge ratio, gene 
expression levels were used as a read-out. HBG gene activation levels were analysed over a range 
of total amounts of pDNA while varying the charge ratio; i.e., the Lipofectamine to pDNA ratio 
(1x–5x). With this design, the increase in total pDNA is linked to a proportional increase in sgRNA 
and thus reveals the dose-dependent effect of the total pDNA (moles of pDNA=total active 
guide=dCas9VP64) (Figure 5-5.A). In other words, this approach should assess if the increase in the 
amount of expression vectors will be reflected by a parallel increase in gene expression across 
various ranges of charge ratios and total pDNA and thus validate the linear range of this system. 
A statistically significant positive linear relationship between the amount of expression vector and 
the fold change in gene activation was observed upon using a charge ratio of 1x (p=0.0051, 
R2=0.976) or 1.5x (p=0.0016, R2=0.98) (Figure 5-5.C1 and 2) indicating that the increase in the 
amount of the expression vector is accompanied by a proportional increase in gene expression for 
these values of charge ratio over the entire range of pDNA under study. However, this relationship 
was not maintained over the range of 2x–5x. The limit of linearity for total pDNA decreased as the 
charge ratio increased (Figure 5-5.C). Therefore, increasing the total pDNA above 1 g using 2.5x 
(as used in the previous experiments in this study) may affect gene expression due to suboptimal 
transfection conditions and therefore invalidate some of the comparisons presented in the previous 
sections. This explains to some extent the decrease in gene expression level observed upon adding 
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dCas9-VP160 in Experiment (C) and that observed for Experiments (A) and (B) with increasing 
total pDNA levels. 
 
Figure 5-5: The effect of charge ratio (1x–5x) on HBG gene expression levels studied over a 
range of total pDNA (0.5–2 µg). (A) Schematic of the experimental design, where solid colours 
indicate the amount of transfected vector expressing the indicated sgRNA, (B) the effect of 
varying the charge ratio on RNA expression levels for cells transfected with the indicated total 
amount of pDNA, and (C) the effect of increasing the total amount of pDNA on RNA expression 
level at the indicated charge ratio. Data are shown as the mean for each technical repeat±SEM. 
These data also indicate that the maximum efficiency of the system is observed at a Lipofectamine 
ratio of 3x using a total of 1 g pDNA per well. A further increase in the expression vectors or 
change of the charge ratio did not result in an increase in gene expression. 
Overall, these data indicate that at the cell density used in these experiments the maximum 
efficiency of a low range of total pDNA (500 ng) was obtained at a charge ratio of 5x. Under these 
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conditions linearity was maintained over the range of pDNA analysed (0.5–2 µg), and the 
maximum efficiency of the system, as assessed by the level of gene expression, was seen at 1 g of 
total pDNA at 3x. For higher levels of plasmid DNA, it would be more appropriate to use a low 
charge ratio in order to keep the data in the linear range of the system (e.g., to eliminate possible 
toxicity). It is clear that these data provide a likely rationale for the variable Cas9-VP16(n) gene 
activation data reported in the literature. For example Maeder et al. [163] used a range of 500 ng to 
1 g of total plasmid at a charge ratio of 5x, which offers conditions that maintain the linear range 
while providing maximum efficiency of the system for the low range of pDNA. If one wishes to 
compare the effect of targeting multiple guides at the cell density and the well format used in this 
study, it is critical to maintain a constant total amount of pDNA at 1 g with a charge ratio of 3x. 
The initial experiment was repeated and the two and four guide combinations were compared using 
the conditions described above, while keeping the total plasmid amount at 1 g (Figure 5-6.A). 
Another experimental condition was included, where cells were transfected with a total plasmid 
weight of 500 ng at a 5x charge ratio in the absence of an empty vector (NsG). Comparing the 
results obtained at different charge ratios will reflect the variability caused by experimental 
conditions for similar amount of guides. The results were consistent with those obtained for 
biological repeats under similar experimental conditions (1 µg/G34 [500 ng per guide] at 3x) 
(Figure 5-5.B2 and Figure 5-6.B). A dose-dependent effect of sgRNA on gene expression level was 
again observed for the two-vector combination G34, which is consistent with previous observations. 
However, in this case the activation level increased from 2.36 to 101.27 as the mass of individual 
vector (expressing G3 or G4) increased from 125 ng to 500 ng (Figure 5-6.B), which is in 
agreement with a previous study [163]. Interestingly, significantly higher activation of gene 
expression was observed upon using a charge ratio of 5x for a total pDNA of 500 ng for G34 
compared to that obtained for similar amounts of vectors with a charge ratio of 3x for a total pDNA 
amount of 1 µg. This may indicate that including non-specific guide (50 per cent of total) may 
compete with the specific guide (25 per cent of total) to form the ribonucleoprotein. The data also 
suggests an inhibitory effect of G1 and G2 on the activity of G34, as the RNA expression level of 
HBG decreased by almost two-fold (8.7 to 4.8) under similar experimental conditions of charge 
ratio and total pDNA (Figure 5-6.B). Previous studies have demonstrated that gRNAs that target 
promoter regions close to TSS (mostly downstream) can interfere with RNA polymerase activity 
(CRISPRi) leading to partial or complete repression of activation [164, 167]. Although G1 for HBG 
is located upstream of the TSS, it overlaps with the TATA box, an RNA polymerase binding site, 
and thus may explain the observed repression of activation. How the sgRNA G2 (-101 upstream of 
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TSS) inhibits transcription induced by G3 and G4 remains unclear at present, but may involve 
interference with nucleosome positioning or Cas9-related characteristics. In fact, evidence suggests 
a long residency for Cas9 at the DNA binding site [71, 72] and also decreased potency in gene 
activation compared to transcription activator-like effectors (TALEs), which have been attributed to 
the intrinsic molecular characteristics of Cas9 [218]. 
The modest activation level observed with the four sgRNA combination is in agreement with that 
observed by Kabadi et al. [216], despite the fact that their system differs from the one used in these 
experiments (stable expression of dCasVP64 vs transient expression in this study). 
 
Figure 5-6: The RNA expression levels for the indicated guide combination carried out under 
similar experimental conditions. (A) Schematic of the experimental design, where solid colours 
indicate the amount of transfected vector expressing the indicated sgRNA. (B) RNA expression 
levels for the indicated amount of multiplex gRNA using a charge ratio of 3x and a constant 
amount of total pDNA. NsG: control vector, ns: nonsignificant. *p,0.05, **p<0.01 and  
****p<0.001 
The inconsistency in the level of gene expression induced by the four sgRNA combination between 
this study and that reported by Perez-Pinera et al. [79] clearly reflect the various levels of vector-
related gene expression, charge ratios or variability in HEK293 cells lines. Moreover, the two guide 
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combination G34 was not examined in Perez-Pinera et al.’s [79] report. Holding the amount of total 
pDNA and sgRNA constant at an optimum pDNA/Lipofectamine ratio is needed for a valid 
comparison for synergistic experiments. Under the experimental conditions used in the present 
study, the maximum efficiency of induction was achieved using a total pDNA mass of 1 g at a 
charge ratio of 3x for Lipofectamine LTX at this cell density. Lastly, different gRNA combinations 
targeting different site at the promoter region of HBG displayed variable levels of induction 
activity, which is consistent with previous studies of synergistic dCas9VP16(n)-mediated gene 
activation [79, 163, 164, 216]. 
 -globin gene activation 
5.2.1.2.1 Activation of the HBB gene with dCas9VP64 and dCas9VP160-expressing vectors 
After optimising the conditions for inducing RNA expression for HBG gene in HEK293FT and 
validating the functionality of the system, the possibility of similar induction of the -globin gene 
was explored.  
 
Figure 5-7: Activation of the HBB gene in HEK293FT cells. (A) Schematic of the targeting 
site for sgRNA in the proximal promoter region of the HBB gene. Red boxes indicate the 
sgRNAs with the highest activation efficiency in this set when tested in combination, while 
green boxes indicates those with a lower efficiency. Numbers indicate their position relative to 
the TSS. (B) RNA expression of the HBB gene using the VP64 system with the indicated gRNA. 
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To achieve this objective, it was first necessary to identify a combination sgRNAs capable of 
inducing expression of the -globin gene at levels sufficient to allow the validation of expression of 
wild type HBB from the corrected gene in beta thalassaemia iPSCs. 
Eight sgRNA were designed and cloned into the BbsI site of a single vector expressing both sgRNA 
and the dCas9VP64 vector. The guides span the proximal promoter region of the HBB gene (-23 to -
212 from the TSS) (Figure 5-7.A). Combinations of two or three guides were transfected into 
HEK293FT cells in order to screen for their activity at inducing HBB gene expression (Figure 
5-7.B). The total pDNA concentration was kept at 1 g and was equally divided between the 
individual sgRNA used. The results indicated that Guides 3, 4 and 5 gave the highest gene 
induction efficiency among the combinations tested, with lower efficiencies observed for Guides 6, 
7 and 8. Interestingly, using a guide (G4) located -20 bp from the TSS that overlaps the TATA box 
did not appear to repress the activity of Guides 3 and 5 (Figure 5-7.B), in contrast the repression 
seen for HBG. 
 
Figure 5-8: Activation of RNA expression from the HBB gene using the VP160 system. (A) 
Transcription activity associated with the indicated gRNA. (B) Comparison between the dCas9-
VP64 or dCas9-VP160 systems for gene activation using the same sgRNA combinations. 
*p<0.05, and **p<0.01. 
Having established that the sgRNA-VP16(n) system could induce HBB RNA expression, the next 
step was to assess whether a putative stronger activation domain could increase the activity at 
gRNA binding sites. Different permutations of sgRNA were selected and assessed for their activity 
using the dCas9VP160 system (Figure 5-8.A). The maximum value of gene activation with VP160 
(under the tested conditions) was obtained for the combination G3-8. However, increasing the 
number of repeats of the VP16 activation domain from four to 10 again did not appear to have a 
substantial effect on the RNA expression level of the HBB gene, as the value for the same multiplex 
115 
 
 
of G345 was comparable (3x10-5 for VP64 (Figure 5-7.B) and 2.7x10-5 for VP160 (Figure 5-8.A). 
To confirm this finding and rule out experimental variability, comparisons between both systems 
were carried out in parallel under similar transfection conditions, using two different combinations 
of sgRNA with a comparable mass of total plasmid (Figure 5-8.B). A slightly higher induction level 
was obtained with the VP64 system; however, this modest increase was not statistically significant 
for G3-8 (p=0.15) while the difference was marginally significant (p=0.047) for G3-5. 
The statistical analysis of the data for off-target HBG gene expression levels in HEK293 cells 
(Figure 5-9.B) indicated that the increase in HBG gene expression was statistically significant 
(p=0.0003) for one combination (G3-8dCas9VP64) compared to untransfected controls. However, 
the same guide combination assessed with the dCas9VP160 system displayed no off-target activity. 
This discrepancy may be related to the potency of activation as displayed by the higher HBB 
induction level for G3-8-dCas9VP64. Overall, these results indicate that it is possible to induce 
HBB expression using VP16(n) systems, but that increasing the VP16 tandem repeat number in the 
activation domain does not lead to a significant difference in the induction of HBB expression for 
the guide combinations assessed under these experimental conditions. 
 
 
Figure 5-9: Off-target effects of different guide combinations targeting the HBB gene on the 
expression of HBG in HEK293FT. (A) Activation levels of the HBB gene by the indicated 
guide combination with either dCas9-VP64 (patterned bars) or dCas9-VP160 (solid bars) 
systems. (B) Non-specific activation of the HBG gene by the indicated guide targeting the 
promoter region of HBB with either dCas9-VP64 (patterned bars) or dCas9-VP160 (solid bars) 
systems. ***p<0.001 
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5.2.2 Activation of HBB in iPSCs 
 Transfection of iPSCs with sgRNA(HBB)-dCas9-VP160 and off-target activity for the 
HBG gene 
To test whether the guides targeting the HBB promoter region are functional in iPSCs, two different 
active guide combinations (VP160 system) pre-validated in HEK293FT cells were assessed. A 
combination of vectors expressing all guides, with the exception of gRNA2 (G1, 3-8), or a 
combination that included gRNAs 4, 5, 6 and 8 were nucleofected into iPSCs. A plasmid carrying 
the green fluorescent protein (pmaxGFP, Lonza) was co-transfected with G4568 in order to assess 
the transfection efficiency. The latter was assessed using fluorescence microscopy (Figure 5-10.A). 
-globin gene activation was measured 72 hours after transfection. The data indicate a significant 
activation of -globin gene expression was induced in transfected iPSCs by the guided 
dCas9VP160 system (Figure 5-10.B). In this series of experiments in iPSCs the normalised relative 
gene expression levels were used instead of the fold change relative to untransfected cells (control) 
because no expression was detected in control cells. Transfection of dCas9VP160 with gRNAs did 
not affect OCT4 or NANOG gene expression in the cell population. Some apparent off-target 
activation of the HBG gene was observed; however, the expression level did not reach statistical 
significance (p=0.442).  
 
Figure 5-10: Activation of the HBB gene in iPSCs. (A) GFP fluorescence and phase contrast 
images of iPSCs nucleofected with G4568-dCas9VP160-expressing vectors and pmax GFP. (B) 
RNA expression levels of the HBB, HBG, OCT4 and NANOG genes for iPSCs transfected with 
the indicated guide combination. 
This small off-target activity was more pronounced when the four guide combination was used than 
with the seven guide combination, which may indicate a dose-dependent effect as the total pDNA 
was equally divided between the vectors expressing independent sgRNAs. Collectively, these data 
117 
 
 
suggested that the off-target effect of HBB sgRNAs on HBG expression may be attenuated by 
reducing the total amount of transfected vector in iPSCs and including the maximum number of 
tiled gRNAs. Therefore, subsequent experiments were carried with 1.2 g of total vector (as 
opposed to 2 g) using the VP160 system with a combination of vector that targets six sites in the 
promoter region (G3-8) and displays minimum non-specific activation of HBG (Figure 5-9, 
combination indicated by an arrow). 
 Transfection method and HBB activation in gene-edited iPSCs compared to cells with 
beta thalassaemia 
Since the transfection efficiency of single cell iPSCs with nucleofection was low, transfecting iPSC 
colonies was tested in an effort to improve the efficiency of gene activation. Moreover, it was of 
interest to determine whether wild type HBB gene expression could be detected in corrected beta 
thalassaemia iPSC clones before exicising the selection cassette, a strategy that was deemed feasible 
because the selection cassette was inserted in the second intron region (Figure 5-11.A and B). 
 
Figure 5-11: G(3-8)-dCas9VP160-mediated gene activation of the HBB gene in control iPSCs 
(wild type allele), iPSCs with beta thalassaemia and in biallelic gene-corrected iPSCs. (A) 
Schematic of the HBB gene showing the location of the RNA processing mutation (red box). (B) 
Schematic of the targeted HBB gene and the proposed splicing of the RNA transcript at the 
normal splice site, and (C) Relative gene expression levels obtained upon targeting the proximal 
promoter region with G(3-8)dCas9VP160 using either nucleofection (solid bars) or Fugene-
based transfection (patterned bar). C9:control iPSCs, C1: iPSCs with beta thalassaemia, C4: 
iPSCs targeted at both alleles, FG: Fugene HD transfection, and N: nucleofection. 
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To this end, Fugene HD-based transfection or nucleofection was used to deliver 1.2 µg of the G(3-
8)-dCas9VP160 vector combination in control iPSCs (wild type allele). Only nucleofection was 
used for comparing HBB gene activation levels in uncorrected iPSCs carrying the beta thalassaemia 
mutation and in gene-corrected beta thalassaemia iPSCs targeted at one or both -globin alleles. 
The results indicated that nucleofection of colonies is a more efficient system for inducing gene 
expression compared to Fugene-based transfection. Surprisingly, a low level of gene activation in 
iPSCs with a splice junction mutation (beta thalassaemia mutation) was detected, albeit at a 100-
fold lower level than in wild type control iPSCs (Figure 5-11.C). The melting profile of q-PCR 
products indicated the presence of a different product in iPSCs with beta thalassaemia compared to 
wild type cells (Figure 5-13.C). To further investigate the nature of this spliced transcript, a primer 
pair that spans intron II was used to PCR amplify the splice region from cDNA samples. The faint 
band observed for beta thalassaemia cells indicates an abnormal splice product with a size that is 
higher than the expected size of 79 bp. The size of the aberrantly spliced product was 126 bp 
indicating the use of an alternate splice site located downstream of the mutation site (Figure 
5-12.B).  
 
Figure 5-12: Aberrantly spliced products observed following RNA-guided gene activation of 
the HBB gene in iPSCs with beta thalassaemia or in gene-edited lines compared to control 
lines. (A) cDNA (RNA from cells transfected with G(3-8)-dCas9VP160) was used as a template 
for PCR. The size of the amplicons observed following gene activation in iPSCs with a beta 
thalassaemia mutation (126 bp and 929 bp Lanes 4 and 5), a monoallelic targeted line (Lanes 6 
and 7), a biallelic targeted line (Lanes 8 and 9), a transfected control line (wild type allele, Lanes 
10 and 11, 79bp), and the untransfected control iPSCs (Lanes 2 and 3). The presence of an 
extremely faint band in the ‘no RT’ control (RT, Lanes 13–17) for the indicated samples 
revealed an insignificant genomic DNA contamination compared to the robust band observed in 
cDNA samples (Lanes 18 and 19). (B) Schematic of the splicing process identified in wild type 
and mutant HBB gene, red box indicate the additional DNA fragment observed in the aberrant 
RNA product. C9:control iPSCs, C1: iPSCs with beta thalassaemia, Ht T: Transfected 
monoallelic, Hm T: transfected cells biallelic, RT: no reverse transcriptase, FG: Fugene HD 
transfection, N: nucleofection. 
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The larger band (929 bp) reflects an insignificant genomic DNA contamination. This is evident 
from the exceedingly faint band observed in the ‘no reverse transcriptase’ samples using primers in 
the exonic region of the housekeeping gene beta actin. Furthermore, although marginal gene 
expression levels were also observed in targeted cells, the size of the extremely faint band was also 
higher than that expected for a normally spliced product. Overall, these data indicate that the 
removal of the selection cassette from HBB gene-corrected iPSC is necessary, since its presence 
interferes with normal splicing of the transcript. More importantly, these data confirm that it is 
possible to model the splice junction defect in iPSCs with a beta thalassaemia mutation using the 
dCas9-activation system. 
5.2.3 Gene expression in iPSCs after gene correction 
To assess the restoration of normal splicing after gene correction and excision of the selection 
cassette, iPSCs derived from gene-edited iPSCs were transfected with the G(3-8)-dCas9VP160 
vector combination and the gene expression levels were assessed using a primer pair that spans the 
intron II region of the HBB gene. Satisfyingly, the data consistently demonstrated the restoration of 
normal splicing (Figure 5-13.A). However, it was noted that the level of -globin gene expression 
in gene-corrected clones remained significantly lower than in control cells. The similar levels of 
expression in two clones derived from the same parental iPSCs (BT-T iPSCs) targeted with two 
different guide combinations indicate a possible variability in the induction efficiency of gene 
expression between clones from different cell lines (control/beta thalassaemia) or different 
transfection efficiencies. Although confirmation of HBB expression at the protein level is needed, 
these observations indicate that gene-corrected beta thalassaemia iPSCs restored expression of HBB 
mRNA and that the presence of the introduced SNP near the splicing regions did not affect the 
splicing process. Moreover, reducing the total amount of the transfected plasmid was an effective 
strategy for mitigating the off-target effect observed in previous experiments. Indeed, the level of 
HBG gene expression in transfected cells was similar to that seen in untransfected cells (Figure 
5-13.B). Melting curve analysis of the q-PCR products indicated the presence of a single peak for 
gene-corrected cells and controls (Figure 5-13.D). To further confirm and assess the type of the 
splice products of the HBB gene, PCR amplicons were generated from cDNA obtained from  
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Figure 5-13: Restoration of normal splicing following the excision of the selection cassette 
and induced gene activation in transfected iPSCs compared to transfected parental beta 
thalassaemia iPSCs. (A) The levels of HBB gene expression in iPSCs determined 72 hours after 
transfection. (B) The level of off-target HBG gene expression. (C) Melt curves showing the 
different patterns for product amplified from iPSCs with beta thalassaemia compared to wild 
type. (D) Melt curve analysis showed overlaps of plots between gene-corrected iPSCs and wild 
type using two different primer pairs. C9: Control iPSCs, and C4/3 and C16/3: Gene-corrected 
beta thalassaemia iPSCs. Untransfected beta thalassaemia iPSCs. ***p<0.001 
transfected gene-edited iPSCs. Similar band sizes were observed upon comparing the products 
obtained from transfected corrected iPSCs to those of the transfected control (the wild type allele). 
Thus, restoration of normal splicing in gene-corrected cell lines was achieved. Notably, the absence 
of bands in the no reverse transcriptase control indicated an absence of any genomic DNA 
contamination. 
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Figure 5-14: Normal splicing products observed following RNA-guided gene activation of the 
HBB gene in gene-corrected iPSCs. C9:Control iPSCs, C1: iPSCs with beta thalassaemia, 
C1R1, C1R2 and C1R3: Cells corrected at both alleles, BL: Blank PCR control, and –RT: no 
reverse transcriptase samples. Primer pairs used were exonic GAPDH (Lanes 1–5), exonic B-
actin (Lanes 6–10), spanning intron II of the HBB gene: BB3 (Lanes 11–15), and BBS (Lanes 
16–20). 
Overall, these data suggest that no cryptic splice site was created by the SNPs and that the splicing 
occurred at the normal splicing site. Therefore, it can be concluded that the Cas9 activation-based 
strategy is effective for assessing the restoration of normal RNA processing in gene-corrected beta 
thalassaemia iPSCs. 
 Conclusion 
This chapter describes a strategy for successful CRISPR-Cas9-mediated HBB gene activation in 
both HEK293FT cells and in iPSCs. The synergistic effect of using multiple gRNAs targeting cis 
regulatory elements has been previously demonstrated to be an effective approach to induce gene 
expression [79, 163, 164]. Building on these data, four pre-validated guide sequences that target the 
HBG gene [79] were selected and used to systematically optimise the transfection conditions of 
sgRNA-dCas9VP16(n) in HEK293FT cells. Interestingly, the data for HBG gene activation differed 
from those reported by Perez-Pinera et al. [79], who reported that the four combination guide 
resulted in a 100-fold increase, whereas in this study, a four-fold activation was achieved. This 
difference is not due to a limitation in VP64-mediated activation power since >100-fold gene 
activation was obtained by targeting the HBG promoter region with only two guides. The 
optimisation studies undertaken here have clearly demonstrated that it is critical in synergistic 
experiments to optimise factors that influence lipid-based transfection and that the total plasmid 
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load should ideally be kept constant using a neutral vector. The dose-dependent effects of sgRNA 
on gene activation levels observed in this study are in good agreement with those seen in previous 
studies [163, 164]. These findings are also in close agreement with a study by Kabadi et al. [216], 
who used an inducible genome-integrated version of the CRISPRa system [216]. It is likely that the 
difference between the current study and that of Perez-Pinera et al. [79] is related to such 
experimental details, or is perhaps due to intrinsic biological differences between the various 
HEK293FT clones used across the world. 
These data indicate that the synergistic guide combination is also an effective approach to induce 
HBB globin gene expression using both the VP64 and VP160 systems. The purportedly stronger 
VP160 activation domain did not lead to a significant increase in gene expression over VP64 in this 
these experiments, an observation that concurs with a previous study [218]. The fact that activation 
of gene expression in corrected beta thalassaemia cells occurred at a lower level compared to that 
seen in control cells is somewhat puzzling. It is possible that this reduced efficiency is due to the 
zygosity of the locus, which can be readily verified by droplet digital PCR [219] or Southern blot, 
SNP location, variable transfection efficiency, or differences in passage number of the cells. This 
study has demonstrated that the CRISPRa system is certainly useful for modelling the RNA 
processing defect resulting from a base substitution at the donor splice site in beta thalassaemia 
iPSCs, and that it can be used to verify the absence of the normal spliced transcript in beta 
thalassaemia iPSCs. Importantly, the data from this study reveal that the splicing defect was 
restored in gene-corrected iPSCs, demonstrating the usefulness of this system for assessing the 
restoration of the normal splice site function of genes that are not necessarily expressed in 
undifferentiated iPSC. As such, this is a valuable tool to validate correctly targeted clones without 
the need for prolonged differentiation into cell types that express the gene of interest. However, it 
remains to be demonstrated that transient transfection of vectors in PSCs can also mediate an 
increase in protein expression, given the difficulty of achieving the efficient plasmid delivery 
needed for endogenous gene targeting in difficult-to-transfect human iPSCs and the variability in 
the induction efficiency. In fact, evidence suggests that an increase in gene expression may be 
associated with an increase in protein translation [79, 160, 166]. Although correlation between 
mRNA abundance and protein synthesis is variable [220], achieving a sizeable -globin gene 
activation may translate into a higher level of protein expression. 
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CHAPTER VI 
DISCUSSION 
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6 DISCUSSION AND FUTURE DIRECTIONS 
The CRISPR/Cas9 system is a rapidly evolving technology that allows for site-specific genetic 
manipulation of iPSCs with remarkable flexibility and efficiency. Combining iPSCs and 
CRISPR/Cas9 platforms offers great potential for both basic and clinical research provided that 
efficient and precise genomic editing is achieved and the genomic integrity of cells is maintained. 
However, the genotoxicity of the nuclease system remains a major concern [55]. Studies that 
explored and validated proposed approaches to enhance both the accuracy of genome editing (i.e. 
decrease unwanted on-target modifications) and its specificity (i.e. decrease unwanted off-target 
modifications), in the context of gene correction in iPSCs, remain limited. Furthermore, CRISPRa 
has the potential to be used as a tool that can aid in modelling molecular defects, (e.g., those 
associated with RNA processing mutations) in addition to validating the restoration of normal 
transcription in gene-edited cells while circumventing the need for directed differentiation. In this 
study, it was hypothesized that it is possible to: (1) derive footprint-free iPSCs from dermal 
fibroblasts of a patients with homozygous mutations for beta thalassaemia using episomal-based 
reprogramming; (2) use a double nickase approach to avoid on-target modification, and a piggyBac 
transposon-based design for the donor template, to achieve a seamless selection cassette excision 
after the gene correction of the disease-causing mutation in iPSCs; and (3) use CRISPRa to activate 
the HBB gene allowing us to model the RNA processing defect, and to initiate normal transcription 
of the gene.   
In this study, although transfection of dermal fibroblasts derived from three patients with 
homozygous IVSII-I (G>A) or IVSI-110 (G>A) mutations and a healthy donor was performed with 
two different combinations of episomal vectors (TPs: C4 or C19), the successful derivation of 
footprint-free iPSCs was achieved in only one patient with the beta thalassaemia mutation IVSII-I 
(G>A) and the control donor. The low efficiency of the episomal system observed in this study is 
consistent with previous reports [45, 46]. Episomes are lost by progressive dilution with successive 
cell divisions, as evidenced by the decrease in fluorescence from a GFP-expressing episomal vector 
to only 2.4% of cells at  four weeks post-transfection (compared to 67.6% observed at week 1)  
[46]. The rapid loss of episomal vectors may limit the expression of reprogramming factors to the 
early stages of reprogramming, possibly contributing to the low efficiency of this approach. Even 
with further enhancement of the episomal-based approach by suppressing TP53 and substituting c-
Myc with L-Myc, the efficiency of the system remains significantly lower than other non-integrative 
approaches, such as the Sendai-virus or mRNA-based reprogramming [186], although one study has 
reported otherwise under feeder-free conditions [221]. The role of TP53 suppression in promoting 
reprogramming has been documented in various studies; however, TP53 plays an important role in 
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surveillance of the maintenance of genomic integrity [222]. Therefore, it is desirable to avoid using 
vector combinations with TP53 suppression in order to allow it to carry out its quality control 
function during the process of reprogramming. Nevertheless, the oncogenic property of some of 
these factors (e.g, cMyc [223]) in the episomal plasmid combinations could be of concern. Under 
the experimental conditions of this study, the high attrition rate of putative iPSC clones was largely 
due to pseudo-iPSCs, abnormal karyotypes, complete reprogramming failure (in one sample with 
the IVSI-110 G>A mutation), or putative iPSC lines that failed to fulfil the stringent criteria of bona 
fide iPSCs. The failure of reprogramming in cells derived from one patient suggest that it may be 
due to sample-dependent factors, such as the establishment of the primary fibroblast cultures, since 
the reprogramming and cell cultures were performed in parallel with the other samples under 
similar conditions. Notably, and in agreement with a previous study [191], one vector combination 
yielded more clones under similar experimental conditions. However, the majority of the clones 
derived with this combination (C19) failed to show complete reprogramming. This may be related 
to variability associated with some technical aspects of transfection, such as the size and number of 
the transfected vectors. Alternatively, the timing, level and stoichiometry of the reprogramming 
factors have been reported to influence the success rate of reprogramming [45, 192, 224]. Both 
vector combinations carried the same number and type of transgenes; however, their arrangement 
varied, with possible subsequent consequences on their expression levels. Indeed, when enhanced 
transgene expression was achieved by including the woodchuck hepatitis virus post-transcriptional 
regulatory element in the design, an improved efficiency of reprogramming in human cord blood 
CD34+ cells was observed [225]. Moreover, these data corroborate evidence that highlights the 
importance of careful screening of iPSC clones for the presence of transgene integration or 
persistent expression of exogenous sequences [46, 186], as one of the iPSC clones (out of six 
screened clones) showed the integration of one of the reprogramming vectors.  
High quality iPSCs are needed for realisation of the potential of iPSC-based cell therapies. 
However, evidence suggests that the combination of reprogramming factors used [226], the length 
of time in culture and the number of passages, in addition to the latency and the limited efficiency 
of the reprogramming process, are factors that may impact on the characteristics of iPSCs [18]. The 
highest efficiency for any of the non-integrative approaches was reported for mRNA-based 
reprogramming [186, 227]. This approximate the efficiency observed with the integrating viral 
vectors which have the highest efficiency of reprogramming; however, its advantage is negated by 
the requirement for repeated transfection [41] and the considerable failure rate in reprogramming 
[186]. Nevertheless, episomal vectors remain a viable option for reprogramming to pluripotency 
[186] that can be compatible with clinical translation [221].  
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Induced PSCs also represent an ideal platform for genetic engineering. Combining strategies that 
enhance the preciseness of available molecular biology tools (i.e. CRISPR/Cas9) can be useful in 
improving the on-target editing rate [145, 212] and in achieving highly specific genome engineering 
[100]. Precisely engineered iPSCs are needed for stem cell-based modelling of genetic disease, and 
for providing an unlimited source of gene-edited lines for potential use in regenerative medicine 
[228, 229]. Recent studies have reported successful gene correction of beta thalassaemia mutations 
using Cas9WT in iPSCs [35-37, 138]. Cooperative strategies, (i.e. double nickase (Cas9n) such as is 
used in the DN strategy), which induce DSBs at the on-target site while only single nicks are 
possible at each gRNA’s off-target sites, would be more advantageous for precise DNA 
modification [96]. Because the on-target editing rate mediated by CRISPR/Cas9 is influenced by 
various factors that include the strategy design [145, 212], it was hypothesised that preventing the 
iterative cycles of dual Cas9n activity (introduction of DSBs) by either separation of the guide pair 
that targets the locus of interest [145] or by introducing a synonymous SNP in the PAM sequence 
[212] would be effective at limiting the on-target mutagenesis using the current approach. The 
double nickase strategy was explored using two different gRNA pairs in conjunction with a 
piggyBac transposon-based design for the donor vector. This study differed from that of Merkle et 
al. [145] in that the evaluation of the DN strategy with spatial separation of the gRNA pair was 
carried out in the context of achieving seamless gene correction with the additional limitations 
associated with the preference for using an endogenous, intronic TTAA sequence for insertion of 
the piggyBac-flanked selection cassette [182]. It also differed from Flynn et al. [212] in the donor 
construct design and the type of corrected mutation. The monogenic disease in the current study is 
autosomal recessive, whereas Flynn et al. [212] studied an X-linked disease (single copy, male 
iPSCs). This study demonstrates that the generation of bi-allelically targeted clones is achievable 
with this strategy. Interestingly, a higher percentage of targeted events was observed in the present 
study compared to a similar investigation, which used Cas9WT in conjunction with a piggyBac-
based approach to correct a beta thalassaemia mutation [35]. Surprisingly, on-target mutations that 
resulted from a single nickase activity at the targeted allele were observed in some clones. 
Notwithstanding this observation, the data is still consistent with the notion that monomeric nickase 
activity is less prone to induction of indels compared to strategies that introduced DSBs. This 
notion is based on the observation of a high frequency of on-target mutagenic activity at the site of 
the induced composite DSBs (at the untargeted allele), whereas none were detected at the targeted 
allele at the site of the induced SSBs of one active guide (sgRNA3), while the frequency was 
considerably reduced at the other site (around 15 per cent at the sgRNA5 binding site). The absence 
of mutagenic activity at the binding site of the active nickase (sgRNA3) in one pair cannot be 
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attributed to inefficient activity, as evidenced by the high rate of mutagenesis at the untargeted 
allele in the presence of a closely placed nick (sgRNA1/sgRNA3). Although titrating the vector 
dosage has been reported to influence Cas9 activity [58, 75], the high frequency of on-target 
mutations observed at the untargeted allele could not be solely attributed to the amount of vector 
used in this study. Indeed, the data indicate that the expression of vector-borne genes is quite low, 
as evidenced by the weak fluorescent signal generated by the expression of EGFP fused to Cas9. 
This low expression can be attributed to a low transfection efficiency. However, the 
disproportionately high number of resistant clones obtained following selection, compared to the 
low number of GFP-positive cells observed, suggests that the low level of gene expression was 
sufficient to induce Cas9n activity. Notably, the strategy of antibiotic selection and clonal 
expansion can capture rare events that are possibly below the detection limit of methods commonly 
used to detect mutations in a heterogeneous cell population. Indeed, in this study, the frequency of 
on-target mutagenesis induced by DN (which produces composite DSBs) in the absence of donor 
was below the detection limit of the Surveyor assay in the bulk iPSC population. However, 
following clonal isolation of resistant clones, the majority of the untargeted alleles (heterozygous 
clones) carried an indel at the DN-targeted site.  
Overall, the data in this study show: (1) a low gene editing efficiency in the bulk iPSC population; 
(2) that a correctly biallelic targeted clone can be achieved; (3) that the DN approach can afford 
high specificity; (4) high Cas9 DN-mediated on-target activity at the on-target site (untargeted 
allele); (5) that using a strategy that prevents on-target activity can improve the editing rate at the 
targeted allele; and (6) that although SSBs can be preferentially resolved by mutagenesis-free 
pathways, the features of the guide sequence or context can be a determining factor of mutagenic 
activity by Cas9n, albeit at a very low frequency compared to the full nuclease.  
The difference in mutagenic activity of Cas9WT associated with a given guide sequence has been 
the subject of intense study [91, 210, 230, 231]. Various factors influence nuclease activity such as 
sgRNA characteristics, Cas9 protein characteristics, and the locus context of the target DNA 
sequence in the cell type under study. In fact, evidence suggests that the stability of sgRNA binding 
influences both on- and off-target Cas9 activities (as measured by indel induction efficiency) [76, 
210]. RNA guide sequences rich in guanine bases displayed a higher efficiency than those rich in 
adenine bases [210]. Interestingly, the guide with the highest number of guanine bases (sgRNA5) 
was associated with mutagenesis. Alternatively, a long residency of Cas9 has been reported at the 
guide RNA-assisted DNA binding site [71, 72]. The intrinsic characteristics of Cas9, which may 
include its binding property, have been implicated in masking the guide binding site leading to a 
reduced potency of the dCas9-activator system at inducing transcriptional activation as compared to 
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the TALs systems [171]. Furthermore, the binding property of Cas9 has also been postulated to play 
a role in concealing the break site from detection by genome surveillance factors [71]. Based on the 
thermodynamic model of activity, decreasing the stability of binding by either changing the guide 
structure [92, 100], or by using a Cas9 variant with altered binding properties [69, 70], has been 
shown to decrease undesired mutagenic activity. A dimerisation-dependent approach (FokI-dCas9) 
retained a low level of activity as monomers [98]. Truncation of the guide by one nucleotide 
considerably reduced this undesired activity, while the removal by three nucleotides abolished the 
desired dimeric activity [100]. The proposed underlying mechanism for this observation was the 
inability to form a stable dimers. These strategies rely on the thermodynamic energy of binding to 
attenuate mismatch tolerance. One could, however, also argue the opposite in so much as given that 
both sgRNA and Cas9 can contribute to the stability of binding, it is possible that a guide sequences 
with increased stability can extend the Cas9 residency, leading to variability in the duration of the 
masking of the DNA break site, or can elicit other mechanisms of DNA repair to evict the bound 
protein with consequent variability in the resolution of the DNA break. A third possibility is that the 
context of the local sequence (e.g. its association with the nucleosome) of the targeted site can 
affect the rate and pathway of the repair by slowing the process, and thus shuttling the repair to 
resection-dependent pathways [131]. The concept of an interplay of factors not related to sequence 
properties that can alter the efficiency of the guide is best exemplified by the occasionally observed 
higher rate of mutagenesis at some off-target sites (with sequence mismatches) compared to the on-
target site (sequence matches) at some loci [74].  
This study has shown that the pattern of mutations generated with different guides with different 
offset varied significantly. Surprisingly, an inversion and insertion was observed in one clone 
targeted with a guide pair with an offset of 30 bp, whereas mostly deletions with micro-homology 
flanking the deleted sequence were associated with a guide pair with an offset of 5bp. The 
alignment of the sequence between the SSB sites in DNA using less than five base pairs of 
homology may indicate that the process occurred through C-NHEJ [110]. However, the presence of 
inversion and a relatively large insertion with the other guide pair indicate that the process occurred 
through the resection-dependent pathway. Although the number of the analysed clones, and targeted 
loci, were limited in this study, this observation may suggest that the guide pair design (e.g., offset 
length) can result in different mutational patterns, indicative of different mechanisms of DNA 
repair. Further, successful piggyBac-mediated biallelic excision of the selection cassette were seen, 
with full and traceless PiggyBac transposon removal resulting in reconstitution of the corrected 
HBB allele.  Additionally, no detectable off-target effects for nickase was detected upon screening 
the top predicted sites based on sequence homology. 
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Overall, these data on gene correction indicate that traceless gene editing is achievable at both 
alleles in iPSCs using a precise editing approach. Both strategies of DN activity on the corrected 
allele used in this study have proven effective in reducing unwanted on-target activity. Precise 
genome editing will harness the potential of nuclease-induced stimulation of repair mechanisms by 
allowing accurate site-specific editing of the genetic mutation while retaining the context of its 
endogenous genomic elements. The ideal cell-based therapy approach will have to preserve genome 
integrity. The data from this study, and those of others [145], show that even single nickase 
(SpCas9N) can be associated with low level mutagenic activity in iPSCs, implying that similar 
activity can occur at off-target sites. We examined the top predicted off-target sites for Cas9n 
activity, but recognise that for future studies undertaking a comprehensive analysis of off-target 
modifications (such as WGS) is a highly desirable validation for this approach. For genome edited 
cells to become clinically relevant the entire gene correction process would need to be carried out 
using processes that are compatible with good manufacturing practice (cGMP) that include defined 
media and xenogenic- and feeder-free processes which, at present, are a challenge. The combination 
of strategies used in this study can be further enhanced by using the truncated RNA guides [92], 
reducing the amount of vectors [75], and by using culture conditions that improve tolerance to 
single cell manipulation [232].     
Disease modelling of beta haemoglobinopathies remains unattained as erythroid cells obtained via 
direct differentiation of iPSCs retain an immature phenotype with little expression of the -globin 
gene [148-152, 154]. This study sought to assess the applicability of CRISPRa for stimulating gene 
expression of the -globin locus inactive in iPSCs, explore the potential of this system for 
modelling the RNA processing defect in beta thalassaemia and validate the restoration of 
functionality of the wild type allele in gene-corrected iPSCs. The results shows that it is possible to 
use the CRISPR/Cas9-assisted genome editing approach to demonstrate restoration of appropriate 
gene expression after gene correction, and its absence in iPSCs with the disease mutation. This 
indicates that a similar approach can be used to model other diseases, including those caused by 
mutations that interfere with normal RNA processing. Confirmation of the zygosity of the locus is 
necessary to determine if the observed reduced expression of the normal transcript reflects 
suboptimal locus activation as a result of the transfection efficiency or is a consequence of 
differences in epigenetic effects at the HBB locus. Western blotting will also be employed to assess 
-globin protein translation in CRISPRa-activated iPSCs. 
In conclusion, this study has optimized and validated an approach that can be used to achieve 
traceless gene correction with enhanced specificity and presents a strategy that permits assessment 
of the success of the gene correction in iPSCs (in this case HBB) without the need to differentiate 
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the iPSCs into specific types of cells (while recognizing that it is still necessary to demonstrate -
globin expression at the protein level in terminally-differentiated cells). This approach may provide 
an example of a viable platform for site-specific gene correction for the locus silenced in hPSCs, 
loci with a low efficiency of editing rate as the rate varied over a broad range at different loci [145]. 
Achieving a high efficiency of targeting can obviate the need for positive/negative selection, and 
allow the identification of corrected clones by direct analysis [233]. The suggestion to exploit the 
high efficiency of NHEJ in achieving a beneficial loss of function of some DNA elements [8, 234] 
can offer a viable approach to overcome the limitation posed by the low HDR editing rate observed 
in quiescent autologous-HSCs [5, 234]. For example, inactivation of a lineage specific enhancer of 
BCL11A can result in an induction of HbF synthesis [235] to such a level that it has the potential to 
ameliorate the phenotype associated with beta haemoglobinopathies [236]. 
 The presence of unwanted mutations in stem cell models of genetic disease can confound the 
association of a certain genotype with its observed phenotype [55]. It can also complicate the 
generation of reliable isogenic controls which are needed for the investigation of the molecular 
mechanisms underlying the pathogenesis of the disease [202]. More importantly, in clinical settings 
even a low, undetectable mutation level can have undesired consequences. This study has 
demonstrated that even the nickase form of SpCas9 can be associated with a low level of 
mutagenesis in iPSCs. Therefore, a DN strategy still carries the risk of off-target activity that can be 
associated with monomeric nickase, albeit at a significantly lower level compared to Cas9WT [96]. 
The dimerization-dependent approach (FokI-dCas9) has also been demonstrated to have monomeric 
activity, that can be the result of a reaction mechanism of FokI [237]. Remarkably, FokI activity 
was shown not to be restricted by spacer size as they can also dimerize across a significant distance 
[237]. Nevertheless, the average frequency of indel associated with monomeric FokI-dCas9 activity 
was less than that observed with monomeric nickase [98].  
The rapid pace of research in this field has recently provided additional tools that can further 
enhance the specificity of inducing DNA breaks to stimulate DNA repair mechanisms. A new 
DNA-guided endonuclease identified in N. gregoryi SP2 (Natronobacterium gregoryi SP2), denoted 
‘NgAgo’, was demonstrated to induce endonuclease activity that was considerably decreased in the 
presence of even a single mismatch [238]. It was also demonstrated to be absolutely intolerant to a 
three consecutive base mismatch, which is a major advantage over the Cas9 system, as it 
significantly limits the screen of the intactness of off-target sites. The system is not restricted by the 
presence of an adjacent motif, and possibly has a higher tolerance of high GC regions as judged 
from the observed activity at the HBA2 locus. More importantly, the size of NgAgo is smaller than 
that of the SpCas9 system, which can be more amenable to packaging in vectors for in vivo 
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delivery. Although recently a small size Cas9 orthologue has been proposed to be useful for in vivo 
gene editing [239], Cas9 derived from Staphylococcus aureus (SaCas9) is restricted by the 
requirement for the PAM sequence needed for activity. NgAgo could be a promising tool, provided 
that aspects such as the transient time, iterative cycle of activity, off-target activity and the 
versatility of this tool prove advantageous for genome engineering. The rapid progress in this field 
has provided a wide array of tools and approaches for genome engineering that may facilitate 
moving this field towards therapeutic applications. Although various bioinformatic tools are 
available that rank guide sequences based on predicted scores for on-/off-target specificity [54], the 
accuracy or specificity of their performance can be affected by factors not yet completely 
understood. We still lack comprehensive methods that will allow us to reliably assess a low level of 
mutation [55], and an effective in silico and in vitro approach that can reduce the empirical testing 
and validation of the off-target activity predicted in the cellular context. 
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